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Dual antiplatelet therapy (DAPT), consisting of aspirin and a P2Y12 receptor antagonist, 
is the standard of care following an acute coronary syndrome (ACS) presentation, and 
oral anticoagulation (OAC) is standard of care for stroke prevention in atrial fibrillation 
(AF) patients. In patients with AF who present with an ACS, it is not clear whether the 
combination of DAPT and OAC, known as triple therapy (TT), should be the preferred 
treatment strategy, or whether DAPT alone is optimal.  
The first two studies in this thesis examined contemporary antiplatelet/anticoagulant 
management in New Zealand. The first study examined management of 93 ACS patients 
with AF from a single-centre. We found DAPT was the preferred treatment regimen, and 
no TT use was observed. Decisions regarding therapy did not appear to be based on 
assessments of stroke or bleeding risk. In the second study, we utilised the national 
ANZACS-QI registry, and examined pharmacy prescription data for 610 ACS patients who 
underwent percutaneous coronary intervention (PCI) with a history of AF. In this cohort 
DAPT was again the most common discharge regimen followed by TT, and their use was 
not driven by stroke risk (CHA2DS2VASc scores). Rates of DAPT and TT declined markedly 
over the 12 months following the ACS event. On the basis of these two studies we 
concluded that no consistent treatment strategy was evident for the management of 
ACS patients with AF.  
A systematic literature review was then undertaken to identify optimal therapy. We 
selected papers describing treatment regimens and one-year outcomes for patients with 
AF and either ACS or PCI. The inclusion of stable PCI patients was necessary as the 
majority of literature featured mixed cohorts of ACS or stable coronary disease 
undergoing PCI. The identified literature was entirely observational in nature and the 
overall quality was poor. The largest studies reported that TT offered significant 
reductions in stroke over DAPT, and a consistent increase in bleeding associated with TT 
was reported.  
On the basis that the available literature did not offer clear guidance on when the 
benefits associated with stroke reduction with TT would be greater than the harm 
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associated with excess bleeding, we constructed a decision analysis model. This model 
addressed likely thresholds at which TT stroke reduction may exceed harm from 
bleeding. Under most modelled scenarios TT was not preferred above DAPT at 
CHA2DS2VASc 2, and only outperformed DAPT when stroke risk was high in the 
CHA2DS2VASc 3-5 range.   
Given the importance of bleeding in determining the net clinical benefit of DAPT versus 
TT we examined how accurately bleeding events could be predicted in a cohort of 1000 
acute myocardial infarction patients. We examined the ACS bleeding scores CRUSADE 
and ACTION as well as low platelet reactivity (LPR) to predict one-year TIMI major and 
minor bleeding.   We found that neither score nor LPR accurately predicted one-year 
bleeding events.  
The clinical problem of optimal antiplatelet/anticoagulant therapy in ACS patients with 
AF remains significant. Our data suggests that at low stroke risks DAPT is probably the 
treatment of choice, with TT becoming more acceptable at higher stroke risk. Accurate 
classification of bleeding risk in this population is needed to minimise potential harms 
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1.1  Acute coronary syndromes 
An acute coronary syndrome (ACS) is a potentially life-threatening condition that occurs 
most commonly when transient or permanent thrombotic occlusion of the coronary 
vasculature results in myocardial ischaemia and/or infarction. The term ACS specifically 
refers to a spectrum of clinical conditions that increase in severity from unstable angina 
(UA), to non-ST-elevation myocardial infarction (NSTEMI) and ST-elevation myocardial 
infarction (STEMI) in its most high-risk form 1.  
 
1.1.1 Pathophysiology 
ACS is the unstable manifestation of coronary artery disease (CAD). The underlying 
pathophysiology of CAD is atherosclerosis, a dynamic and ongoing process of plaque 
formation and stenosis within artery walls. Two key processes, namely endothelial 
dysfunction and inflammatory response, are crucial to the development of 
atherosclerotic lesions and therefore ACS. Traditional CAD risk factors including 
hyperlipidaemia, hypertension, diabetes and smoking, cause damage to the 
endothelium 2. Under normal conditions the endothelium maintains a delicate balance 
of anti and pro thrombotic, inflammatory, atherogenic and coagulant functions, and 
when damage ensues one or more of these functions are lost resulting in endothelial 
dysfunction 3. Now the vasculature is predisposed to a vasoconstrictive state, platelet 
aggregation and adhesion, thrombosis, impaired coagulation, and vascular 
inflammation 4.  
In addition to endothelial dysfunction, a highly specific series of cellular and molecular 
inflammatory responses also contribute to the development of atherosclerotic lesions 
2. Once the endothelium has been damaged, leukocytes bind and migrate to the sub-
endothelial space where they digest oxidised low density lipoprotein cholesterol that 
has also crossed the artery wall. The artery walls now store large amounts of cholesterol 
with a yellow appearance- the constituent of an atherosclerotic plaque 5. A fibrous cap 
isolates the contents of the plaque from the circulatory system however further 
inflammatory responses degrade the integrity of this cap thereby creating an 
3 
 
environment conducive to plaque rupture 6. Inflammatory activation also increases the 
production of tissue-factor, a potent activator of the clotting cascade, which on plaque 
rupture will trigger thrombus formation and potentially occlude the coronary artery 7.  
Despite the chronic nature of atherosclerotic lesion development, the acute 
presentation often occurs spontaneously and without warning. 
  
1.1.2 Burden of disease 
Internationally ACS is a significant healthcare problem. CAD has been the leading cause 
of mortality globally for the past 15 years. Rates of CAD related deaths continue to rise 
and approximately half occur as a result of ACS 8. In 2000, 6.88 million deaths from CAD 
were recorded, increasing most recently to 8.75 million deaths in 2015. This increase is 
equivalent to 112 deaths per 100,000  in 2000, to 119 deaths per 100,000 in 2015 9. 
Cardiovascular disease is also the leading cause of mortality in New Zealand. Annually 
cardiovascular disease accounts for 33% of all deaths and, of these, 49% are attribute to 
CAD.  For Maori males and non-Maori males CAD is the leading cause of mortality, and 
this is true for non-Maori females also. For Maori females CAD is the second highest 
cause of death behind lung cancer 10.  
CAD also carries significant morbidity for the New Zealand population. Heart disease is 
the leading cause of health loss (loss of healthy years lived) in New Zealand. Among New 
Zealand males CAD is the leading cause of quality years lost and accounts for 10% of all 
health loss. For females CAD is the second most common cause, accounting for 6% of all 
health loss 11. Despite advances in CAD therapies, ACS results in persistent mortality, 
medical, social and economic burden 12,13.  
 
1.1.3 Clinical treatment of ACS 
There are two main goals for the management of an ACS. This first is to reduce 
myocardial necrosis and in doing so preserve cardiac function, particularly left 
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ventricular function. Treatment is dependent on where the patient falls on the ACS 
spectrum 14. Diagnosis of STEMI requires timely reperfusion therapy to restore blood 
flow through the coronary arteries and limit infarct size. Percutaneous coronary 
intervention (PCI) is the preferred treatment of choice when it can be performed with 
90 minutes of first medical contact and this strategy successfully restores coronary 
artery flow in approximately 90% of patients. If time to PCI is expected to exceed 90 
minutes, often due to geographical factors, then fibrinolysis should be administered as 
time delay negates the benefit of PCI over immediate fibrinolytic therapy. Patients with 
non-ST-segment elevation acute coronary syndromes (NSTEACS) are recommended to 
receive angiography with coronary revascularisation (PCI or coronary artery bypass graft 
[CABG]) as appropriate. Adjunct therapies to manage the acute phase may also include 
oxygen, nitro-glycerine, analgesia, antiplatelet agents, beta-blockers, anticoagulation, 
and angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers 1. 
The second goal in the management of an ACS is to limit disease progression through 
secondary prevention strategies and risk management. This is critically important as 
after an ACS event patients remain at high risk of recurrent ischaemic events 15. Long-
term patient adherence to cardioprotective medications is necessary and includes 
therapies such as antiplatelet agents, statins, ace inhibitors/angiotensin II receptor 
blockers and beta-blockers.  Intensive risk factor modification is also required and may 
include antihypertensive therapy 16, glucose-lowering therapy for diabetics 17 and 
lifestyle changes (e.g. smoking cessation, diet modifications and physical activity) 18,19. 
Referral to cardiac rehabilitation services is also an effective strategy to aid patient 
compliance as well as assisting in their transition to chronic self-management after an 
ACS event 20.        
 
1.1.4 Platelets in ACS 
The integrity of the circulatory system is maintained by haemostatic processes. When 
vessel walls are compromised, like in the instance of plaque rupture or erosion, 
circulating platelets are recruited to the site of injury where they are integral to healing. 
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As part of normal regulatory processes platelets play a key role in thrombus formation, 
and when an artery is sufficiently occluded by a thrombus an ACS event is initiated 21. 
In the setting of plaque disruption two distinct pathways activate platelets: one 
generated by exposed collagen, the other by exposed tissue factor. Collagen from the 
sub-endothelium binds to platelet glycoprotein VI facilitating platelet adhesion. In 
addition, glycoprotein VI is a major agonist for platelet activation and granule release. 
Amongst other compounds, adenosine diphosphate (ADP) and thromboxane A2 are 
both released during degranulation and both are potent platelet agonists, further 
perpetuating the cycle.  Collagen also binds to von Willebrand factor, and this complex 
binds to platelet glycoprotein Ib-V-IX resulting in further platelet adhesion, or ‘rolling’ of 
platelets on the vessel wall 22 . Tissue factor on the other hand binds with factor VIIa 
(activated factor VII), and this complex activates factor IX, initiating a cascade that 
generates thrombin. Thrombin acts to further stimulate platelets, but also ensures 
stability by cleaving fibrinogen to fibrin- the insoluble mesh encapsulating the platelet 




Figure 1-1 Platelet activation after vascular injury 
Endothelial damage results in platelet exposure to collagen and other extracellular membrane (ECM) proteins, facilitating platelet adhesion to the 
substratum. The adherent platelets then aggregate and release potent platelet agonists including adenosine diphosphate (ADP) and thromboxane A2. 
Following activation the platelets produce thrombin which initiates the coagulation cascade. This leads to the generation of fibrin, a mesh-like deposition 




1.1.5 Thrombosis in ACS 
The small amount of thrombin generated by the tissue factor-factor VIIa complex as 
outlined above is considered the initiation phase of coagulation and is very inefficient. 
This is because the activated forms of factors VIII and V (pro-cofactors) are not yet 
available.  However, once thrombin is formed it acts to convert these pro-cofactors to 
factor VIIIa and factor Va respectively, leading to a burst of thrombin generation.  As a 
measure of amplification, the thrombin generation with factor V is less than 1% the rate 
compared when factor Va is present 25. Pathophysiologically thrombi formed in the 
arterial system, like those in ACS, are predominantly platelet rich or ‘white clots’. In 
contrast, thrombi formed in other body systems (e.g. low-pressure systems such as the 
venous system or cardiac atria) are fibrin rich or ‘red clots’ 26-28.   
In the context of ACS platelets play an important role in the process of thrombus 
formation. The platelet therefore is a logical therapeutic target to prevent further 
coronary artery occlusions 25 and this is achieved through the administration of 
antiplatelet agents.  
 
1.1.6 History of Aspirin 
1.1.6.1 Salicylic acid 
Today, daily aspirin as an antiplatelet medication is a mainstay preventative treatment 
after an ACS event, proven to reduce secondary events in a safe and efficacious manner. 
However, arriving at this point is the product of a long and rich history.  
Aspirin is one of the worlds most prescribed drug and originates from the Salicaceae 
family of plants. The Salicaceae are a willow family of flowering plants, and the willow 
tree itself has an abundantly watery bark with a high salicylic acid component; the 
organic compound for which willow gets its medicinal effects 29. The therapeutic use of 




In March 2017 a study of Neanderthal dental plaque from an abscessed jawbone, dating 
from around 42,000 to 50,000 years ago, identified genetic material from the poplar tree 
(also of the Salicaceae family), indicative of therapeutic use 30. Historical evidence in the 
form of markings on clay tablets has indicated that ancient Egyptians of the Sumerian 
period (5500 – 4000 BC) used willow bark to alleviate rheumatic pain. Observations by 
Greek physician Hippocrates around 400 BC testified to the antipyretic and analgesic 
properties of salicylic tea, and this was later echoed by Galen in 200 AD who recorded 
the anti-inflammatory, analgesic and antipyretic effects of willow bark 31. These 
observations, although anecdotal, indicate that the therapeutic use of salicylic acid has 
a very long and enduring history until integration into modern medicine.     
The first scientific description of willow bark is attributed to the Reverend Edward Stone 
in 1763. Stone wrote a letter to the President of the Royal Society of London describing 
the use of powder derived from willow bark to treat ague (fever) in 50 patients 32. His 
interest in Willow was acknowledged as being due to the ancient Doctrine of Signatures 
which dated from the time of Galen, and may go some way towards explaining the 
modernisation of salicylic acid 33. The doctrine details that clues to the treatment of a 
disease will be found in the cause of the disease. According to Stone:  
As this tree delights in a moist or wet soil, where agues chiefly 
abound, the general maxim that many natural maladies carry their 
cures along with them or that their remedies lie not far from their 
causes was so very apposite to this particular case that I could not 
help applying it 34.  
In the 19th century developments in chemical techniques led to a flurry of activity in 
characterising the components of willow bark. In 1826 Henri Leroux, a French 
pharmacist, isolated a crystalline compound, later to be called salicin for the first time. 
Two years later Johann Buchner, a German Professor of Pharmacology, purified the 
same compound and named it the Latin translation of willow, salicin.   In 1838 an Italian 
chemist named Raffaele Piria resolved the chemical structure of salicin as a glucosidic 
salicyl alcohol. Then Piria oxidized salicyl alcohol in a pioneering move to generate 
salicylic acid.  In 1853 French chemist Charles Gerhardt was the first to perform 
acetylation of salicylic acid to create acetylsalicylic acid (ASA) 31,35. Later this 
development was acknowledged as a momentous modification for user experience; 
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unfortunately for Gerhardt he did not use or market this modified version of salicylic 
acid 36. In 1859 Hermann Kolbe, a German chemist, succeeded in artificially creating 
salicylic acid’s chemical structure and this allowed for industrial scale production and an 
end to the willow bark powder era. By 1874 artificial salicylic acid was being sold at a 
tenth of the price of extracted willow bark and physicians began to prescribe the 
medication for pain relief with good effect 37.       
Despite the therapeutic advantages of salicylic acid administration, side effects, 
predominantly gastric irritation and unpleasant taste, were common. Approaching the 
turn of the century, Felix Hoffman, a German chemist working for the Bayer Company 
set to the task of finding a more palatable alternative; it is generally accepted that 
Hoffman’s father was suffering side effects from taking salicylic acid for rheumatism. In 
1897, nearly half a century after Gerhardt, Hoffman through acetylation created ASA, 
named and branded as Aspirin 38.  Aspirin was indeed more palatable and far gentler on 
the stomach. After this breakthrough the Bayer Company performed what is believed to 
be the first mass-marketing of any drug.  Information about aspirin was sent to 30,000 
doctors and by 1914 Bayer was reaping large profits from this wonder drug 33. 
However Hoffman’s development of Aspirin had more untapped potential which would 
not be realised for many more years; the acetylation of salicylic acid is what allows 
aspirin to inhibit platelet activation and aggregation and therefore prevent 
cardiovascular events 39. 
 
1.1.6.2 Aspirin the antiplatelet 
Despite the widespread use of aspirin in the early 20th century its role in cardiovascular 
health was unknown. In 1945, questions begun to surface regarding the interaction 
between salicylates and haemostasis; this was born out of observations that salicylate 
administration (not ASA) was associated with increased prothrombin time, but not 
increased rates of bleeding. Stirrings were enough that the Wisconsin Alumni Research 
Foundation (creators of Warfarin) were prompted to apply for a patent for a combined 
salicylic acid and vitamin K tablet; the incorrect assumption being that vitamin K might 
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be compensatory in this context 40. What is now known is that despite the increased 
prothrombin time, the absence of increased bleeding events was due to lack of 
acetylation- the key to aspirin’s therapeutic effectiveness in the setting of cardiovascular 
disease. 
During the 1950’s the theory of aspirin having a role in myocardial infarction (MI) 
prevention got more traction due to the publications of a Californian general 
practitioner named Dr Lawrence Craven. In 1950 Craven reported higher rates of 
haemorrhage following tonsillectomy when Aspergum (chewable aspirin) was 
prescribed for pain relief, sometimes so severe, patients were re-hospitalised and in 
each instance the laboratory reported a prolonged coagulation time. Further, given the 
dose of aspirin was far less than what would be prescribed for rheumatic conditions 
Craven suspected the surgical wound to be of particular pertinence to this observation. 
Craven hypothesised that the drug might be of value as a preventative of vascular 
thrombotic conditions, including coronary thrombosis. He finished by declaring that for 
two years he had been advising his male patients aged 40-65 years to take ASA daily, 
and that with more than 400 doing so, none has suffered a coronary thrombosis 41. Thus, 
the seed was planted into the medical community. Later in 1950 Craven reiterated 
similar findings, this time with 600 male patients prescribing to daily aspirin with great 
effect 42. Craven’s 1953 publication reported on his self-administration of high dose 
aspirin (12 tablets/day, for 5 days) which resulted in profuse nose bleeding; he repeated 
this three times and implored to scientific community to perform clinical trials on the 
basis of his observations 43. Craven’s final publication shortly before his death was 
powerful; according to Craven:  
To date, approximately 8,000 men have adopted a regime calling for 
from 5 to 10 gr. of aspirin daily, with a surprising result. Not a single 
case of detectable coronary or cerebral thrombosis has occurred 44. 
During this time gastric bleeding was attributed to direct mucosal irritation from 
ingesting aspirin, however similar observations after intravenous administration 
suggested a systemic effect on haemostasis 45. In the late 1960s Dr Harvey Weiss asked 
the next logical question, does aspirin affect platelets? Weiss theorised that aspirin 
associated bleeding might result from defective platelet aggregation. After conducting 
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experiments in 20 patients (10 case, 10 control) he reported that aspirin significantly 
prolonged bleeding time and significantly decreased platelet aggregation, the latter 
attributed to impaired intrinsic ADP release. Moreover the aggregation of platelets with 
added ADP was not affected in subjects taking aspirin 46. Weiss was also the researcher 
who performed experiments confirming the importance of acetylation; by comparing 
ASA with sodium salicylate Weiss found that unlike ASA, sodium salicylate did not impair 
platelet aggregation nor inhibit ADP release 47. This mechanism of action discovery was 
confirmed shortly thereafter by other research groups 48,49 and was a key step in the 
progression of cardiovascular preventative medicine.  
Around the same time in a seemingly unrelated area of research, Sir John Vane through 
the use of bioassays discovered the release of prostaglandins and “rabbit aorta 
contracting substance” (to be later named thromboxane A2) during anaphylaxis 50. In 
further studies Vane found that aspirin antagonised the release of “rabbit aorta 
contracting substance” and prostaglandins in a dose-dependent manner 51. Support for 
Vane’s findings were soon published with one study isolating and stimulating platelets 
from patients on aspirin, concluding that prostaglandin synthesis was specifically 
inhibited by aspirin 52.  The enzyme inhibited by aspirin was later revealed as 
cyclooxygenase-1 (COX1). Collectively the results from many years of research revealed 
that aspirin’s effect on platelet aggregation results from the inhibition of COX1 which 
reduces thromboxane A2 synthesis, and, inhibits the response to thromboxane which is 
dependent on ADP for amplification 35. In 1982 Vane was jointly awarded the Nobel prize 
for physiology or medicine alongside Sune Bergstrom and Bengt Samuelsson, for their 
discoveries of prostaglandins and related biologically active substances, with particular 





1.1.7 Aspirin’s therapeutic evidence 
With biochemical mechanisms more readily understood concentrated research of 
aspirin as a secondary preventative measure commenced. In the 1970s six double-blind, 
placebo-controlled randomised trials examined the efficacy of aspirin for secondary 
prevention after MI (definitions here forth pertain to the vernacular of the time and are 
not necessarily consistent with contemporary definitions) (see Table 1-1).  All reports 
except one (the Aspirin Myocardial Infarction Study [AMIS] trial 54) showed a trend in 
favour of aspirin but firm conclusions could not be drawn. None of the studies 
demonstrated a statistically significant difference between the aspirin intervention and 
placebo control groups for total mortality. In retrospect, it is evident that the aspirin 
doses administered in these trials were relatively high, with five of the six trials using 
daily doses in excess of 900mg.  Side-effects or bleeding complications were not 
reported well in these studies, with the exception of the PARIS study which reported 
significantly higher rates in the aspirin intervention arm compared with placebo of, 
hematemesis/melaena (6.4% vs. 2.5%, p=0.002) and symptoms of peptic ulcer/gastritis 
(18.1% vs. 13.2%, p=0.02) 55.  
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Table 1-1 Early aspirin versus placebo randomised control trials: total mortality 





Elwood et al  
(1974) 56 
Men with prior MI 
(n=1239) 
300 mg/day 12 months 9.8 7.6 0.22 
Coronary drug project 
aspirin study  
(1976) 57 
Prior MI (n=1529) 972 mg/day 22 months 8.3 5.8 0.07 
German-Austrian 
multicentre prospective 
clinical trial (1979) 58 
Prior MI (n=626) 1500 mg/day 24 months 7.1 4.1 0.14 
Elwood & Sweetnam  
(1979) 59 
Prior MI (n=1725) 900 mg/day 12 months 14.5 12.2 0.18 
AMIS (Aspirin myocardial 
infarction study)  
(1980) 54 
Prior MI (n=4524) 1000 mg/day 40 months 9.7 10.8 0.22 
PARIS (Persantine aspirin 
reinfarction study  
(1980) 55 
Prior MI (n=2026) 972 mg/day or 
 




MI = myocardial infarction 
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1.1.7.1 Aspirin for secondary prevention 
The 1980s saw further randomised control trials (RCT) conducted with a focus on 
secondary prevention. During this period the dosing of aspirin was greatly reduced 
(75mg-325mg/day) when compared to trials from the 1970’s and results in favour of 
aspirin’s efficacy emerged (Table 1-2). Of particular importance was the 1988 landmark 
trial, the Second International Study of Infarct Survival (ISIS-2)60. Preceding ISIS-2, two 
smaller studies by Lewis et al (1983)61 and Cairns et al (1985) 62 produced strikingly 
similar results in UA patients. Both studies found daily aspirin resulted in a respective 
50% and 51% relative risk reduction in the composite endpoint of death/nonfatal MI, 
and therefore a therapeutic benefit for secondary prevention was first observed. With 
regard to adverse effects Cairns et al did not present data, and Lewis et al reported no 
detectable difference although their measurements are somewhat irregular (as they 
were conducted at any time within the trial period of 12 weeks).  
When ISIS-2 was conducted 417 hospitals enrolled 17,187 patients within 24 hours of 
suspected MI symptom onset. Patients were randomized to receive: 1) 1 month of 
160mg/day aspirin; 2) 1-hour intravenous infusion of 1.5 million units of streptokinase; 
3) both; 4) neither. Focusing on the aspirin only group, at 5 weeks treatment with aspirin 
resulted in a 23% relative risk reduction in vascular mortality (9.4% vs. 11.8% placebo, 
p<0.0001), and despite small convergence this survival benefit remained at 15 months 
(p<0.001). Aspirin therapy versus placebo also resulted in fewer nonvascular deaths 
(0.3% vs. 0.5%) and therefore when combined with vascular death, all-cause mortality 
was also significantly reduced with aspirin in the first 5 weeks (p<0.001). Aspirin was also 
associated with significantly less non-fatal reinfarctions (1% vs. 2%) and non-fatal stroke 
(0.3% vs. 0.6%), and was not associated with significant increases in cerebral 
haemorrhages or haemorrhages requiring blood transfusion. ISIS-2 also examined 
streptokinase alone which resulted in an excess of non-fatal reinfarctions, however this 
was not observed in the streptokinase-aspirin arm. After ISIS-2 the role of aspirin for 
secondary prevention was further supported by  smaller studies confirming its ability to 









Major findings Adverse effects 








12 weeks Aspirin resulted in a 50% RR reduction for the 
combined endpoint of death/nonfatal MI  
(5% vs. 10.1%, p=0.0005) 
No difference found for the outcome 
measures: 1) Hg drop; 2) stool test 
for occult blood. 









18 months Aspirin resulted in a 51% RR reduction for the 
combined endpoint of cardiac death/nonfatal MI  
(8.6% vs. 17%, p=0.008) 
(No observed benefit from sulfinpyrazole) 










5 weeks 5 weeks: 23% RR reduction in total vascular 
mortality with aspirin 
(9.4% vs. 11.8%, p<0.0001). 
15 months: survival benefit persisted (p<0.001). 
No difference in haemorrhage or 
bleeds requiring transfusion  
(0.4% aspirin vs. 0.4% placebo). 
Small increase (0.6%) in absolute 
number of bleeds on aspirin (p=0.01) 




325mg aspirin b.i.d. 
vs. 
placebo 
6 days Aspirin resulted in a 29% RR reduction in MI 
compared with placebo  
(3.3% vs. 11.9%, p=0.012) 
Total bleeding similar across both 








75mg aspirin/day  
vs. 
placebo 
3 months Aspirin resulted in 36% RR reduction for the 
combined endpoint of death/MI  
3 months: (6.5% vs. 17.1%, p<0.0001) RR 0.36 
Negligible side effects recorded 
b.i.d. = twice daily; Hg = haemoglobin; MI = myocardial infarction; q.i.d. = four times daily; RR = relative risk; UA = unstable angina. 
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1.1.7.2 Meta-analyses of antiplatelet data  
With a large body of aspirin research having been conducted the synthesis of all results 
proved to be a valuable tool. Where, in the 1970’s, studies were indicative but not 
conclusive, these results were considered in addition to more recent research of the 
1980’s and 1990’s, to provide high-level evidence of aspirin’s ability to prevent 
secondary cardiovascular events.  
The Antiplatelet Trialists’ Collaboration first published in 1988 and included meta-
analyses of 25 randomised trials of antiplatelet medication. Twelve of these studies 
pertained to MI (10) and UA (2) patients of which ten analysed aspirin, either alone or 
in conjunction with sulphinpyrazone or dipyridamole. The regimen most studied was 
300-325 mg aspirin.  When all trials were considered together antiplatelet therapy 
(predominantly aspirin) resulted in a significant 25% relative risk reduction in the MI 
trials, and a significant 36% relative risk reduction in the UA trials, for the combined 
endpoint of stroke, MI and vascular death 65. From this publication until the early 2000’s 
aspirin endured as the mainstay preventative therapy for secondary MI and UA, as 
comparisons of aspirin and dipyridamole, or aspirin and sulfinpyrazone, failed to provide 
evidence that either therapy was more effective than 75-325mg doses of aspirin alone 
62,66,67.  
In 1994 the Antiplatelet Trialists’ Collaboration published an updated collaborative 
overview of randomised trials of antiplatelet therapy. This analysis now involved 145 
randomised trials and included 100,000 patients, of which 70,000 were high risk 
(defined as patients with acute MI, prior MI, prior stroke/transient ischaemic attack 
[TIA], or other relevant cardiovascular history e.g. UA). This meta-analysis differed from 
the 1988 precursor analysis in that only trials that assessed prolonged antiplatelet 
therapy (one month or more) were eligible for inclusion. Once again, the most widely 
tested therapy was aspirin (75-325 mg). For secondary prevention, overwhelmingly 
antiplatelet therapy was found to be superior to control treatment for the protection 
against vascular events (non-fatal MI, non-fatal stroke or vascular death) in acute MI 
patients (10% vs. 14%, p<0.00001), prior MI patients (13% vs. 17%, p<0.00001) and UA 
patients (9% vs. 14%, p<0.00001). When the results from the acute MI subset are 
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examined alone (as a surrogate for ACS patients) antiplatelet therapy consistently 
resulted in significant relative risk reductions for the endpoints of combined vascular 
events (29%), non-fatal MI (54%), vascular death (22%) and death from any cause (23%). 
The expansion to 145 trials also resulted in more variation of antiplatelet agents (e.g. 
the additional of ticlopidine and suloctdil) however analysis of aspirin only trials (n=49) 
found aspirin alone persisted to significantly reduce vascular events by demonstrating a 
25% relative risk reduction. The investigation into low risk patients (primary prevention) 
yielded no clear evidence that antiplatelet therapy was beneficial for routine use. The 
clinical implications of this meta-analysis were that for secondary prevention 
antiplatelet therapy protects patients against vascular events, and no other regimen was 
more effective at preventing MI, stroke or death than aspirin at doses ranging from 75-
325mg 68.  
The most recent meta-analysis of the Antithrombotic Trialists’ Collaboration (previously 
Antiplatelet Trialist’ Collaboration) was published in 2002 and results can be seen in 
Figure 1-2. Where this paper differed from previous reports was that its focus was on 
high-risk patients only (acute MI, previous MI, UA, stable angina, acute ischaemic stroke, 
previous ischaemic stroke, peripheral artery disease or atrial fibrillation). This analysis 
included 287 studies of 135,000 patients comparing antiplatelet therapy to control, and 
once again the primary outcome was serious vascular events (non-fatal MI, non-fatal 
stroke or vascular death). Aspirin remained as the most widely studied antiplatelet drug, 
this time at 75-150mg daily and follow up ranged from 1 to 27 months.  Overall 
antiplatelet therapy had a 22% relative risk reduction in serious vascular events when 
compared to control groups (10.7% vs. 13.2%, p<0.0001).  
When the trials were subdivided into categories of high risk patients it was evident that 
the effect of antiplatelet medication differed among them, largely due to the effect on 
patients with acute stroke. That is, in the previous MI, acute MI, previous stroke and 
other high-risk groups, antiplatelet therapy reduced the primary endpoint by one 
quarter to one third, with a combined risk reduction of 25% (11.7% vs. 14.8%, p<0.0001). 
However in the acute stroke subgroup alone the risk reduction was by 11%, although 
still significant (8.2% vs. 9.1%, p=0.0009). The greatest benefit was observed in the acute 
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MI subgroup with a risk reduction of 30% (p<0.0001). What’s more, in each of the high-
risk categories the absolute benefits substantially outweighed the absolute risks of 
major extracranial bleeding. Other measures of bleeding were not included in this 
analysis. What this meta-analysis added was that 75-150mg doses of aspirin daily were 
as effective as higher doses (160-325mg and 500-1500mg), and that this regimen is 
suitable for the long-term secondary protection against vascular events in high-risk 





Figure 1-2 Meta-analysis of antiplatelet therapy effect on serious vascular events 
Proportional effects of antiplatelet therapy on serious vascular events (non-fatal MI, non-fatal stroke or vascular death) in high risk categories. Stratified 
odds ratios are plotted for each group of trials (black square) along with its 99% confidence interval (horizontal line). Meta-analyses of results for all 
trials (and 95% confidence interval) are represented by an open diamond. Figure reproduced with permission from the rights holder, BMJ publishing 




Platelets can be activated by multiple pathways. While aspirin blocks platelet activation 
mediated by thromboxane A2 it does not block platelet activation by ADP, another 
important platelet activation pathway. The specific blocking of ADP is therefore a 
sensible target to induce further platelet inhibition. Thienopyridines are a class of drug 
that selectively and irreversibly inhibit the binding of ADP to P2Y12 receptors on platelets 
70. ADP is also a key factor in the activation of the glycoprotein IIb-IIIa complex, the main 
receptor for fibrinogen on the surface of the platelet and therefore thienopyridines 
possess antithrombotic effects beyond inhibition of ADP-induced aggregation alone 71. 
The first P2Y12 receptor inhibitor, Ticlopidine was identified in the 1970’s and showed 
greater antithrombotic efficacy over aspirin in many clinical settings including patients 
with previous stroke/TIA, peripheral artery disease, ischaemic heart disease and those 
at high risk of thrombosis 72,73. Unfortunately ticlopidine was not well tolerated with 
approximately 50% of patients experiencing adverse side effects including nausea, 
vomiting and diarrhoea 74. Furthermore, within the first 3 months of ticlopidine use 
some patients experienced rare yet serious toxic side effects including leucopenia, 
thrombocytopenia, agranulocytosis and pancytopenia. This led health authorities to 
enforce haematological and clinical monitoring during the first three months of 
ticlopidine prescription, but also made way for clopidogrel, a newer P2Y12 receptor 
inhibitor with a more favourable side effect profile and better activity/toxicity ratio in 
humans 72.   
 
1.1.8.1 Clopidogrel 
Clopidogrel is a prodrug that requires hepatic biotransformation into its active 
metabolite. Approximately 85% of the drug is metabolised into an inactive carboxylic 
acid metabolite and excreted from the body while the remaining 15% undergoes 
biotransformation. The active metabolite binds to the P2Y12 receptor irreversibly 
blocking ADP binding and receptor activation 75.  After cessation of oral administration, 
platelet inhibition is still detectable at a rate consistent with platelet turnover (7-10 
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days) which is consistent with the permanent effects of clopidogrel on platelets and 
allows a once a day dosing regimen 72. Clopidogrel is well tolerated when compared to 
ticlopidine and for the most part side effects centre on increases in minor bleeding and 
gastric irritation 76,77. Remarkably clopidogrel was discovered by chance when scientists 
went in search of new thienopyridine derived anti-inflammatory drugs. In 1972 it was 
observed that after oral administration to rats of (the compound later to be named) 
clopidogrel, despite the absence of any anti-inflammatory profile, unexpected 
antiplatelet and antithrombotic activities were displayed. Preclinical development of 
clopidogrel did not take place until 1987, and after 10 years of development and large 
scale clinical trials this new and improved P2Y12 inhibitor was approved for use in 1997 
for the secondary prevention of cardiovascular disease 78, and in 2011 was named the 
second best-selling drug of all time 72. Interestingly, some commentators believe that 
clopidogrel could not be discovered today. This is because clopidogrel requires 
biotransformation into an active metabolite, its metabolite is very unstable and cannot 
be stored, its structure cannot be predicted by rational drug design, and its detection is 
only possible through in vivo screening which is rarely used by the pharmaceutical 
industry in the present day 72.   
The major efficacy and safety analyses that preceded the approval of clopidogrel 
occurred in the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events 
(CAPRIE) trial. CAPRIE was a large randomised trial of over 19,000 patients at high risk 
of ischaemic events and the primary endpoint was a composite of ischaemic stroke, MI 
or vascular death. Treatment with clopidogrel resulted in a significant relative risk 
reduction of 8.7% for the primary endpoint and fewer gastrointestinal haemorrhages 
(0.49% vs. 0.71%, p=0.05). Other safety and tolerability measures showed clopidogrel 
was at least as good as aspirin with no differences in rates of neutropenia and 
thrombocytopenia like that of its predecessor ticlopidine 79. Furthermore, secondary 
analyses of the CAPRIE trial showed that greater benefit was gained from clopidogrel 
administration in the high-risk subgroups including patients with a medical history of MI, 




1.1.9 Dual antiplatelet therapy 
The combination of aspirin and a P2Y12 receptor inhibitor is known as dual antiplatelet 
therapy (DAPT). Due to their differing mechanism of action the addition of a P2Y12 
receptor inhibitor to aspirin was in theory a sensible therapeutic option to potentiate 
antiplatelet effects. However, it was not known if DAPT would result in a reduction in 
ischaemic events or whether any benefit would be outweighed by increases in bleeding 
events. The 2001 breakthrough Clopidogrel in Unstable angina to prevent Recurrent 
Events (CURE) trial set out to establish the efficacy and safety of DAPT with clopidogrel 
and aspirin, compared to aspirin alone in 12,562 ACS patients without ST elevation 83. 
The CURE study demonstrated that for the primary endpoint of cardiovascular death, 
nonfatal MI and stroke, patients randomised to the DAPT arm had a 20% relative risk 
reduction (9.3% vs. 11.4%, p<0.001). A relative risk reduction of 14% was also 
demonstrated with DAPT for the secondary endpoint of cardiovascular death, nonfatal 
MI, stroke and refractory ischaemia (16.5% vs. 18.8%, p=0.001). For both the primary 
and secondary composite endpoints the benefit observed with DAPT therapy was largely 
driven by the 23% relative risk reduction in rates of MI. With regards to safety analyses 
treatment with DAPT resulted in a significantly higher rate of major bleeding (3.7% vs. 
2.7%, p=0.001), and this was driven by increases in gastrointestinal bleeds (1.3% vs. 
0.7%) and arterial puncture site bleeding (0.6% vs. 0.3%). There were no differences 
detected between the arms with regards to fatal bleeding, life-threatening bleeding or 
haemorrhagic stroke. Rates of minor bleeding were also higher with DAPT (5.1% vs. 
2.4%, p<0.001).   
In a sub study of CURE patients who received PCI (PCI-CURE), benefit from DAPT was 
also observed with the primary endpoint (composite of cardiovascular death, MI, or 
urgent target-vessel revascularisation within 30 days of PCI) occurring less often in the 




1.1.9.1 Dual antiplatelet therapy integration into guidelines 
The results from the above trials resulted in DAPT with clopidogrel and aspirin, being 
integrated into international guidelines as the recommended therapy after an ACS, 
replacing aspirin alone.  Subsequent studies of DAPT further enhanced its therapeutic 
profile with benefit demonstrated in patients presenting with STEMI 85, those managed 
with PCI 86, as well as exhibiting a mortality benefit over aspirin alone in a RCT of 45,852 
acute MI patients 87.  Current ACS guidelines including but not limited to those from the 
American Heart Association (AHA) 88,89, the European Society of Cardiology (ESC) 90,91, 
and locally from the Cardiac Society of Australia and New Zealand 1 all recommend DAPT 
after an ACS for 12 months and this is strongly supported (Level of Evidence A). For 
patients considered to be at high risk of recurrent ischaemic events extending DAPT 
beyond 12 months is reasonable also.  
 
1.1.9.2 Newer P2Y12 inhibitors  
Despite the success of treatment with clopidogrel in ACS and post PCI, the drug has 
important limitations. The most important of which is the considerable variability in the 
level of platelet inhibition observed in patients treated with clopidogrel and aspirin 
following ACS 92-94.  Those patients with high platelet reactivity on treatment clopidogrel 
with have been shown to have an increased risk of death, MI and stent thrombosis 95,96. 
Subsequently newer P2Y12 inhibitors were developed which were more potent and had 
a more consistent pharmacodynamic effect. 
Prasugrel, like clopidogrel is a prodrug that requires biotransformation into its active 
form however unlike clopidogrel its metabolism is highly predictable. Prasugrel also 
irreversibly blocks P2Y12 receptors but exhibits faster and more profound inhibition than 
clopidogrel 97.  In the TRITON-TIMI 38 (Trial to Assess Improvement in therapeutic 
Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial 
Infarction) trial for ACS patients with a scheduled PCI, treatment with a combination of 
prasugrel and aspirin was found superior to treatment with clopidogrel and aspirin in 
reducing the primary endpoint, a combination of cardiovascular death, non-fatal MI or 
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non-fatal stroke, but also carried significantly higher rates of major bleeding including 
fatal bleeding.  This trial also showed that DAPT with prasugrel resulted in net harm for 
patients with prior stroke/TIA and therefore prasugrel is contraindicated for this patient 
subgroup in clinical guidelines. For patients over 75 years of age or body weight less than 
60kgs no added benefit from prasugrel was observed 98.  
Ticagrelor is a reversible, direct acting, non-thienopyridine P2Y12 inhibitor. Because of 
this ticagrelor has a much faster onset of action and must be taken twice daily, unlike 
the once a day dosing of clopidogrel and prasugrel 99. DAPT with ticagrelor was 
compared to DAPT with clopidogrel in the PLATO (Platelet Inhibition and Patient 
Outcomes) trial of ACS patients. The ticagrelor arm was found to be superior to the 
clopidogrel arm with regard to the primary end point of cardiovascular death, MI or 
stroke (9.8% vs. 11.7%, p<0.001). The rates of death from any cause (4.5% vs. 5.9%, 
p<0.001) and MI (5.8% vs. 6.9%, p=0.005) were also lower with ticagrelor.  No difference 
was detected between the treatment groups with regard to major bleeding (ticagrelor 
11.6% vs. clopidogrel 11.2%, p=0.43), however ticagrelor did result in significantly higher 
levels of non-CABG related bleeding (4.5% vs. 3.8%, p=0.03) including fatal intracranial 
haemorrhage (0.1% vs. 0.01%, p=0.02) 100.  
On the basis of the above results both STEMI and NSTEACS guidelines recommend 12 
months of DAPT (or more) for the prevention of secondary cardiovascular ischaemic 
events however a hierarchy of preference with regard to P2Y12 inhibitors has emerged.  
In general, ticagrelor or prasugrel is preferred over clopidogrel, however prasugrel’s use 
is limited given it is only recommended post PCI and is contraindicated in certain 
subgroups 1,88-91. In New Zealand both clopidogrel and ticagrelor are funded by 
PHARMAC for patients who have experienced an ACS event 101,102. Prasugrel is only 
available funded for patients who have received PCI and have a clopidogrel allergy, or 
who have had stent thrombosis while on clopidogrel in New Zealand, and this therefore 
limits its accessibility to a large degree 103,104.    
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1.2 Atrial Fibrillation 
Atrial Fibrillation (AF) is the most commonly sustained arrhythmia and is characterised 
by a loss of coordinated atrial systole with irregular ventricular response. Chaotic 
electrical impulses in the atria, as a result of re-entry circuits and enhanced automaticity, 
overwhelm the AV node and result in irregular ventricular depolarisation. The rate of 
ventricular response is dependent on the rate at which atrial electrical impulses are 
generated, and the conduction and refractory properties of the AV node. The various 
categories of AF are defined by duration (Table 1-3). Patients with AF may be 
asymptomatic but when cardiac output is sufficiently reduced, clinical manifestations 
including fatigue, palpitations, hypotension, dyspnoea, syncope and heart failure 
manifest. However, the most well-established health risk for patients with AF is risk of 
thromboembolic stroke 105.     
 
Table 1-3 Definitions of AF 
Paroxysmal AF AF that terminates spontaneously or with 
intervention within 7 days of onset. 
Episodes may recur with variable frequency. 
Persistent AF Continuous AF that is sustained for greater than 
7 days. 
Long-standing persistent AF Continuous AF greater than 12 months in 
duration 
Permanent AF This term is used when the patient and clinician 
make a joint decision to stop further attempts to 






It is generally accepted that the mechanisms that cause AF are not completely 
understood and as such AF is a phenotype which represents diverse pathophysiological 
processes. Abnormal impulse formation occurs when electrophysiological and structural 
abnormalities cause alterations to atrial tissue, and the mechanisms that initiate and 
sustain this are multifactorial.  Electrophysiological abnormalities that trigger AF are 
complex and it is likely that multiple factors are present in any given patient.  Structural 
abnormalities that sustain AF most commonly occur in the setting of heart disease. 
Conditions such as heart failure, hypertension, CAD, valvular heart disease and 
cardiomyopathies result in increases in left atrial pressure, which over time cause atrial 
dilation, inflammation, fibrosis and hypertrophy. Infiltrative diseases such as 
amyloidosis, sarcoidosis and hemochromatosis also contribute to structural changes 
that promote AF 106.  
 
1.2.2 Burden of Atrial Fibrillation 
The prevalence of AF increases with age and ranges from 1% in those under 60 years of 
age to 9% in those over 80 107. The incidence of AF is expected to rise over time in part 
due to better detection strategies 108-110 but mostly due to the fact that the populations 
mean age is increasing 111, with numbers expected to increase 2.5-fold by 2050 112. AF is 
independently associated with a 2-fold increase in all-cause mortality for women and 
1.5-fold for men, particularly cardiovascular death. In addition, AF is independently 
associated with increased morbidity from heart failure, reduced quality of life, longer 
hospitalisations, cognitive decline, but for the most part morbidity from stroke.  The risk 
of stroke in patients with AF is 5-fold that of the general population and strokes are more 
often fatal. When AF patients survive stroke they experience greater disability, have 





1.2.3 Mechanisms of stroke in atrial fibrillation 
The processes that contribute to thrombus formation in an AF patient reflect the criteria 
of Virchow’s triad of thrombogenesis: 1) structural abnormalities and endothelial 
damage; 2) abnormal blood stasis; 3) abnormal blood constituents 114. 
1.2.3.1 Prothrombotic atrial anatomy 
The left atrial appendage (LAA) is the most common site of intra-atrial thrombus 
formation 115,116 and this is due to its long, tubular and hooked morphology which 
promotes blood stasis in the absence of coordinated atrial contraction. In contrast the 
right atrial appendage is broad and triangular 117.   Endothelial damage seen in the atria 
and LAA of AF patients has been well described and results in haemostatic disruption. 
This in turn contributes to thrombus formation by mediation of hypercoagulable state 
through the release of prothrombotic and proinflammatory molecules 118. There is also 
evidence of AF impairing extracellular matrix degradation 119 which in addition to 
perpetuating the AF cycle (through promotion of fibrosis and infiltration) is itself a 
promotor of thrombosis 28.     
1.2.3.2 Abnormal blood stasis 
Blood stasis in the setting of AF not only occurs due to loss of atrial systole but also due 
to the progression of left atrial dilatation. Left atrial dilatation is a key factor in 
thrombogenesis as left atrial size, once corrected for body surface area, is independently 
associated with stroke risk 120,121.     
1.2.3.3 Abnormal blood constituents  
It has been well documented that AF is associated with a hypercoagulable state as 
demonstrated by high levels of plasma fibrinogen, von Willebrand’s factor and fibrin D-
dimer 122-125. Other prothrombotic factors including prothrombin fragments 1 and 2 and 
thrombin-antithrombin complexes are significantly higher in stroke patients with AF 
when compared to stroke patients with normal sinus rhythm 126, and these elevated 
levels persist in the absence of stroke when AF patients and healthy subjects are 
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compared 127. Associations between various prothrombotic factors and thrombus 
formation have also been described. D-dimer and von Willebrand’s factor have been 
shown to independently predict LAA thrombi on transoesophageal echocardiography 
128,129. Markers of platelet activation (platelet factor 4 and beta-thromboglobulin) are 
also significantly higher in AF patients when compared to controls 127. 
 
1.2.4 History of Warfarin 
Warfarin has been the mainstay oral anticoagulant (OAC) for stroke prevention in AF 
patients for at least six decades. However the discovery of warfarin occurred by chance, 
with a fascinating set of circumstances that began in 1920s in the agricultural sectors of 
North America and Canada 130. Reports of otherwise healthy cattle dying from internal 
bleeding became frequent and no precipitating factors were apparent. This was an 
economic blow for farmers, especially with financial factors that contributed to the great 
depression also taking place. Two veterinarian scientists, Schofield and Roderick, took 
to investigating the cattle “bleeding disease”. Schofield noted that the characteristics 
appeared very similar to haemorrhagic septicaemia, however upon multiple attempts 
to establish causation, bacteria could not be found. In addition Schofield documented 
the absence of heat or pain in affected cattle which indicated the disease process was 
non-inflammatory, the absence of temperature, and the consistent presence of a weak 
and accelerated pulse 131. At the same time, repeated reports emerged of cattle in the 
same area being dehorned then dying 5-6 hours later. There was a lack of apparent 
pathogen or nutritional deficiency and therefore the diet of the livestock was examined 
with a common thread established- sweet clover silage.   
Schofield and Roderick performed a basic experiment; three calves each fed for several 
weeks with hay, spoiled sweet clover and normal sweet clover respectively, before 
castration surgery was performed. The calf fed spoiled sweet clover died within hours 
of surgery while the other two made a healthy recovery 131.  Sweet clover has a coumarin 
content that gives it a distinct sweet smell. Its use as silage was widespread in the 1920’s 
and a series of wet summers led to improper curing and storage. The sweet clover 
29 
 
became soiled with mould, however the economy of the time left farmers with little 
choice but to feed out the compromised silage; in more prosperous times silage of this 
quality would have been discarded. It was later discovered that certain moulds 
metabolised the coumarin into toxic dicoumarol – a potent vitamin K antagonist (VKA). 
By 1931 the pair had established that the disease now known as “sweet clover disease” 
was due to a plasma prothrombin defect but the biochemical agent was still 
unbeknownst 132.  
In 1932, a decade after the first outbreak of haemorrhagic disease Professor Karl Link of 
the Wisconsin Alumni Research Foundation was unexpectedly confronted by an 
exasperated farmer one Saturday morning. As the story goes Link was the only person 
on site in the biochemistry lab when the farmer delivered a dead heifer, a can of 
unclotted blood, and 100 pounds of spoiled sweet clover, the only fodder he could 
afford. The farmer was frustrated with the repeated death of his stock and was reluctant 
to believe sweet clover, a silage that had been used for generations, could be the cause.  
Over the next six years Link, alongside one of his PhD students Mark Stahmann, set out 
to isolate the active principal in spoiled sweet clover, and through the use of an in-vitro 
clotting assay of rabbit plasma the pair isolated dicoumarol 133. Dicoumarol was found 
to have a similar structure to vitamin K and when consumed by livestock inhibited 
vitamin K production, a necessity for the activation of prothrombin to thrombin and 
therefore clot formation. Link and colleagues also demonstrated that effects of 
dicoumarol in rabbits could be reversed by the administration of vitamin K, however it 
would be many years before the relationship between clotting time, dicoumarol and 
vitamin K were completely understood. Shortly after the chemical structure of 
dicoumarol was identified, synthesis of the compound saw it released into medical 
practice by 1941 134.  
 
1.2.4.1 Dicoumarol to warfarin  
Despite the novelty of being the first anticoagulant to treat thrombosis in humans, 
dicoumarol had many limitations. Dicoumarol’s narrow therapeutic window exposed 
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patients to abnormal rates of bleeding; and this was compounded by its 12-24-hour lag 
phase, long excretion time, and the cumulative effect of repeated administration. Link 
was suspicious that if not used properly dicoumarol administration was risky, and his 
concerns were justified as the anticoagulant gained a reputation of being dangerous due 
to episodes of uncontrolled bleeding.  After a decade of fine-tuning through the 
development of vitamin K ready antidotes, and, through the thorough assessment of 
patient kidney and liver function, vitamin K status and prothrombin clotting time, 
dicoumarol remained the anticoagulant of choice until the mid-1950s 134.    
In 1945 whilst staying in a sanatorium due to tuberculosis Link had the idea to use a 
coumarin derivative as a rodenticide.  Believing dicoumarol would be a poor rodenticide 
due to its slow mechanism of action and the ability of rats to achieve a high vitamin K 
diet through natural grains, Link set out to find an analogue of dicoumarol, from the 150 
compounds synthesised during the 1930s with his then PhD student Stahmann. Link 
selected the particularly active and more potent compound number 42, which was later 
named warfarin, “WARF” after the funding body (Wisconsin Alumni Research 
Foundation) and “-arin” after coumarin.   Unlike dicoumarol warfarin was potent enough 
to kill rats despite the simultaneous ingestion of regular amounts of vitamin K, and in 
1948 was first promoted as rat poison 132,135.  
 
1.2.4.2 Therapeutic warfarin use in humans 
Although warfarin toxicity and effectiveness had been studied extensively on various 
animals its application for use as an anticoagulant in humans was still unknown. 
However, in 1951 a then 22-year old army inductee attempted suicide through repeated 
warfarin ingestion over six days. The patient presented to hospital with severe flank 
(kidney) pain, generalised abdominal tenderness and a history of intermittent epistaxes.  
Over 48 hours the patient was transfused with whole blood and administered 
intravenous vitamin K. After 5 days it was considered that the patient had made a full 
recovery and this became the catalyst for investigations into warfarin therapy for 
humans 136.  
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Subsequent studies concluded that warfarin was more favourable than dicoumarol as it 
possessed a higher degree of predictability, ease of control, faster onset of action and 
increased safety due to its prompt counteraction by high dose vitamin K. Further, 
warfarin could achieve the desired therapeutic effect at a dose approximately one fifth 
that of dicoumarol and with all other things being equal this quality alone demonstrated 
its superiority 137,138. It is now well established that warfarin works by inhibiting the 
epoxide reductase enzyme which impedes the vitamin K oxidation-reduction reaction, 
thereby attenuating carboxylase production (Figure 1-3).  The coagulation factors II, IX 
and X, prothrombin, as well as other regulatory factors require carboxylation for their 
pro-coagulant activity and therefore with warfarin administration the coagulation 
factors are produced, but have decreased functionality due to under-carboxylation 139. 
Therapeutic use of warfarin must be monitored, and doses adjusted accordingly. 
Specifically a measure of the patients’ prothrombin time is standardised to an 




Figure 1-3 Warfarin mechanism of action 
Warfarin antagonises epoxide reductase which impedes the vitamin K oxidation-reduction 
reaction. This results in decreased carboxylase production which is required to convert 
inactive coagulation factors (prothrombin, FVII, FIX and FX) to an active form. Figure 
reproduced with permission from the rights holder, Wolters Kluwer Health Inc. 141. 
 
1.2.5 Warfarin for stroke prevention: the evidence 
The late 1980s and 1990s was an era where the implications of thromboembolism for 
patients with AF became explicitly evident. The Framingham study published results in 
1991 demonstrating that after following patients for 34 years, AF patients had a 5-fold 
increased chance of stroke when compared to patients without (p<0.001) 105 and this 
fact is consistently referenced within AF literature.  At the same time results of RCTs 
examining anticoagulation with warfarin versus placebo for stroke prevention in AF 
emerged. During this period, it was still ethically appropriate to perform comparisons of 
warfarin with placebo, and overwhelming these studies demonstrated benefit from 
warfarin therapy for the prevention of stroke in patients with AF (Table 1-4). There was 
an associated increase in the rate of major and minor bleeding with warfarin also. Some 
of these trials, AFASAK (Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation 
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Study), SPAF I (Stroke Prevention in Atrial Fibrillation) and EAFT, also compared aspirin 
versus placebo but results were less convincing, with only SPAF I showing a non-
significant trend in favour of aspirin over placebo. A specialised review of these RCTs in 
1996 concluded that for the prevention of TIA and stroke, AF patients with any clinical 
risk factors including hypertension, age over 75 years, diabetes mellitus or previous 
stroke/TIA, should be administered dose-adjusted warfarin with a target INR of 2.0-3.0, 
and that aspirin is ineffective 142.  
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Table 1-4 Warfarin for stroke prevention: randomised placebo-controlled trials 
Trial Patient cohort Intervention Mean 
follow-up 






Warfarin (INR 2.8-4.2) 
vs.  
placebo 
2 years Embolic events per year lower in the 
warfarin arm  
(2% vs. 5.5%, p<0.05).  













86% RR reduction of stroke in 
warfarin arm  
(0.41% vs. 2.98%, p<0.002) 
No significant difference in major 
bleeding. Warfarin resulted in a 1.6-











1.3 years 67% RR reduction in annual rate of 
ischaemic stroke or systemic 
embolism in warfarin arm 
(2.3% vs. 7.4%, p=0.01) 













Terminated early due to AFASAK and 
SPAF I results: non-significant 37 % RR 
reduction in stroke or systemic 
embolism with warfarin 








(n = 571) 






Stroke rate per year significantly 
lower with warfarin  
(0.9% vs. 4.4%, p=0.001) 
No difference detected with respect 
to major bleeding. Significant increase 
in minor bleeding with warfarin 




AF with recent 
TIA/stroke 
(n=1007) 
Warfarin (INR 2.5-4)  
vs. 
placebo 
2.3 years 62% RR reduction of stroke in 
warfarin arm  
Major bleeds  
Warfarin: 2.8% 
Placebo: 0.7% 
AF= atrial fibrillation; INR = international normalised ratio; RR = relative risk; TIA = transient ischaemic attack; ᵻ indicates aspirin versus placebo also examined in trial (results not shown).  
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1.2.5.1 Stroke prevention with warfarin and aspirin 
Once the efficacy of warfarin had been established, further research was conducted to 
see if the additive effects of aspirin were beneficial. It was hypothesised that low-
intensity, fixed-dose warfarin and aspirin (300-325mg/day) would exert sufficient 
efficacy but with less haemorrhagic side effects when compared to adjusted-dose 
warfarin (INR 2.0-3.0).  In addition, this newer therapy would reduce the need for 
medical monitoring and overall be an easier regimen to follow. However the findings of 
AFASAK-2 149 and SPAF III 150 which both examined this hypothesis found that dose-
adjusted warfarin was the superior therapeutic option, and thus a low-dose warfarin 
plus aspirin therapy for stroke prevention was short lived. 
 
1.2.5.2 Meta- analysis of warfarin data 
In 2007 a seminal meta-analysis conducted by Hart et al 151 convincingly established the 
efficacy of warfarin for the prevention of stroke in AF patients, despite its use over 
previous decades. One of the contributory factors that gave the meta-analysis authority 
was due to the inclusion of the valuable warfarin-placebo trials discussed earlier. The 
results showed that compared with placebo, dose-adjusted warfarin resulted in a 64% 
relative risk reduction of stroke (Figure 1-4). By comparison, antiplatelet therapy 
(predominantly aspirin) reduced stroke by only 22%. Direct warfarin-antiplatelet 
comparisons were also conducted and demonstrated that warfarin was superior, with a 
significant 37% relative risk reduction in stroke events (Figure 1-5). The meta-analysis 
also reported that the risk of major bleeding on warfarin was double that of antiplatelet 
therapy, but the study concluded that this was acceptable given that absolute rates of 
these adverse events were only 0.2% per year.   The implication of this study was that 
additional trials were unlikely to change current estimates of warfarin; that is, for stroke 




Figure 1-4 Meta-analysis: warfarin versus placebo for stroke prevention 
Adjusted-dose warfarin compared with placebo in six randomised trials. Treatment with 
warfarin resulted in a 64% (95% CI, 49% to 74%) relative risk reduction in stroke. Horizontal lines 





Figure 1-5 Meta-analysis results: warfarin versus antiplatelet for stroke 
prevention 
Adjusted-dose warfarin compared with antiplatelet agents in 11 randomised trials. Treatment 
with warfarin resulted in a 37% (95% CI, 23% to 48%) relative risk reduction in stroke. Horizontal 
lines represent 95% confidence intervals around point estimates. Reproduced from Hart et al 




1.2.6 Stroke risk stratification tools 
Given there is risk associated with oral anticoagulation, predominantly an increased risk 
of bleeding, is sensible to establish who will benefit from such therapy. Risk stratification 
tools are a method in which clinicians can perform stroke risk assessment and to date 
there have been over twelve schemas published with variable predictability and 
performance 152-154.  
In current times none has been more widely accepted and utilised than the 
CHA2DS2VASc stroke risk assessment tool 155. The CHA2DS2VASc schema was developed 
in 2009 and demonstrated modest predictive ability (c-statistic 0.606) in its derivation 
cohort. The components of CHA2DS2VASc can be seen in Table 1-5 and stratify patients 
as low, intermediate or high risk of stroke. Prior to CHA2DS2VASc the CHADS2 score, 
which was validated in 2001, was commonly used, and differed from the former as it did 
not include the risk factors of age (65-74 years), vascular disease and female sex 156. In 
the most recent comparative analyses CHA2DS2VASc performed with similar predictive 
ability when compared with eight other risk stratification tools including its predecessor 
CHADS2, however it demonstrated superiority over other scores when identifying those 
patients at low-risk of stroke 157. There is consensus that a patient at low risk of stroke 
does not require oral anticoagulation and therefore the CHA2DS2VASc score carries the 
advantage of identifying these patients with greater accuracy, therefore reducing the 
risk of bleeding that would have been received through oral anticoagulation 
administration. What’s more, the CHA2DS2VASc schema does not differ depending on 
the type of non-valvular AF being assessed (paroxysmal, persistent or permanent), 
although there is a reasonable argument that stroke risk is not equal across these groups 
158. These factors have seen the CHA2DS2VASc schema adopted into guideline 




Table 1-5 CHAD2S2VASc schema 
Predictor Score Stroke risk (points) 
Congestive heart failure 1  
 
Low risk (0) 
 
Intermediate risk (1) 
 




Age >75 years 2 
Diabetes mellitus 1 
Stroke/TIA/embolism history 2 
Vascular disease 1 
Age 65-74 years 1 
Sex category female 1 
Max total 9 
 
 
1.2.7 Limitations of warfarin 
There are many limitations associated with warfarin use.  Some commentators believe 
that if invented today, warfarin would not be adopted into clinical practice.  The main 
adverse effect of warfarin is of course bleeding, and this is closely related to the 
pharmacodynamics of warfarin and its dosing. Warfarin has a very narrow therapeutic 
index and maintaining this can be problematic. This is partly due to high interpatient 
variability in its dose-response relationship 159, but also because the measurement of 
INR is invasively obtained via a blood test, and also has innate factors that may 
contribute to erroneous readings 160. This monitoring also comes at financial cost to 
health providers. Interpatient variability may be due to genetic factors including 
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impaired ability to metabolise warfarin (mutations in CYP2C9 gene) that lead to 
decreased elimination, and, mutations in the gene responsible for the epoxide reductase 
enzyme that leads to varying levels of inhibition by warfarin.    
Warfarin, being a VKA is also highly susceptible to drug-drug and food-drug interactions. 
The Bristol-Myers Squibb produced patient information sheet lists 165 drugs and 29 
natural remedies that interact with warfarin 161. Some drugs can reduce the absorption 
of warfarin (e.g. cholestyramine), some increase clearance (e.g. barbiturates) while 
others potentiate effects by inhibiting warfarin’s clearance (e.g. sulfinpyrazone or 
amiodarone). In a similar fashion the pharmacodynamics of warfarin may be affected by 
drugs that interfere with the cyclic interconversion of vitamin K (e.g. antibiotics).  
Fluctuating levels of dietary vitamin K predominantly derived from plant material also 
has implications; high dietary vitamin K will reduce response to warfarin while low 
dietary vitamin K will potentiate effects.  Long term alcohol consumption may also 
increase warfarin clearance.  In summary, although warfarin shows good efficacy for 
stroke prevention is not an easy drug to use. Bleeding is a common side effect, frequent 
and invasive monitoring is required, there is high interpatient variability and numerous 
food and drug interactions. For these reasons it is easy to appreciate why warfarin is the 
third most common drug (behind non-steroidal anti-inflammatory drugs and diuretics) 
to cause hospital admission through adverse effects 162,163. Despite these limitations 
warfarin remains the reference standard treatment for patients with AF and risk factors 
for stroke.  
 
1.2.8 Non-vitamin K oral anticoagulants 
In more recent time the development of non-vitamin K oral anticoagulants (NOACs), also 
known as novel oral anticoagulants, has provided alternative options for the prevention 
of thromboembolism. Through direct targeting of key coagulation factors such as 
activated thrombin and factor Xa (Figure 1-6), NOACs can inhibit clot formation without 
the need for frequent INR monitoring, dose adjustments and the excess food and drug 
interactions when compared with warfarin. Therefore, NOACs also have a more user-
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friendly profile which is important given its use for chronic AF.  In New Zealand to date 
three NOAC dugs have been approved for use in AF; dabigatran, a direct thrombin 
inhibitor, and apixaban and rivaroxaban, both factor Xa inhibitors. Phase III RCTs have 




Figure 1-6 NOAC agents and their targets in the coagulation cascade 
Dabigatran is a direct thrombin inhibitor; thrombin is required for the conversion of fibrinogen 
to fibrin. Apixaban and rivaroxaban are factor Xa inhibitors; factor Xa is required for the 






In the RE-LY RCT (Randomized Evaluation of Long-Term Anticoagulation Therapy), 
dabigatran at two doses, 110mg and 150mg, were compared to warfarin with a primary 
endpoint of stroke or systemic embolism in 18,113 AF patients at risk of stroke (defined 
as previous stroke or TIA, heart failure [New York Heart Association class II or higher], 
≥75 years of age, or 65-74 years with diabetes, hypertension or CAD). The 110mg dose 
of dabigatran was associated with annual rates of stroke and systemic embolism similar 
to that of warfarin (1.53% vs. 1.69%, p=0.34), but with significantly less major bleeding 
(2.71% vs. 3.36%, p=0.003). The 150mg dose of dabigatran was associated with 
significantly less stroke or systemic embolism (1.11% vs. 1.69%, p<0.001) and similar 
major bleeding rates (3.11% vs. 3.36%, p=0.31). In addition, rates of life-threatening 
bleeding and intracranial bleeding were significantly higher in the warfarin arm when 
compared to both doses of dabigatran (p<0.05 for all comparisons) 164.  
 
1.2.8.2 Apixaban 
The factor Xa inhibitor apixaban was compared to warfarin in the ARISTOTLE RCT 
(Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial 
Fibrillation) 165.  The primary endpoint of stroke or systemic embolism was examined in 
a cohort of 18,201 patients with AF, who were randomly assigned to receive either 
apixaban (5mg, twice daily) or warfarin, over a median follow up period of 1.8 years. To 
be eligible for inclusion AF patients had to have at least one additional risk factor for 
stroke defined as ≥75 years of age, previous stroke/TIA/systemic embolism, heart 
failure, diabetes or medicated hypertension. Results were overwhelmingly in favour of 
apixaban with the NOAC demonstrating less stroke or systemic embolism (1.27% vs. 
1.60%, p<0.001 for non-inferiority; p=0.01 for superiority), less major bleeding (2.13% 






Rivaroxaban was also compared to warfarin for non-inferiority, for the prevention of 
stroke and systemic embolism, in the ROCKET AF trial (The Rivaroxaban Once Daily Oral 
Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of 
Stroke and Embolism Trial in Atrial Fibrillation) 166. In this study 14,264 AF patients at 
moderate to high risk of stroke (CHADS2 score of 2 or more) were randomly assigned to 
receive either 20mg of rivaroxaban daily or warfarin. Rivaroxaban was found to be non-
inferior to warfarin with one-year rates of stroke or systemic embolism similar across 
both groups (rivaroxaban 1.7% vs. warfarin 2.2%, p<0.001 for non-inferiority). There was 
no difference detected with regard to one-year rates of major or non-major clinically 
relevant bleeding (rivaroxaban 14.9% vs. warfarin 14.5%, p=0.44), however rivaroxaban 
resulted in significantly fewer intracranial and fatal bleeds (0.5% vs. 0.7%, p=0.02; 0.2% 
vs. 0.5%, p=0.003, respectively). 
On the basis of these trials a 2013 meta-analysis concluded that for patients with non-
valvular AF, NOACs decrease stroke or systemic embolism (odds ratio 0.82, 0.74-0.91, 
p<0.001) (Figure 1-7), hemorrhagic stroke (odds ratio 0.44, 0.30-0.66, p<0.001) and 
mortality (odds ratio 0.88, 0.82-0.95, p=0.001), and demonstrate similar risk of major 
bleeding compared to warfarin (odds ratio 0.85, 0.69-1.05, p=0.14) (Figure 1-8)167. The 
authors concluded that NOACs approved by regulatory bodies should be the first-line 
therapies used for the antithrombotic management of patients with AF. In New Zealand 




Figure 1-7 NOACs versus warfarin meta-analysis: stroke or systemic embolism 
Effect of NOACs versus warfarin on the primary endpoint of stroke or systemic embolism. The RE-LY trial examined dabigatran, the ROCKET AF trial 




Figure 1-8 NOACs versus warfarin meta-analysis: major bleeding 
Effect of NOACs versus warfarin on the safety endpoint of major bleeding. The RE-LY trial examined dabigatran, the ROCKET AF trial examined 




1.2.9 AF guidelines 
Internationally guidelines for the prevention of stroke in AF patients are generally 
consistent, of which the AHA and ESC are predominant authority bodies. Both 
organisations have a Class I recommendation that advocates the use of the 
CHA2DS2VASc score as the risk stratification tool of choice to assess annual stroke risk. 
In brief, the 2016 ESC guidelines for thromboprophylaxis in AF patients recommend no 
therapy for patients with a CHA2DS2VASc score of 0, consideration of OAC therapy for 
patients with a CHA2DS2VASc score of 1, and OAC therapy for those with a CHA2DS2VASc 
score of 2 or more, with OAC being in the form of VKA or NOAC. The exception to this is 
if the patient’s only risk factor is female gender (CHA2DS2VASc = 1), then they would also 
benefit from no therapy. The ESC continues that high bleeding risk is not reason enough 
to withhold anticoagulation, instead reversible factors contributing to bleeding risk 
should be corrected113. The 2014 AHA guidelines are subtly different; for patients with 
a CHA2DS2VASc score of 1 they suggest no therapy or aspirin or OAC therapy, however 
this is based on weak evidence (level of evidence C)106. In contrast the ESC explicitly state 
that antiplatelet therapy cannot be recommended for stroke prevention due to it 
possessing similar bleeding risk to OAC therapy, but without the corresponding 
reduction in stroke events. New Zealand does not publish an AF guideline but are largely 
influenced by the ESC and AHA.  In summary all patients with a CHA2DS2VASc score of 
two or more, and some with a CHA2DS2VASc score of 1, are indicated to receive VKA or 




1.3 ACS patients with AF 
Patients who experience an ACS and have medical history of AF are high risk and difficult 
to manage; they tend to be older, have more co morbidities and worse outcomes 106. In 
acute MI populations up to 21% of patients will have AF 169 and approximately 30% of 
all AF patients have vascular disease 170,171.  In the SNAPSHOT study from Australia and 
New Zealand 15% of those presenting with ACS patients were found to have a prior 
history of AF 172. With the incidence of AF expected to rise overtime the absolute 
numbers of patients with AF who also experience an ACS will likely grow.  
For AF and ACS, the recommended therapy for each condition is well validated, OAC and 
DAPT respectively. However, this rich evidence base falls away when AF and ACS are 
combined. Further, OAC therapy and DAPT are each alone insufficient protection for this 
patient group as established in earlier trials. In brief, OAC therapy with warfarin is 
superior to DAPT (aspirin and clopidogrel) for the prevention of stroke and systemic 
embolisation in AF patients173, whilst DAPT is superior to OAC therapy for the prevention 
of recurrent cardiovascular events in patients presenting with ACS or managed with 
PCI174,175. Therefore, the combination of DAPT and OAC, known as triple therapy (TT), in 
theory seems a logical solution for the treatment of ACS patients with AF as it provides 
both atherothrombotic and thromboembolic protection. However, to date no RCTs have 
been conducted that have specifically addressed optimal therapy for this patient group. 
This is also complicated by the fact that any protection achieved from TT is likely 
counter-balanced by an increased risk of bleeding176. 
Defining optimal medical therapy for ACS patients with AF is further complicated by the 
variety of drugs that can constitute triple therapy and the corresponding lack of clinical 
trials.  VKAs, particularly warfarin, have traditionally been the OAC of choice, but the 
recently developed NOACs have shown superiority with regard to patient convenience 
and efficacy with no increase in bleeding events164-166,177. For the treatment of ACS, 
aspirin and clopidogrel have been standard of care, but the introduction of the newer 
P2Y12 receptor antagonists, such as prasugrel and ticagrelor, have added complexity to 
DAPT in the context of TT. There have been a small number of trials assessing TT for the 
treatment of ACS to assess whether it was superior to DAPT at reducing ischaemic 
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events, and these have yielded unfavourable results largely due to significant increases 
in bleeding risk, 178-181 however these findings are not necessarily applicable to AF 
patients, and their unique antithrombotic requirements. 
 
1.3.1 Guidelines for the treatment of ACS patients with AF 
Guidance for the treatment of ACS patients with AF can be found in publications from 
different international societal bodies, and in each case the lack of evidence to guide 
recommendations is acknowledged. The trade-off between protection from ischaemic 
events and bleeding risk is always a key factor and no evidence based consensus is made 
across the different publications. 
It is a challenge to synthesis the information across guideline and consensus documents 
due to their differing content. However, in general, the notion is that an ACS patient 
with AF is identified as either having high risk of stroke or low risk of stroke and treated 
accordingly. A patient with high stroke risk is believed to receive benefit from TT (of a 
variable duration) before transitioning to OAC and single antiplatelet. On the other 
hand, a patient at low risk of stroke does not require OAC therapy and is believed to 
receive benefit from DAPT alone. Overarching this is the belief that an ACS patient with 
AF who has unacceptably high bleeding risk would most likely benefit from DAPT. OAC 






Figure 1-9 Schematic summary of guidelines for ACS patients with AF 
Schematic shows generalised decision process as per clinical guidelines for the discharge 
management of ACS patients with AF.  
AP = single antiplatelet agent; DAPT = dual antiplatelet therapy; OAC = oral anticoagulant; TT = triple therapy. 
 
What is not consistent is how these patients (high stroke risk, low stroke risk and 
unacceptable bleeding risk) are identified (Table 1-6). The most recent American 
perspective for AF patients undergoing PCI does not put forward risk stratification tools 
to assess stroke and bleeding risk, but rather refers to a patient’s ratio of risk, without 
providing definition. For example, a patient deemed at high thrombotic risk/low 
bleeding risk is suggested to receive TT for 3-6 months 182. However, methods to quantify 
patient risk are not prescribed. Currently the AHA guideline for AF refers to 
CHA2DS2VASc to assess stroke risk, and suggests that those with a score of 2 or more 
should receive TT with warfarin (but not the newer NOACs), although duration is not 
defined (Level of Evidence C)106. In addition the AHA guidelines for NSTEACS 88 and 
STEMI 89 suggest that if TT is used, then therapy should be administered for as shorter 
duration as possible.  None of the American based guidelines define bleeding risk.  
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The Canadian Cardiac Society’s AF recommendations are different again and use a novel 
tool to assess stroke risk in the context of AF patients with NSTEACS or STEMI; High 
stroke risk is defined as age > 65 years or CHADS2 ≥1, whereas low stroke risk is defined 
as age <65 years and a CHADS2 score of 0. Utilising this schema some ACS patients with 
AF could indeed have a CHADS2 score of 0 as vascular disease is not a component of this 
score. Patients at high risk of stroke are suggested to receive 3-6 months of TT. 
Consistent with the above no explicit detail is provided regarding bleeding risk 183.  
In contrast the ESC consensus document for AF patients with ACS/PCI is very 
prescriptive. Stroke risk is determined using CHA2DS2VASc, with a CHA2DS2VASc of 1 an 
indication for TT, which qualifies all ACS patients given the 1 point received for vascular 
disease (as per Table 1-5). TT duration is variable and ranges from 1 to 12 months.  
Bleeding risk is defined using the HAS-BLED score (Hypertension, Abnormal renal and 
liver function, Stroke, Bleeding, Labile INRs, Elderly, Drug or Alcohol), with a score of 3 
or more being high risk 184. The ESC NSTEACS 90 are subtly different in that they refer to 
a CHA2DS2VASc score of 2 more as a consideration for TT, for as short a duration as 
possible, and this is echoed closely in the ESC STEMI guideline 91. 
New Zealand guidelines regarding the ACS patient with AF are very brief. There is not a 
dedicated consensus document, but rather scant details can be found in NSTEACS 185 
and STEMI 186 guidelines.  The NSTEACS guidelines put forward that TT consisting of 
aspirin, P2Y12 inhibitor (not prasugrel) and OAC, should be used for as short a period as 
possible but do not provide details as to the patient characteristics or level of risk this 
recommendation would apply to. The STEMI guidelines outlines TT for 1 month, 
followed by cessation of aspirin if long-term oral anticoagulation is indicated, e.g. 
CHA2DS2VASc  score of 2 (Level of Evidence C). Once again bleeding risk is not adequately 
detailed.  
Finally, the Australian position which is published in their ACS guidelines suggests a  
CHA2DS2VASc score of 1 as low risk of stroke, and ≥2 as high risk of stroke, with the 
duration of TT in the latter group (ranging from 1 -6 months), dependant on their 
bleeding risk as defined by HAS-BLED score 1.   
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Table 1-6 Summary of guidelines for ACS patients with AF 
 High stroke risk 
definition 
Suggested 




guidelines (incl. AHA) 
Not defined 3-6 months Not defined 
ESC guidelines CHA2DS2VASc =1 1-12 months HAS-BLED≥3 
Canadian Cardiac 
Society guidelines 
Age > 65 years or 
CHADS2 ≥ 1 
3-6 months Not defined 
New Zealand guidelines Not defined Not defined Not defined 
Australian guidelines CHA2DS2VASc ≥2 1-6 months HAS-BLED ≥3 
  
In summary, the above guidelines demonstrate inconsistencies regarding discharge 
therapies for ACS patients with AF, and this largely centres on variations in stroke and 
bleeding risk assessment. There also appears to be discordance between publications 
from the same societies, if to a lesser extent.  Where risk stratification tools are 
suggested, that is CHA2DS2VASc, CHADS2 and HAS-BLED, these scores are validated in AF 
cohorts only and not in cohorts of ACS patients with AF, which adds further complexity 
to the matter. The implication is that there is confusion and lack of certainty regarding 
what optimal therapy is for ACS patients with AF, and indecision about which patients 





1.4 Overall aims 
This thesis aimed to explore optimal therapy for patients with a medical history of AF 
who have experienced an ACS. Such patients are at high risk of repeat events and careful 
management is required. However, a lack of sufficient evidence-based research 
combined with the numerous therapeutic agents available have resulted in confusion 
and uncertainty about how to best treat this patient group.  
Therefore, the overall aims of this thesis are: 
1. To describe discharge prescription of antiplatelet and anticoagulant therapy in 
ACS patients with AF 
2. To describe national prescription patterns of antiplatelet and anticoagulant 
therapies in ACS patients with AF 
3. To examine whether prescribed therapies for this patient group were associated 
with one-year outcomes 
4. To systematically review published literature to determine whether DAPT or TT 
is optimal therapy for ACS patients with AF 
5. To construct a decision analysis model to evaluate bleeding and stroke risk in ACS 
patients with AF 
6. To determine likely thresholds of stroke risk at which the benefits of TT may 
exceed harm from bleeding 
7. To characterise in-hospital and one-year bleeding events in a real world MI 
cohort 
8. To evaluate the ability of CRUSADE and ACTION bleeding risk scores to predict 
in-hospital and one-year bleeding events 
9. To examine whether low platelet reactivity is predictive of in-hospital and one-






2  Management of ACS patients with AF 










Publication arising from this chapter: 
Fake, A. L., Harding, S. A., Matsis, P. P. & Larsen, P. D. Pharmacological therapy following 
acute coronary syndromes in patients with atrial fibrillation: how do we balance 





The previous chapter has identified that international guidelines for the treatment of 
ACS patients with AF are inconsistent and lack clarity with regard to optimal antiplatelet 
and anticoagulant strategies. However, in general terms it is accepted that patients at 
high risk of stroke would likely be candidates for TT and those at low risk of stroke 
candidates for DAPT.  
In our local setting, New Zealand guidelines offer very limited detail as to how best treat 
ACS patients with AF. The NSTEACS guidelines briefly mention TT may be used for as 
short a period as possible, but do not offer direction as to which patients to apply this 
recommendation to. The STEMI guidelines offer little more, suggesting TT for 1 month 
after PCI in patients with a CHA2DS2VASc score of 2, but do not describe any further 
supporting detail to aid decision making. Neither guideline adequately discusses stroke 
risk or considers bleeding risk. By comparison to other guideline documents, New 
Zealand guidelines are the least prescriptive, lack detail and therefore offer little 
guidance to clinicians.   
Given this lack of detail we set out to describe current practice in prescribing 
antithrombotic therapies for ACS patients with AF, with particular focus on whether the 
use of oral anticoagulation was related to stroke or bleeding risk. 
Therefore, the aim of this study was: 
 To describe discharge prescription of antiplatelet and anticoagulant therapy in 






2.2.1 Patient enrolment 
Patients enrolled into the Wellington ACS study between January 2012 and February 
2015, who also had a recorded medical history of AF were eligible for inclusion into the 
present study. Entry criteria for the Wellington ACS study were patients presenting to 
Wellington Regional Hospital with an ACS event that had been adequately pre-treated 
with DAPT (chronic therapy or loading doses) and who required angiography; the 
Wellington ACS study was set up to examine platelet reactivity and clinical outcomes, 
hence the above enrolment criteria.  
Exclusion criteria for the Wellington ACS study and therefore the present study, were a 
platelet count ˂100 x 109/L, haemoglobin ˂100 g/L, and administration of a fibrinolytic 
agent within 24 hours prior to enrolment or glycoprotein IIb/IIIa antagonist within 1 
week prior to enrolment.  This study was approved by the Lower Regional South Ethics 
Committee (ref: LRS/11/09/035/AM01). All patients provided informed written consent 
at the time of enrolment. 
2.2.2 Data collection 
Patient demographics, clinical characteristics, clinical management, in-hospital 
outcomes and discharge information were recorded prospectively from patient medical 
records and from the cardiac catheterisation database. Clinical management, including 
discharge medication prescription was at the discretion of the attending physician.  
2.2.3 Definitions 
An ACS was defined as symptoms of myocardial ischaemia lasting > 10 minutes and 
either troponin elevation or acute electrocardiogram (ECG) changes (≥ 1mm of new ST 
segment deviation or T wave inversion in at least 2 contiguous leads).  A patient was 
deemed to have AF if they either had a documented past medical history of AF, or no 
prior AF but who were in AF at the time their pre-angiogram enrolment ECG was 
performed. Patients who had new onset AF later during their hospital admission or post-
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procedural AF were not included in this analysis. Adequate DAPT pre-treatment was 
defined as: 
 chronic therapy with aspirin (≥75mg/day) and either clopidogrel (≥75mg/day) or 
ticagrelor (90mg/bd ), or, 
 loading doses of ≥300mg aspirin (at least 2 hours prior) and either ≥300mg 
clopidogrel (at least 6 hours prior) or 180mg ticagrelor (at least 1.5 hours prior)  
Risk of stroke for AF patients was calculated on admission and at discharge (including 
index event) using the CHA2DS2VASc assessment tool 155; a score of ≥2 = high risk, 1 = 
intermediate risk and 0 = low risk (see Chapter 1, Table 1-5). Bleeding risk was calculated 
post-admission using the ACS bleeding score CRUSADE (Can Rapid risk stratification of 
Unstable angina patients Suppress Adverse outcomes with Early implementation of the 
ACC/AHA guidelines) 187; a score of ≤20 = very low risk, 21-30 = low risk, 31-40 = 
moderate risk, 41-50 = high risk and >50 = very high risk (Table 2-1). Admission 
medication was defined as the patients’ regular medication prior to index admission. 
Discharge medication was defined as the medication prescribed at the time of discharge 
from Wellington Regional Hospital.  
 
2.2.4 Statistical analysis 
Categorical variables are expressed as frequencies and percentages. Continuous 
variables are expressed as mean and standard deviation. We compared characteristics 
of AF and non-AF patients using Chi squared tests for dichotomous data and 
independent t-tests for continuous data. Use of oral anticoagulants was examined for 
dichotomous data using binary logistic regression and continuous data using 
independent t-tests. Risk scores were analysed using Spearman rank tests. For all 
statistical analyses a p-value ≤0.05 was considered significant. All statistical tests were 




Table 2-1 CRUSADE bleeding risk score 










≤20 = very low risk  
21-30 = low risk  
31-40 = moderate 
risk  
41-50 = high risk 
>50 = very high 
risk 
 
<31 9 Male 0 
31-33.9 7 Female 8 
34-36.9 3 CHF at presentation  
37-39.9 2 No 0 
≥40 0 Yes 7 
Creatinine clearance, * mL/min  Prior vascular disease**  
≤15  39 No 0 
>15-30 35 Yes 6 
>30-60 28 Diabetes mellitus  
>60-90 17 No 0 
>90-120 7 Yes 6 
>120 0   
Heart rate (bpm)  Systolic blood pressure, mmHg 
≤70 0 ≤90 10 
71-80 1 91-100 8 
81-90 3 101-120 5 
91-100 6 121-180 1 
101-110 8 181-200 3 
111-120 10 ≥201 5 
≥121 11   
    
CHF indicates congestive heart failure. 
*Creatinine clearance was estimated with the Cockcroft-Gault formula. 




2.3.1 Patient selection 
Between January 2012 and February 2015 a total of 1090 patients were enrolled into 
the Wellington ACS study. We identified 93 patients within this data set with AF, 
composed of 77 (83%) patients with a past history of AF, and 16 (17%) with no medical 
history who were in AF at the time of their enrolment ECG (Figure 2-1). 
 
Figure 2-1 Flow diagram of the patient selection process 





2.3.2 Patient characteristics 
Many characteristics of the AF cohort (n=93) differed compared to the non-AF patients 
(n=997) and this data is shown in Table 2-2.  The AF cohort was older (mean age in years 
69.8 ± 9.6 vs. 62.4 ± 11, p ˂0.001), however there was no difference seen in percentage 
female or body mass index between the two groups.  The AF cohort had significantly 
higher rates of hypertension (83% vs. 60%, p ˂0.001), diabetes (31.2% vs. 18.5%, 
p=0.003), heart failure (6.5% vs. 2.3%, p=0.018), previous stroke/TIA (12.9% vs. 6.3%, 
p=0.017) and previous MI (36.6% vs. 23.2%, p=0.004). The non-AF cohort had 
significantly more current smokers (22.7% vs. 8.6%, p=0.002) and family history of CAD 
(37.5% vs. 26.9%, p=0.04).  All AF patients were considered to have non-valvular AF as 
none had greater than mild valve disease and none had received valve replacement 
surgery.  
In the AF cohort, the predominant presenting ACS was NSTEMI (75.3%) followed by 
STEMI (18.3%) and UA (6.5%) Overall, post angiography clinical management was as 





Table 2-2 Demographics and clinical characteristics 
 ACS-AF (n=93)  
 
Total n (%) 
Non ACS-AF 
n=93 
Total n (%) 
p-value 
Demographics 
Age (year, mean ± SD) 69.8 ± 9.6 62.4 ± 11 0.001 
Female gender 29 (31.2) 298 (29.9) 0.800 
BMI (mean ± SD)  30.1 ± 5.1 29.2 ± 5.6 0.130 
Stroke risk factors 
Previous stroke/TIA 12 (12.9) 63 (6.3) 0.017 
Hypertension 77 (83) 598 (60) 0.001 
Heart failure 6 (6.5) 23 (2.3) 0.018 
Diabetes 29 (31.2) 184 (18.5) 0.003 
Vascular disease    
Previous MI  34 (36.6) 231 (23.2) 0.004 
PAD 7 (7.5) 73 (7.3) 0.940 
Cardiovascular risk factors 
Hyperlipidaemia 69 (74.2) 643 (64.5) 0.067 
Current smoker 8 (8.6) 226 (22.7) 0.002 
Angina 29 (31.2) 238 (23.9) 0.106 
Prior PCI 15 (16.1) 147 (14.7) 0.723 
Prior CABG 9 (9.7) 68 (6.8) 0.305 
Angiogram showing CAD 26 (28) 205 (20.6) 0.098 
Family history CAD 25 (26.9) 374 (37.5) 0.040 
 
ACS-AF = acute coronary syndrome patients with atrial fibrillation; BMI = body mass index; CABG = coronary 
artery bypass graft; CAD = coronary artery disease; MI = myocardial infarction; PAD = peripheral artery disease; 
PCI = percutaneous coronary intervention; SD = standard deviation.  
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2.3.3 Drug therapy 
The use of OACs in the AF cohort was low. Of the patients with a known history of AF 
(n=77) a total of 15 (19.5%) patients were on an OAC at admission for the treatment of 
AF (not for any other clinical indication) and this was OAC alone in 12 (15.6%) patients, 
and an OAC-aspirin combination in 3 (3.9%) patients (Table 2-3). Admission OAC use was 
not related to risk of stroke as defined by the patients admission CHA2DS2VASc risk score 
(odds ratio = 1.3, [0.93-2], p=0.116).  
 




n = 5 (%) 
Intermediate (1) 
n = 8 (%) 
High (≥2) 
n = 64 (%) 
Total 
n = 77 (%) 
Total OAC use 0 0 15 (23.4) 15 (19.5) 
 OAC alone - - 12 (18.8) 12 (15.6) 
 OAC + aspirin - - 3 (4.7) 3 (3.9) 
 OAC + P2Y12 inhibitor - - - - 
 OAC + DAPT (TT) - - - - 
Aspirin 3 (60) 1 (12.5) 29 (45) 33 (42.9) 
DAPT 0 0 6 (9.4) 6 (7.8) 
 Aspirin + Clopidogrel - - 5 (7.8) 5 (6.5) 
 Aspirin + Ticagrelor - - 1 (1.6) 1 (1.3) 
Nil 2 (40) 7 (87.5) 14 (22) 23 (29.9) 
DAPT = dual antiplatelet therapy; OAC = oral anticoagulant; TT = triple therapy.  
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Based on admission CHA2DS2VASc calculations 6.5% of the AF cohort were at low risk of 
stroke (score of 0) and 10.4% were at intermediate risk of stroke (score of 1), and no 
OAC use was observed in either group. The remaining 83.1% were at high risk of stroke 
(score ≥2) and OAC use was seen in patients with a CHA2DS2VASc score of 2, 3, 4 and 5. 
No OAC use was observed in patients with the highest risk of stroke, in this cohort a 




Figure 2-2 Admission data: OAC use by CHA2DS2VASc score 
No OAC use was observed in patients at low (CHA2DS2VASc = 0) or intermediate (CHA2DS2VASc 
= 1) risk of stroke at admission. OAC use was observed in patients at high risk of stroke for the 
CHA2DS2VASc scores 2 through 5 were, with CHA2DS2VASc 4 patients having the highest rate 
of admission OAC prescription at 7.8%. We did not observe OAC use in the patients at highest 












































OAC use in the AF cohort at discharge (n=93) was again low with 11 patients (11.8%) 
discharged on an OAC; this was OAC alone (2 patients), OAC and aspirin (4 patients), and 
OAC and P2Y12 inhibitor (5 patients). No patient was discharged on OAC and DAPT (triple 
therapy) in this cohort (Table 2-4). Discharge OAC use was not related to discharge 
CHA2DS2VASc score, nor to any other clinical characteristic. However, discharge on an 
OAC was more likely in patients treated with an OAC prior to admission (odds ratio = 14, 
[3.4 – 58], p ˂ 0.001) (Table 2-5).  Of the 15 patients admitted on an OAC, 7 remained on 
an OAC at discharge.  
 




n = 0 (%) 
Intermediate (1) 
n = 6 (%) 
High (≥2) 
n = 87 (%) 
Total 
n = 93 (%) 
Total OAC use 0 0 11 (12.7) 11 (11.8) 
 OAC alone - - 2 (2.3) 2 (2.2) 
 OAC + aspirin - - 4 (4.6) 4 (4.3) 
 OAC + P2Y12 inhibitor - - 5 (5.7) 5 (5.4) 
 OAC + DAPT (TT) - - - - 
Aspirin 0 1 (16.7) 13 (15) 14 (15.1) 
Clopidogrel 0 0 1 (1.1) 1 (1.1) 
DAPT 0 5 (83.3) 62 (71.3) 67 (72) 
 Aspirin + Clopidogrel - 5 (83.3) 55 (63.2) 60 (65) 
 Aspirin + Ticagrelor - - 7 (8) 7 (7.5) 
DAPT = dual antiplatelet therapy; OAC = oral anticoagulant; TT = triple therapy. 
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Table 2-5 Odds ratios for being discharged on an OAC 
 Odds ratio 95% CI p-value 
Demographics    
Age 1.06 0.98 – 1.15 0.16 
Female gender 0.81 0.20 – 3.30 0.77 
Risk factors    
Previous stroke/TIA 0.65 0.08 – 5.55 0.69 
Hypertension 1.17 0.97 – 1.28 0.19 
Heart failure 1.54 0.16 – 14.55 0.71 
Diabetes 1.3 0.35 – 4.86 0.69 
Vascular disease 0.87 0.8 – 1.05 0.31 
Hyperlipidaemia 0.65 0.33 -8.24 0.54 
Current smoker 1.07 0.12 – 9.64 0.95 
History of angina 0.75 0.19 – 3.24 0.75 
Clinical characteristics    
STEMI 0.41 0.05 – 3.46 0.42 
NSTEMI 1.65 0.33 – 8.24 0.54 
Unstable angina 1.54 0.16 – 14.55 0.71 
OAC on admission 14 3.4 - 58 <0.001 
Discharge CHA2DS2VASc  1.27 0.83 – 1.94 0.28 
Discharge CRUSADE score 1.01 0.96 - 1.05 0.82 
Clinical management    
Medical management 2.35 0.64 – 8.66 0.20 
PCI 0.23 0.05 – 1.15 0.07 
CABG 2.40 0.43 – 13.26 0.32 
BMI = body mass index; CABG = coronary artery bypass graft; CAD = coronary artery disease; MI = myocardial infarction; NTEMI = 
non ST-segment elevation myocardial infarction; OAC= oral anticoagulant; PCI = percutaneous coronary intervention; STEMI = ST-
segment elevation myocardial infarction; TIA = transient ischaemic attack.
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At discharge CHA2DS2VASc calculations included the index event and therefore no 
patient was at low risk of stroke, while 6.5% of patients were at intermediate risk of 
stroke and 93.5% at high risk of stroke. Discharge OAC use was observed in high risk 
patients only (CHA2DS2VASc ≥2) (Figure 2-3). The clinical management of each patient, 
be it medical therapy, PCI or CABG surgery, was not associated with the discharge use 




Figure 2-3 Discharge data: OAC use by CHA2DS2VASc score 
At discharge OAC use was observed in high risk patients only (CHA2DS2VASc ≥2). No OAC use was 
observed in the patients at highest risk of stroke (CHA2DS2VASc =7). Overall OAC use at discharge 











































Of the patients admitted on an anticoagulant (n = 15) this was warfarin in 10 (66%) 
patients and dabigatran in 5 (33%) patients. For patients prescribed an anticoagulant at 
discharge (n = 11) this was warfarin in 9 (82%) patients and dabigatran in 2 (18%) 
patients.  
At discharge DAPT was the most common treatment regime. A total of 67 (72%) patients 
in this cohort were discharged on DAPT, 83.3% of intermediate risk patients and 71.3% 
of high risk patients (Table 2-4).  
 
2.3.4 Bleeding risk 
CRUSADE bleeding scores were calculated for each AF patient after the index admission. 
Figure 2-4 shows a significant relationship between CRUSADE bleeding score and 
CHA2DS2VASc score; that is, as risk of bleeding increases so does risk of stroke (r = 0.683, 
p = 0.01). Numerically this relationship is evident in Table 2-6 where all patients who are 
at moderate (22, 23.7%) or high/very high (21, 22.6%) risk of bleeding were also at high 
risk of stroke. However, there was a group of patients who were at high risk of stroke 
and low/very low risk of bleeding (n=44, 47.3%), who may have been suitable candidates 
for OAC therapy (see Table 2-6). Risk of bleeding based on CRUSADE scores was not 





Figure 2-4 CRUSADE bleeding score and risk by discharge CHA2DS2VASc score 
Correlation between stroke risk (CHA2DS2VASc) and bleeding risk (CRUSADE) is statistically significant (r = 0.683, p = 0.01). A CHA2DS2VASc score of 1 
indicates intermediate risk of stroke and a CHA2DS2VASc score of 2 or more indicates high risk of stroke. 
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Table 2-6 Composite bleeding and stroke risk 
  CHA2DS2VASc risk of stroke (points) 

























High/very high (≥41) 0 0 21 
Moderate (31-41) 0 0 22 







There is limited information available about how patients with the combination of AF 
and ACS are being currently managed. There are many therapeutic options and decision 
making is complex in this group of patients. In our study of patients with ACS and AF we 
observed low use of OACs prior to hospital admission. Furthermore, OAC use at 
discharge was lower again, with DAPT being the predominant discharge regime. 
Decisions surrounding OAC use did not appear to be based on stroke or bleeding risk 
analysis, or any other identifiable clinical factors. The probability of being discharged on 
an OAC was substantially higher if the patient was on an OAC at admission.  
At the time of hospital admission, only 19.5% of patients with a known history of AF 
were on an OAC. In the group classified as high risk on the basis of CHA2DS2VASc score 
only 23% were on an OAC.  Both the AHA and the ESC recommended OAC therapy for 
AF patients with a CHA2DS2VASc score of 2 or more 106,188,189. Despite this, significant 
underutilisation of OACs in eligible AF patients has been widely reported 190-194, similar 
to that seen in our cohort. In addition, of those admitted on an OAC, most (10/15) were 
on warfarin treatment despite randomised trials demonstrating the superiority of 
NOACs when compared to warfarin therapy 164-166,177, and the availability of dabigatran 
through New Zealand government funding since 2011 168. Our study has not examined 
reasons for the low use of OACs in the AF patient group. It has previously been suggested 
that lack of knowledge of trials and guidelines, and overestimation of potential 
contraindications and risk, including fear of bleeding, may be contributory 191.   
On discharge from hospital following an ACS event we observed an even lower rate of 
OAC prescription in AF patients at high risk of stroke. In our cohort only 12% of such 
patients were prescribed an OAC. Use of an OAC was not related to stroke risk 
(CHA2DS2VASc score) or bleeding risk (CRUSADE score), nor to any other clinical 
characteristic. This is despite consensus that decisions regarding OAC therapy should be 
based on careful considerations of stroke and bleeding risk 195,196.  The only statistically 
significant factor contributing to discharge OAC prescription in our cohort was whether 
the patient was admitted on an OAC. We did identify a group of patients with high risk 
of stroke and low/very low risk of bleeding on the basis of risk scores, and in theory this 
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is the group who may have had greatest opportunity to benefit from OAC use with 
lowest risk of potential harm. When OACs were prescribed a variety of strategies were 
used, including with or without a single antiplatelet agent (aspirin or P2Y12 inhibitor). No 
triple therapy was observed in this cohort.  
DAPT was the predominant discharge regime and was prescribed to 72% of patients. 
Given that clinical guidelines advocate DAPT as best practice for post-ACS patients, and 
de-emphasize the use of OACs due to risk of bleeding, this result is not entirely surprising 
91.  While DAPT may offer some protection from stroke in AF patients, antiplatelet agents 
do not prevent the activation of coagulation factors that play a greater role in the 
development of fibrin-rich thrombi, as seen in AF 197, and are not as effective as OAC at 
preventing stroke 198,199.   
In estimating bleeding risk, we have used an ACS based bleeding risk score (CRUSADE) 
rather than a bleeding score developed for AF patients on chronic OAC (such as HAS-
BLED200). Bleeding risk scores have been developed for either AF or ACS, but not the 
combination of AF and ACS. Use of an AF-based bleeding score may have identified a 
slightly different cohort as having low bleeding risk. 
 
2.4.1 Limitations 
Firstly, as enrolment criteria for the Wellington ACS study and therefore this study, 
included adequate pre-treatment on DAPT we may have introduced a selection bias in 
our AF cohort.  AF patients on OAC may have been less likely to be given DAPT due to 
concerns regarding bleeding risk. If this was the case, then our cohort may under-
represent the use of OAC in AF patients in our community. In addition the DAPT entry 
criteria has prevented any patients managed with an OAC and a single antiplatelet agent 
being included. Whilst this was not a guideline recommended therapy at the time of this 
study we cannot exclude this possibility. 
Secondly, from our initial ACS study cohort 8.5% were identified as having a medical 
history of AF. Whilst this is within the expected range for ACS patients with AF based on 
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previous publications (6-21%), it is towards the lower bounds 169. Given that we know 
advancing age is a risk factor for AF 201, and that increasing age may deter invasive 
management 202,203, it is also possible that the angiography entry criteria has also 
resulted in fewer ACS patients with AF being eligible for inclusion into this study. The 
consequence of this is that our study has not described the prescription patterns for ACS 
patients with AF, managed without angiography, and this may account for the lower 
rate of AF seen in our ACS cohort.  
Thirdly, we observed lower than anticipated use of OACs at discharge (12%). As a result, 
determining factors associated with discharge OAC use was statistically challenging.  We 
identified OAC use on admission as the only independent driver of OAC use at discharge, 
however had OAC use at discharge been more prevalent we may have identified other 
factors due to greater statistical power.   
Lastly, this study was performed opportunistically in a pre-existing Wellington ACS 
study. As a consequence the results detailed above only pertain to a single-centre and 
are not representative of New Zealand practice in its entirety. Further examination of 
nationwide practice would be advantageous to adequately characterise the discharge 
management of ACS patients with AF in New Zealand.  
  
2.5 Conclusion 
This study suggests that for ACS patients with AF, the default discharge therapy is DAPT. 
What’s more, OAC use is minimal and does not appear to be driven by stroke or bleeding 
risk. However, given the limitations associated with selection bias in this cohort were 
significant, and data was representative of single-centre practice only, it is possible that 
our findings are not representative of overall patient management strategies in this 
patient group. In order to examine practice without selection bias, and at a national 
level, we chose to utilise the All New Zealand Acute Coronary Syndrome - Quality 
Improvement data registry to examine treatment strategies for ACS patients with AF. 





3 Management of ACS patients with AF: 





In Chapter 2 we described management of a cohort of ACS patients with a medical 
history of AF from a single-centre study. We observed DAPT to be the most common 
discharge therapy for this patient group, with limited use of OACs regardless of 
CHA2DS2VASc score. Because this cohort was derived from a pre-existing study of ACS 
patients, one of the enrolment criteria was that patients were on DAPT at the time of 
angiography. This may have excluded patients who were managed with an OAC and a 
single antiplatelet agent. In addition, the cohort only represented practice at one centre.  
In order to examine in more detail how ACS patients with AF were managed in New 
Zealand we chose to use the All New Zealand Acute Coronary Syndrome - Quality 
Improvement (ANZACS-QI) registry data set. ANZACS-QI was implemented with the 
primary aim of supporting evidence-based management of ACS patients in New Zealand, 
through both quality improvement and research 204. The ANZACS-QI programme is a 
nationalised collaboration between all publicly funded District Heath Boards (40 
hospitals) that admit ACS patients, as well as 6 private hospitals that provide coronary 
angiography services, and aims to capture data on all patients treated in New Zealand 
for an ACS complaint 205.  This registry collects information including patient 
demographics and clinical management during hospital admission for ACS. The registry 
data can then be linked to Ministry of Health datasets to examine patient outcomes and 
pharmaceutical dispensing data. 
Therefore, the aims of this study were: 
 To describe national prescription patterns of antiplatelet and anticoagulant 
therapies in ACS patients with AF  






3.2.1 Registry description 
There are two complementary data sources within ANZACS-QI that generate two 
overlapping cohorts: 1) The ACS routine information cohort which captures patients 
aged 20 years or more who are admitted to hospital with an International Classification 
of Disease 10 (ICD-10) code consistent with ACS, and; 2) The ACS-CathPCI registry cohort 
which systematically collects data on coronary angiography and PCI procedures, 
including those undertaken in private hospitals 204,206.  
Once data has been entered into the ANZACS-QI registries patients are only identifiable 
by their National Health Index (NHI) number.  Using encrypted NHI numbers it is then 
possible to link ANZACS-QI registry data with New Zealand Health databases collected 
by the Ministry of Health. These are the National Minimum Dataset, Pharmaceutical 
Collection and Mortality Collection and details can be seen in Table 3-1 204.  
To access data from ANZACS-QI we completed a Data Access Proposal (DAP) that was 
submitted to the ANZACS-QI governance board outlining the proposed study and 
analysis. This DAP was reviewed by that board, and approved under the umbrella ethical 
approval for the ANZACS-QI registries granted by the National Multi-Region Ethics 
Committee (MEC07/19/EXP). In order to access Ministry of Health Datasets, the DAP 
was then viewed by the Vascular Informatics using Epidemiology and the Web (VIEW) 
governance board, and this group approved access to this data under the VIEW ethical 





Table 3-1 National Databases linked with ANZACS-QI registries 
Name of dataset Data collected 
National Minimum Dataset Admission related data: date of admission, date of 
discharge, ICD-coded discharge diagnoses, ICD-coded 




Pharmaceutical Collection  Government subsidised medication dispensing claims 
from community pharmacies 
Mortality Collection Date of death and ICD-coded underlying and 
contributing causes of death 
  
3.2.2 Data extraction 
From 1st January 2012 through to the 31st of December 2015 a total of 19,295 patients 
with a final diagnosis of ACS were identified from the ANZACS-QI database. This registry 
does not currently record data on AF, although as a process of this DAP this has been 
recognised as an important missing piece of data and the next update of ANZACS-QI will 
add an AF data field. Patients with a history of AF were identified from the National 
Minimum Dataset as those having an ICD-10 discharge code of AF at any point in the 
preceding 10 years including the index admission. This identified 3,730 patients with a 
medical history of AF. Utilising the ACS-CathPCI registry 1101 of these patients received 
PCI and 610 of this group had one-year follow-up data available and defined the study 
cohort. The process of cohort identification can be seen in Figure 3-1.  
Of the 610 patients in our target cohort demographic data (age, gender) and information 
regarding clinical presentation (STEMI, NSTEMI, UA) were extracted from the ACS 
routine information cohort. Information detailing past medical history and co-
morbidities were obtained from the National Minimum Dataset. CHA2DS2VASc scores 
were calculated using data from both sources (Table 3-2). Data regarding therapies for 
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the 12 months post ACS were extracted from the Pharmaceutical Collection in quarterly 
blocks. This dataset provided information on prescriptions filled by patients during the 
quarter. Mortality data was sourced from the Mortality Collection and are based on 
underlying and/or contributory causes of death from a death certificate. Other one-year 
outcome data including ischaemic (stroke and MI) and bleeding events were extracted 
from the National Minimum dataset and are based on discharge coding following 




Figure 3-1 Flow chart of cohort identification 







Definitions used in the study are presented in Table 3-2. Prescription data was based on 
filled prescriptions within the quarter following the index admission for each patient and 
included oral antiplatelet agents (aspirin, clopidogrel, ticagrelor and prasugrel) and oral 
anticoagulants (warfarin, dabigatran, apixaban, rivaroxaban). DAPT was defined as the 
combination of aspirin and a P2Y12 inhibitor. TT was the combination of aspirin, P2Y12 
inhibitor and any OAC. Single antiplatelet was the use of aspirin or P2Y12 inhibitor alone.  
 
3.2.4 Statistical analysis 
Categorical variables are expressed as frequencies and percentages. Continuous 
variables are expressed as mean and standard deviation. We compared treatment 
groups using independent t-tests for continuous data and Chi squared tests for 
dichotomous data. Survival analysis was performed using the Kaplan-Meier method. For 
all statistical analyses a p-value ≤0.05 was considered significant. All statistical tests were 





Table 3-2 Definitions of data collected from national databases  
Acute coronary 
syndrome 
Final diagnosis within ANZACS-QI dataset of UA, NSTEMI or STEMI 
Atrial 
fibrillation 






ICD-10 coded heart failure at any time in the past 
or 
Worst Killip class of 2, 3 or 4 recorded in ANZACS-
QI during index admission 
 Hypertension Dispensing of two or more blood pressure 
lowering medications the previous 6 months 
or  
SBP >150 mmHg recorded in ANZACS-QI during 
index admission 
 Age As recorded in ANZACS-QI during index admission 
 Diabetes As recorded in ANZACS-QI during index admission 
 Previous 
stroke/TIA 
ICD-10 coded ischaemic stroke  or  TIA at any time 
in the past 
or 
Recorded in ANZACS-QI during index admission 
 Vascular disease ICD-10 coded ACS , coronary  procedure, PVD, or 
peripheral vascular procedure at any time in the 
past  
or 
Recorded in ANZACS-QI during index admission 
 Sex As recorded in ANZACS-QI during index admission 
Bleeding events Any bleeding ICD-10 discharge code from primary or secondary 
diagnosis for any bleeding  
 Intracranial 
bleeding 
ICD-10 discharge code from primary or secondary 
diagnosis for intracranial bleeding 
 Gastrointestinal 
bleeding 
ICD-10 discharge code from primary or secondary 
diagnosis for gastrointestinal bleeding 
ICD = international classification of disease; NSTEMI = non-ST-segment elevation myocardial infarction; PVD = peripheral vascular 






The demographic details of the 610 patients can be seen in Table 3-3. In our study cohort 
the mean age was 71.3 ± 10.7 years and 186 (30%) were female. Hypertension was the 
most common risk factor and was recorded in 530 (87%) of patients. A history of CHF 
was documented in 237 patients (39%), diabetes in 147 patients (24%) and prior stroke 
in 74 patients (12%). The presenting ACS was NSTEMI for 50% of cases, and STEMI and 
UA occurred in 37% and 13% of cases respectively. The average CHA2DS2VASc score for 
this cohort was 4.2 ± 1.6.  
On the basis of the prescriptions filled in the first quarter, 469 patients (77%) were 
initially on either DAPT (370 patients, 61%) or TT (99 patients, 16%).  The demographics 
of these two groups were compared and are given in Table 3-3. No significant difference 
was detected between TT and DAPT patients with regard to age, gender, presenting ACS 
or the clinical risk factors of CHF, hypertension or prior stroke. The only significant 
difference was that the TT group had a significantly higher rate of diabetes compared to 
DAPT patients (37% vs. 22%, p=0.002).  The average CHA2DS2VASc score of the TT group 





Table 3-3 Demographic data 







Age 71.3 (10.7) 71.3 (10.3) 70.8 (10.9) 0.83 
Female gender 186 (30%) 30 (30%) 115 (31%) 0.88 
History of CHF 237 (39%) 40 (40%) 117 (32%) 0.10 
History of Hypertension 530 (87%) 90 (91%) 311 (84%) 0.85 
Diabetes 147 (24%) 37 (37%) 82 (22%) 0.002 
Prior stroke 74 (12%) 10 (10%) 40 (11%) 0.84 
CHA2DS2VASc score 4.2 (1.6) 4.3 (1.5) 4.1 (1.6) 0.82 
STEMI 226 (37%) 29 (29%) 139 (38%)  
NSTEMI 303 (50%) 54 (54%) 183 (49%) 0.29 
Unstable angina 81 (13%) 16 (16%) 48 (13%)  
CHF = congestive heart failure; DAPT = dual antiplatelet therapy; NTEMI = non-ST-segment elevation myocardial infarction; STEMI = 
ST-segment myocardial infarction. 
 
3.3.2 Distribution of treatment strategies 
For ACS patients with AF there were multiple variations of prescriptions filled in the 12 
months (four quarters) post ACS event and these can be seen in Figure 3-2. Overall DAPT 
was the most commonly occurring therapy in each quarter but a steady decline over 
time was identified. In the first quarter 61% of patients received DAPT and this dropped 
to 34% in the fourth quarter. If the first quarter alone is examined we see that after 
DAPT, TT is the next most common prescription filled at 16%.  This is followed by a close 
grouping of   OAC + P2Y12 inhibitor (7.2%), single antiplatelet (6%), no therapy (5.5%) 
and OAC + aspirin (4%).  The least common therapy in the first quarter was OAC alone 
at 0.2%.   
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Alongside declining DAPT rates over time it is also evident that TT rates decline over 
time. Starting at 16% in the first quarter this rate is halved by the second quarter (8%), 
and by the fourth quarter (3.3%) TT is the least common prescription filled.  
In the first quarter 5.5% of patients did not have any prescriptions filled for either 
anticoagulants or antiplatelet agents. It is possible that some of these patients may have 
been transferred to palliative care settings and therefore not have had outpatient 
prescriptions filled. For quarters two through four, proportions of patients on each 
treatment were adjusted for the number alive at the start of the quarter. We observed 
rates of no therapy rise to 14% in the second quarter before reaching a high of 19% in 
both the third and fourth quarters. In the second and third quarters no therapy was the 
second most common treatment regimen behind DAPT. At 12 months no therapy was 
the third most common prescription filled behind DAPT (34%) and single antiplatelet 
therapy (23.5%). 
OAC + aspirin and OAC + P2Y12 regimens displayed similar rates of prescription. Both 
showed a gradual rise over time with OAC + aspirin rising from 4% in the first quarter to 
11.5% in the fourth quarter, while OAC + P2Y12 increased from 7% to 10% over the same 
time period.  As mentioned OAC alone was the least prescribed therapy in the first 




Figure 3-2 Distribution of treatment therapies by quarter 

































3.3.3 Oral anticoagulant use 
Initial therapy with an OAC (prescription of any OAC in the first quarter) was 27.5% The 
mean CHA2DS2VASc score for patients with initial OAC therapy was 4.5 ± 1.5 and this 
was significantly higher than the mean score of 4.14 ± 1.59 for patients not on an OAC 
(p=0.01). Figure 3-3 demonstrates the number of patients at each CHA2DS2VASc score 
for the cohort and the percentage that were initially treated with an OAC. OAC use was 
lowest at CHA2DS2VASc 1 with 10% and this gradually increased to 36% at CHA2DS2VASc 
4. OAC use was similar at CHA2DS2VASc 5 through 8 before peaking at 60% (3 patients 






Figure 3-3 Percentage OAC use by CHA2DS2VASc score 





















3.3.4 One-year outcomes 
Overall there were 74 deaths (12%) at one-year follow up with mortality of 5% within 
the first month following the index event (see Figure 3-4). Based on death certificate 
coding 45 deaths (61%) were due to ischaemic heart disease, 8 (11%) to cancer, 1 (1.4%) 
to intracranial haemorrhage and the remaining 20 (27%) to various other causes. At one-
year there were hospital admissions for non-fatal MI in 13 patients (2%), ischaemic 
stroke/TIA in 9 patients (1.5%) and intracranial bleeding in 3 (0.5%) patients.  
Survival did not differ between initial treatments of DAPT or TT (6.3% vs. 8%, 
respectively, p=0.51) (Figure 3-4). With regard to one-year rates of non-fatal MI, stroke 
and bleeding events there was no significant difference between patients initially 
treated with TT or DAPT.  
There was no difference in survival between those initially on OAC therapy compared to 
patients without OAC therapy. There was also no difference in MI or stroke rates 
between those on initial OAC therapy and those not on an OAC.  
Hospital admissions for bleeding occurred for 22 patients (3.6%) and these patients were 
more likely to be on an OAC (7.1%) than not (2.2%, p=0.004). Fourteen patients were 
admitted to hospital for gastrointestinal bleeding (2.3%) and again these patients were 
more likely to be on OAC therapy (4.7% vs. 1.3%, p=0.01). Intracranial bleeding rates did 






Figure 3-4 12 month survival analysis 
Kaplan-Meier graph shows patient survival rates (%) one-year post ACS event. Overall one-year mortality was 12%. Mortality did not differ between 




In this analysis of patients with ACS and AF treated with PCI, we observed that DAPT was 
the most common initial treatment strategy, although the rate of DAPT declined 
significantly across the 12 months following ACS. TT was the second most common initial 
strategy, but also declined markedly over time. There was a small, but not significant 
difference in CHA2DS2VASc score between DAPT and TT groups, suggesting treatment 
options were not heavily driven by stroke risk. Overall initial OAC use was associated 
with a higher CHA2DS2VASc score, although OACs were not used in more than 50% of 
patients except at CHA2DS2VASc 9.  The proportion of patients not on any OAC or 
antiplatelet therapy was high, with nearly 20% of patients during the period of 6-12 
months post ACS not filling prescriptions for these therapies. Overall mortality in this 
group was high at 12% at one-year, and likely reflects the high-risk characteristics of this 
patient group. 
The results of this study are consistent with the observations in Chapter 2 that DAPT is 
the preferred treatment after an ACS for patients with concurrent AF, and that this 
treatment strategy was not strongly influenced by stroke risk. The duration of DAPT was 
less than 12 months in almost half those initially prescribed this therapy. TT duration 
was less than 12 months in more than half those on this treatment initially. Some of the 
decline in these more intensive therapies is accounted for by an increase over time in 
either single antiplatelet therapy or OAC, but in addition there is an increase over time 
in the number of patients not filling prescriptions for either antiplatelet or oral 
anticoagulant drugs.  Because this data is based on what prescriptions are filled, and not 
what prescriptions are written, we are not able to distinguish between patient non-
compliance and clinician prescription choices. However, the observed treatments 
strategies are not consistent with current guidelines regarding optimal medical therapy 
in patients with ACS and PCI, regardless of AF 1,88-91. 
Patients with higher CHA2DS2VASc scores were more likely to receive therapy that 
included OAC. However there was only a small amount of OAC use in this cohort, and 
the relationship with CHA2DS2VASc scores was not strong. It is possible that many of the 
patients included in our study were not in AF during the index admission. The way we 
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have identified AF is based on any hospital admission with AF within 10 years. The 
absence of observed AF during an ACS event could have contributed to the low observed 
use of OAC. However, a history of AF should have been noted for these patients, and AF 
is likely to become increasingly present for most patients over time, as AF begets more 
AF 207,208. It is also possible that some of the patients we have classified as having an AF 
history may represent coding error in the past.  
The most common outcome of interest in this cohort at one-year was mortality, with a 
12% rate and this did not differ by treatment. We observed a one-year stroke/TIA rate 
of 1.5% in this cohort, which is lower than expected based on the cohort’s mean 
CHA2DS2VASc score of 4.2 209. This may suggest that DAPT is providing a level of 
protection against stroke. It is also possible that there may have been stroke events 
contributing to mortality that have not been correctly identified in death certificate 
coding. In addition, particularly TIA events may not have resulted in hospital admission, 
as these may be treated in emergency department (ED) alone, and so some cases may 
have been missed. Given the low rate of stroke/TIA, we had insufficient statistical power 
to detect any relationship between treatment strategies and stroke events.  
Hospital admissions for bleeding occurred at a rate of 3.6% in this cohort. All minor-
moderate bleeding events that were treated in the community or ED were not part of 
this analysis. Patients on OAC were more likely to experience both any bleeding and 
gastrointestinal bleeding which is consistent with wider literature 210-213.  
 
3.4.1 Limitations 
In order to describe discharge therapy for ACS patients with AF on a national scale we 
were restricted to the parameters of the national databases utilised. Firstly, as 
mentioned in the methods section, ANZACS-QI does not collect information regarding 
AF and therefore identifying this subgroup had challenges. We chose to identify AF 
based on prior discharge coding of AF within the National Minimum Dataset.  The 
accuracy of this coding is not clear, and patients with AF may have been missed, and we 
90 
 
cannot be certain that all patients coded as having AF did in fact have this arrhythmia. 
Secondly, the use of national data meant we could only extract information pertaining 
to prescriptions filled by patients, not what was prescribed to patients. The difference 
here is potentially a significant one.   
Our ability to examine the relationship between treatment strategies and clinical 
outcomes was limited. While we requested this dataset at the end of 2016, we had not 
appreciated that the Ministry of Health datasets at that time were only complete until 
the end of 2015. This meant that almost 500 patients did not have one-year follow-up 
data available. In addition, the proportion of patients with ACS and AF undergoing PCI 
was lower than we anticipated (1101 out of 3730, 29%), and this resulted in a final 
cohort of only 610 patients. While this is large enough to describe national prescription 
behaviour reasonably it does limit our ability to look at outcomes by treatment. We 
identified multiple drug regimens with small event numbers that were all restricted to 
those requiring hospital admission, this has meant that differences in outcomes 
between therapies are not detectable and lack statistical power.  
Finally, we chose to only look at ACS patients managed with PCI and therefore this 
cohort does not detail the management of ACS patients with AF, managed with medical 
therapy or CABG. Whilst this does add some limitation to our study, this was a deliberate 
step to overcome the difficulties of assessing those managed with CABG (CABG increases 
the risk of new AF occurring post-surgery, has bleeding risk associated with the 
operation, and it is unclear how commonly DAPT in used post-CABG in New Zealand). 
Limiting the cohort to those managed with PCI also eliminated the complexities of 
medically managed patients (e.g. very frail patients who may have contraindications to 






Through the utilisation of the ANZACS-QI registry we were able to describe prescriptions 
in a larger cohort of ACS patients with AF. Overall ACS patients with AF filled 
prescriptions for multiple drug regimens and rates were inconsistent and variable 
overtime. DAPT was the most common prescription filled in the 12 months post PCI and 
its use over TT was not driven by stroke risk, nor did it impact mortality. A growing 
number of patients were considered to be undertreated, filling prescriptions for either 
no therapy or single antiplatelet therapy. It is therefore evident that no clear treatment 
strategy was utilised for this patient group.  To examine optimal therapy for ACS patients 
with AF a comprehensive review of clinical evidence is necessary. This is explored in 
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In the previous two chapters we have described the prescription rates for ACS patients 
with a medical history of AF. On the basis of current guidelines, it may have been 
reasonable to expect that for the most part, patients at high risk of stroke would be 
prescribed TT, and those at low risk of stroke or with excessive bleeding risk would 
receive therapy with DAPT. Instead we observed DAPT to be the most common strategy 
employed in both the single-centre and national cohorts, with TT was used minimally in 
the national cohort and not at all in the single-centre. What’s more, the use of these 
therapies did not appear to be based on assessments of stroke risk (Chapter 2 and 3) or 
bleeding risk (Chapter 2). We therefore concluded that in these cohorts, no clear 
treatment strategy was evident for the management of ACS patients with AF.  
We have previously discussed the inconsistencies in clinical guidelines with regard to 
this patient group, particularly the brevity of New Zealand guidelines, and this may 
account for our observations in New Zealand practice. In addition, there is a lack of RCTs 
that specifically address therapy for ACS patients with AF, and this has unquestionably 
impacted guideline quality and clinical practice. However despite this lack of RCTs it may 
be possible to synthesise any observational studies for this patient group, with a view to 
establishing best practice. As DAPT and TT are guideline recommended therapies, yet 
the majority of ACS patients with AF receive DAPT, we set out to compare the safety and 
efficacy of DAPT and TT for the discharge management of this patient group.  
Therefore, the aim of this study was to: 
 Systematically review published literature to determine whether DAPT or TT is 







4.2.1 Search strategy 
We electronically searched Medline, Medline pending, EMBASE and Evidence-Based 
Medicine Reviews (EBMR) databases, using the MeSH terms “atrial fibrillation” AND 
“acute coronary syndromes” (all fields), “anticoagulants” OR “platelet aggregation 
inhibitors” (all fields), and the key words “OAC”, “NOAC”, “warfarin”, “apixaban”, 
“rivaroxaban”, “dabigatran”, “darexaban”, “triple therapy” “dual antiplatelet therapy”, 
“clopidogrel”, “prasugrel”, “ticagrelor” and “antiplatelet” in all fields.  Results were 
limited to English language and human populations. In addition, the reference lists of 
pertinent articles were manually screened for eligible articles. We limited the search 
strategy to results from 1st January 2000 to 31st December 2016. 
4.2.2 Inclusion criteria 
Studies had to meet all of the following criteria: (1) AF patients with an ACS or CAD 
undergoing intervention; (2) comparison of DAPT and TT; (3) inclusion of either 
ischaemic and/or bleeding outcomes.  Studies that were based on mixed populations on 
anticoagulant therapy that were not purely an AF population were excluded. Where 
more than one study reported on the same patient population only the most recent 
report was included. 
4.2.3 Data extraction 
Abstracts were screened to assess eligibility. The full text article was examined for all 





The search strategy identified 1888 titles. After the removal of duplicates 1599 abstracts 
were screened. A final set of 10 papers met the inclusion criteria (Figure 4-1) and details 
of these are given in Table 4-1. Where author groups published more than one study 
from largely the same patient population (Sambola et al 214,215, Lamberts et al 199,216 and 
Fosbol et al 217,218) only the most recent study was included in the current review.  There 
was considerable heterogeneity between studies with respect to outcomes, patient 
numbers in the DAPT and TT arms (range n=67 to n=5486) and follow-up periods (6 
months – 42 months). Of the 10 studies, only Sambola et al (2016) 214 and Rubboli et al 
(2014) 219 were prospective in nature. 
The proportion of patients with ACS ranged from 40% in Suh et al (2014)220 to 100% in 
Fosbol et al (2013) 217. In 6 of the 10 studies the proportion of patients with ACS was 
higher in the DAPT treatment arm than in the TT arm. Details of paroxysmal, persistent 
and permanent AF groups could not be determined and in all cases the term AF was 
used to collectively represent these groups. Allocation to DAPT or TT was at the 
discretion of the physician in 6 studies and not described in the remaining 4 studies 
(Table 4-1). When treatment was determined by a physician there were no reports of 
institutional protocols or schema to assist physician decision making. Nine studies had a 
follow up duration greater than or equal to 12 months and in these studies there were 
no statements regarding the duration of either DAPT or TT, or what therapy was adopted 







Figure 4-1 Flow chart of study selection 





Table 4-1 Overview of included studies 
Study Follow-up Population Design Data Source Groups Allocation 
Sambola et al  
(2016) 214 




De Vecchis  et al  
(2016) 221 




Kang et al  
(2015) 222 




Mennuni et al  
(2015) 223 




Rubboli et al  
(2014) 219 




Suh et al  
(2014) 220 
42.0 ± 29.0 
months 






Fosbol et al  
(2013) 217 
12 months AF + NSTEMI with 
PCI 





Lamberts et al  
(2013) 199 
12 months AF + MI and/or PCI Retrospective Not stated DAPT (n=3590) 
TT (n=1896) 
Not stated 
Ho et al  
(2013) 224 
5.9 ± 5.0 months AF + PCI Retrospective Not stated DAPT (n=220) 
TT (n=382) 
Not stated 
Maegdefessel et al 
(2008) 225 
16.8 (2-68) months AF + PCI Retrospective Hospital database DAPT (n=103) 
TT (n=14) 
Not stated 
Length of follow up is in months ± standard deviation or months (range); AF = atrial fibrillation; DAPT = dual antiplatelet therapy; DES = drug eluding stent; MI = myocardial infarction; NSTEMI = non-ST-segment 
elevation myocardial infarction; PCI – percutaneous coronary intervention; TT = triple therapy. 
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4.3.1 Composite Ischaemic outcomes 
While it was common to report on a composite endpoint, the components of this 
endpoint differed across the 10 studies. In 7 studies adjusted composite endpoint results 
were given (Table 4-2).  No individual study found a significant difference in composite 
end points between groups, although in 4 of the 7 studies there was a trend towards 
lower rates on TT (odds ratios ranged from 0.71 to 0.94) 199,217,223,224.  
 
4.3.2 Mortality 
While all studies reported unadjusted mortality only 3 studies reported adjusted results 
for mortality (Table 4-2). In Mennuni et al there was 8.6% 12 month mortality in the 
DAPT arm compared to a 7.1% rate on TT with an adjusted odds ratio of 0.62, (0.35-
1.08). 223. In Lamberts et al the 12 month mortality rates for the DAPT and TT arms were 
12% and 4% respectively, with adjusted all-cause mortality reduced with TT (odds ratio 
0.61 [0.47-0.77]) 199. Ho et al reported a 6.8% mortality on DAPT compared to 6.5% on 
TT with an adjusted odds ratio of 0.96 (0.49-1.86) 224. In addition Kang et al reported 
propensity-score matched results and found a 3% mortality rate in the DAPT group 
compared to 7% in the TT group 222.  In the remaining studies Fosbol et al reported 
mortality of 13.3% on DAPT versus 12.9% on TT without adjusted results being given 217, 
Suh et al reported 11.4% mortality on DAPT, with no deaths in the 37 patients treated 
with TT 220, and Rubboli et al reported 11% mortality rates in both groups 219. Sambola 
et al reported no difference in mortality with DAPT and TT arms with respect to patients 
with a CHA2DS2VASc of 1 (5.5% vs. 7.4%, respectively) and those with CHA2DS2VASc of 2 
or more (10.6% vs. 9.2%, respectively) 214. DeVecchis et al reported 5 all-cause deaths, 1 
in the DAPT group and 4 in the TT group 221 and Maegdefessel et al reported 4 
cardiovascular deaths, 3 in the DAPT group and 1 in the TT group 225.
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OR Composite OR Mortality OR Stroke OR Bleeding 











1.05 (0.67-1.86) - - 2.97(1.25-7.02)** 










1.57 (0.82-2.99) † 3% DAPT vs 7% TT† 0% DAPT vs 4% TT† 6.8(1.98-23.6)** † 








0.77 (0.52-1.14) 0.62 (0.35-1.08) 4.4 (0.45-42.3) 1.79 (1.11-2.89)* 












- - - 








0.94 (0.73-1.21) - - 1.29 (0.96-1.74) 








0.83 (0.68-1.0) 0.61 (0.47-0.77)* 0.67 (0.46-0.98)* 2.08 (1.64-2.65)* 









0.71 (0.37-1.38) 0.96 (0.49-1.86) 1.15 (0.21-6.35) 1.25 (0.6-2.6) ‡ 
Odds ratios (OR) are given relative to DAPT; Statistically significant results are given by * p < 0.05, ** p < 0.01, *** p <0.001.†=results were propensity-score matched, not adjusted; ‡ Bleeding odds ratio was for 




All 10 studies reported unadjusted stroke rates and these are given in Table 4-3. Stroke 
risk information (using CHADS2 226 or CHA2DS2VASc 155) were given in 8 of these studies. 
In 2 of the studies the TT group had higher stroke risk than the DAPT group (Mennuni et 
al CHADS2 scores 2.9 vs. 2.5, p<0.01 223; Ho et al CHADS2 scores 2.6 vs. 2.1, p<0.001 224), 
while in 1 the DAPT group had a higher stroke risk (Kang et al, CHADS2 scores 2.06 vs. 
1.68, p= 0.003) 222.  In the studies by Suh et al 220, Rubboli et al 219 and Fosbol et al 217 the 
TT and DAPT groups had no statistical difference in their stroke risk. Lamberts et al 199 
and Sambola et al 214 did not report statistical comparison of stroke risks between 
treatment arms, but data given appear similar.   
DeVecchis et al did not report stroke risk for the DAPT and TT arms, but reported 1 stroke 
event (2%) in the 48 patients in the TT arm and no strokes in the 19 patients in the DAPT 
arm 221. Maegdefessel et al also did not report stroke risk, and reported the highest 
stroke rate in the DAPT arm (8.7%), and reported no stroke in the 14 patients treated 
with TT 225.  
In the other 8 studies the stroke rate varied between 0.2 and 5.3%.  Of the 7 studies that 
performed statistical analyses only Sambola et al reported significantly different stroke 
rates based on unadjusted results, with 5.3% in the DAPT group and 1.7% in the TT group 
(p=0.03) 214,217,219,220,222-224.  
Three studies presented adjusted results for stroke, with variable findings (Table 4-2). 
Lamberts et al reported that TT significantly reduced the risk of stroke compared to 
DAPT (odds ratio 0.67, [0.46-0.98]) 199.  Both Mennuni and Ho reported results favouring 
DAPT (odds ratio 4.4, [0.45-42.3] 223 and odds ratio 1.15, [0.21-6.35] 224 respectively), 
however neither of these results were statistically significant. In addition, Kang et al 
presented propensity-score matched stoke results, reporting no strokes in the DAPT 
group and 4% in the TT group 222.
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Table 4-3 Unadjusted stroke rates 
Study DAPT Patients DAPT Stroke Risk DAPT Stroke Rate (%) TT Patients TT Stroke Risk TT Stroke Rate (%) 




45% CHA2DS2VASc 2+ 5.3* N=319 
68% ACS 
56% CHA2DS2VASc 2+ 1.7 




Not given 0 N=48  
69% ACS 
Not given 2 




Mean CHADS2: 1.68* 2.1 N=131,  
77.8% ACS 
Mean CHADS2: 2.06 3 




Mean CHADS2: 2.5* 0.2 N=371,  
54% ACS 
Mean CHADS2: 2.9 1.2 




Mean CHADS2: 2.1 4 N=679,  
54% ACS 
Mean CHADS2: 2.3 2 




65% CHADS2 2+ 
Mean score: 1.95 
3.6 N=37,  
33% ACS 
57% CHADS2 2+ 
Mean score: 1.81 
2.7 




Median CHA2DS2VASc: 4 2.2 N =448,  
100% ACS 
Median CHA2DS2VASc: 4 1.6 




90% CHA2DS2VASc 2+ 4.2† N=1896,  
53% ACS 
90% CHA2DS2VASc 2+ 1.8 




Mean CHADS2: 2.1* 0.9 N=382,  
71% ACS 
Mean CHADS2: 2.6 1.1 




Not given 8.7† N=14,  
72% ACS 
Not given 0 




Different definitions of bleeding were used across the 10 studies (Table 4-4), and this 
resulted in differing rates of bleeding observed from no bleeding to a high of 16.7% 
bleeding. Bleeding risk, using either HAS-BLED 200 or ATRIA (anaemia, renal disease, age 
≥75, prior haemorrhage, hypertension) 152 scores were reported in 7 of the 10 studies. 
In 5 of these studies there was no statistical difference in bleeding risk between 
treatment arms 217,219,220,222,223. Lamberts et al 199 and Sambola et al 214 did not perform 
statistical analysis however bleeding risk appears to be similar in both treatment arms.  
Unadjusted bleeding rates were presented in all 10 studies and significant differences 
were observed in 3. Kang et al reported a 16.7% bleeding rate in the TT group, 
significantly higher than the 4.6% in the DAPT group 222, and Mennuni et al reported an 
11.5% bleeding rate for TT group compared with 6.4% for DAPT 223. Sambola et al 214 also 
showed higher bleeding in the TT group (8.4%) when compared to the DAPT group 
(3.1%). Four studies (DeVecchis et al 221, Rubboli et al 219, Suh et al 220 and Ho et al 224) 
did not find significant differences between bleeding rates while 3 studies (Fosbol et al 
217, Lamberts et al 199 and Maegdefessel et al 225) did not perform statistical analyses on 
unadjusted bleeding rates.  
Adjusted bleeding results were presented in 6 studies (Table 4-1) and in 4 of these there 
was a statistically significant increase in bleeding associated with TT (Sambola et al odds 
ratio 2.97, [1.25-7.02] 214, Kang et al odds ratio 6.84, [1.98-23.6] 222, Lamberts et al odds 
ratio 2.08, [1.64-2.65] 199 and Mennuni et al odds ratio 1.79, [1.11-2.89] 223). The other 
2 studies reported non-significant increases in bleeding with TT (Fosbol et al ods ratio 
1.29, [0.96-1.74] 217, Ho et al odds ratio 1.25, [0.6-2.6]) 224.   
  
Statistically significant differences between treatment arms are indicated by * p <0.05.† statistical comparison of stroke rates not performed. ACS = acute coronary syndrome; BARC = Bleeding academic research 
consortium. TIMI = thrombolysis in myocardial infarction criteria.      103 







TT Patients TT Bleeding risk TT Bleeding 
rate (%) 
Bleeding Definition 








HASBLED ≥3, 42% 8.4 TIMI Major 




Not given 5.3 N=48  
69% ACS 
Not given 8.3 Major bleeding – not 
defined 










16.7 Intracerebral or 
hemodynamic compromise 










11.5 BARC 2+ 227 










10 BARC 3 & 5 227 










2.7 Overt bleeding, need for 
transfusion, intracranial 
bleeding 










14.4 Bleeding causing hospital 
admission 
Lamberts et al  









6.2 Bleeding causing hospital 
admission or death 




No bleeding risk 
score 
9.6 N=382,  
71% ACS 
No bleeding risk 
score 
10.6 Bleeding requiring 
transfusion 




No bleeding risk 
score 
1.9† N=14,  
72% ACS 
No bleeding risk 
score 
0 Not defined in methods – 
requiring transfusion 
stated in results 
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4.4 Discussion 
The quality of studies identified comparing clinical outcomes for patients with AF and 
ACS/PCI treated with DAPT or TT was poor. Eight of the ten studies included in this 
review were retrospective in nature, and none of the studies adequately described the 
basis of treatment allocation. Only one study was of a pure ACS population, the other 
nine containing a mix of stable coronary artery disease patients undergoing PCI and ACS 
patients. There was consistency in the observation that TT was associated with an 
increase in the rate of bleeding. While the largest study of the ten observed a reduction 
in stroke and in mortality associated with TT compared to DAPT, this was not a 
consistent finding.  
This systematic review highlights a large gap in current literature. As we know up to 21% 
of patients with ACS may have concurrent AF, therefore this is a common clinical 
presentation 169. In addition, a number of studies have shown that patients with AF have 
worse clinical outcomes following ACS than those without AF 228-230. The absence of 
robust data on which to base treatment recommendations is therefore a significant 
concern and is reflected in the quality of guideline publications for this patient group 
(mostly expert consensus).  
The studies included in this review were all observational, mostly retrospective, and 
some very small. A number of these studies incorporated treatment groups other than 
DAPT and TT although these have not been discussed here. The original intent of this 
review had been to limit the studies discussed to pure ACS with AF populations. 
However, this would have left only the study by Fosbol et al included 217. The change to 
a mixed ACS and stable coronary disease inclusion expanded the number of studies 
included, but at the risk of altering the characteristics of the patient population.  
Treatment allocation was inadequately described in all studies. While consensus 
documents suggest stratifying patient by risk to determine treatment regimen 90,106,231, 
none of the studies included in this review have stated that this was done. The similarity 
in stroke and bleeding risk scores between the treatment arms in the majority of studies 
supports this notion.  
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On the basis of the small number of studies in this systematic review it is evident that 
bleeding rates are significantly higher in patients treated with TT compared to DAPT. 
This was demonstrated consistently in the adjusted results, including the two largest 
studies, Fosbol et al 217 and Lamberts et al 199 with the former particularly pertinent as it 
was the only study to only include patients with ACS. Greater bleeding in TT groups was 
also supported in the majority of unadjusted results. There are some limitations that 
need to be noted here. Bleeding definitions used varied considerably, and the observed 
bleeding rates varied in part as a consequence of this. However, some of the studies that 
only included major bleeding reported higher rates of bleeding than others that had 
broader definitions of bleeding. It is possible that some bleeding was not captured in 
some of these studies due to the retrospective nature of most of the studies.  
The bleeding results reported in this study are consistent with the data from RCTs 
conducted in ACS populations that have compared TT to DAPT. In ATLAS ACS 2-TIMI 51 
(Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in 
Subjects with Acute Coronary Syndromes – Thrombolysis in Myocardial Infarction) 
patients were randomised to rivaroxaban low dose (2.5mg twice daily) or high dose 
(5mg twice daily) plus DAPT or DAPT alone 179. This study reported a reduction in 
cardiovascular and all-cause mortality associated with the low dose of rivaroxaban (but 
not the higher dose) and an increase in non-CABG related major bleeding but not fatal 
bleeding in both TT groups. The APPRAISE-2 (Apixaban for Prevention of Acute Ischemic 
Events 2) study examined the addition of apixaban (5mg twice daily) to DAPT. This study 
was halted prematurely as there was no evidence of a reduction in the composite end 
point of cardiovascular death, MI or ischaemic stroke associated with TT, and a 
significant increase in major bleeding was observed in the apixaban group 178. In our own 
national cohort reported in Chapter 3 event numbers restricted our ability to detect 
differences between DAPT and TT arms, but despite this we found patients treated with 
an OAC were more likely to be hospitalised for bleeding events (7.1% vs. 2.2%, p=0.004) 
with no detectable difference in stroke/TIA rates. 
A recent meta-analysis including the two phase III trials APPRIASE-2 and ATLAS ACS2-
TIMI 51, and 5 phase II trials in ACS with DAPT and TT arms, reported an increased risk 
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of bleeding associated with TT (Hazard Ratio 2.34; 2.06-2.66) with a modest reduction 
in major adverse cardiovascular events (MACE) (HR 0.87;0.80-0.95 )232. A similar 
association was described in a sub-study of the RE-LY trial, demonstrating that for 
warfarin and both 110mg and 150mg doses of dabigatran, addition of antiplatelet 
agents resulted in increased major bleeding 233.  Furthermore, nationwide registry data 
from Denmark of 40,812 MI patients showed that risk of bleeding causing hospitalisation 
increased with the number of antithrombotic drugs used, with those on TT at highest 
risk (compared to aspirin, DAPT hazard ratio 1.47, [1.28-1.69], TT hazard ratio 4.05, 
[3.08-5.33]) 176. Taking the results from these studies together with the findings in this 
review, it seems highly likely that TT in AF and ACS patients will result in an increase in 
clinically important bleeding.  
The efficacy of TT was less clear in the studies reviewed here. It might have been 
expected that the major benefit of TT would be seen in a reduction in the rate of stroke.  
This is based on meta-analysis of AF studies, showing superiority of warfarin to 
antiplatelet therapy for the reduction in stroke 234.  Consistent with this, the largest 
study included in this review did observe a reduction in stroke associated with TT 199. 
However the second largest study, Fosbol et al reported a 2.2% rate of stroke on DAPT 
and a 1.6% rate on TT, which were not significantly different in unadjusted analysis. 
Three other studies reported a trend towards higher stroke rates on TT in adjusted 
analysis, although in none of these cases was a statistically significant result observed 
222-224. These results suggest that the advantage of adding warfarin to DAPT for stroke 
prevention in the context of ACS in AF patients is not clear, but benefit may exist. 
It is also unclear that there is a reduction in composite ischaemic endpoints or in 
mortality associated with TT, although in the case of mortality Lamberts et al did 
demonstrate a mortality advantage 199.   Whilst it is conceivable that addition of and 
OAC to DAPT may reduce mortality related to thromboembolic events 179, it is also clear 
that major bleeding events in patients with ACS are associated with an increase in 
mortality235,236.  
As discussed in the introductory chapter, the ESC is the most prescriptive in its 
recommendations for the treatment of ACS patients with AF, and includes a structured 
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algorithm based on stroke risk and bleeding risk to determine the combination of 
antithrombotic and antiplatelet therapy 184. The associated ESC NSTEACS guidelines of 
2015 90 presents a simplified version that does recommend TT for all ACS patients with 
AF undergoing PCI, for 1 month in those with high bleeding risk and 6 months for those 
with lower bleeding risk, followed by dual therapy (clopidogrel and anticoagulation) out 
to 12 months. Bleeding risk in this context is defined by HAS-BLED 200, and while this 
score has been well validated in AF, it has not been validated in AF and ACS.  On the 
other hand, only the AHA guideline for AF references a CHA2DS2VASc ≥2 to indicate TT 
106, whereas the associated NSTEMI and STEMI guidelines do not offer specific detail 
regarding stroke risk thresholds, and do not reference a bleeding score 88,89. The studies 
included in the current review showed similar bleeding scores in both treatment arms 
suggesting that bleeding risk was not strongly associated with treatment allocation. In 
three studies there was a higher stroke risk in the TT arm, which may indicate stroke risk 
was a factor in treatment allocation in at least some cases.  
Within the ESC guidelines 90,184 the term OAC is used and refers to either well-controlled 
warfarin or one of the newer NOACs. It is important to note that all of the studies in this 
review that used OACs were using a VKA, predominantly warfarin, and it is entirely 
possible that the use of NOACs would result in a different safety-efficacy ratio. Whilst 
there is lack of supporting evidence in this context, the superiority of the NOACs over 
warfarin for stroke prevention in AF patients has been demonstrated 164-166,177 and 
therefore the ESC suggestion of anticoagulation using these agents may be logical. 
Current AHA guidelines limit comment to warfarin on the basis that data is lacking for 
the newer agents 89.  
With regard to DAPT therapy all of the studies in this review are referring to an aspirin 
and clopidogrel combination. The ESC guidelines advocate the use of aspirin and 
clopidogrel to constitute DAPT in the context of AF, but not the newer P2Y12 receptor 
inhibitors prasugrel and ticagrelor, based on no proven benefit in the AF and ACS 
population. Both prasugrel and ticagrelor have both been shown to be superior to 
clopidogrel on the basis of the ACS trials TRITON-TIMI 38 237 and PLATO 238 respectively. 
However, these agents were both associated with increased risks of non-CABG related 
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bleeding compared to clopidogrel. The absence of even observational data describing 
outcomes in AF and ACS patients treated with the NOACs and antiplatelet agents is 
striking and further demonstrates the paucity of data to guide clinical decision making 
in treating this group of patients.  
The ongoing MUSICA-2 trial of DAPT (aspirin and clopidogrel) versus TT (aspirin, 
clopidogrel and VKA) in patients with AF and low to moderate thromboembolic risk 
undergoing PCI 239, when completed may provide more guidance regarding optimal 
pharmacological therapy, however does not include the newer antithrombotic agents, 
nor directly addresses ACS patients with AF.  
This review has focused exclusively on the comparison of DAPT and TT. However, the 
combination of OAC and a single antiplatelet agent for AF and ACS patients may be 
important to consider. Lamberts et al included both aspirin and warfarin, and aspirin 
and clopidogrel treatment arms in their study, and found both resulted in significantly 
less bleeding than TT, without any difference in rates of stroke 199. Examining the utility 
of an oral anticoagulant and a single antiplatelet agent may therefore have merit.  This 
area is now considerably more complex, as the newer NOACs and antiplatelet drugs 
provide an increased range of possible therapeutic combinations, at a range of dosing 
options, that adds to the confusion in how best to treat AF patients with ACS. 
 
4.4.1 Study limitations 
We excluded a number of studies that were based on populations on OAC therapy at 
the time of ACS event. These studies would have included mostly AF patients, mixed 
with a smaller proportion of patients with mechanical valves, deep vein 
thrombosis/pulmonary embolism, or other indications for anticoagulation. Our 
rationale for this exclusion was that the non-AF patients included have quite a different 
risk profile, and that many patients with AF and ACS may not have been on an 
anticoagulant at the time of the ACS.  We did choose to include studies that were not in 
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pure ACS patients, as had we not done so, only one study would have been included in 
the review.  
Meta-analyses were not performed due to heterogeneity of eligible studies and absence 
of RCTs. As a result, we have not been able to further synthesise our observations with 
regard to the increased bleeding risks demonstrated with TT. Further, due to the 
variations in bleeding definitions used across studies, we cannot characterise the 
increased risk of bleeding on TT with accuracy (e.g. increases in major bleeding, minor 
bleeding etc.).     
Information regarding the duration of either DAPT or TT, or what default therapy was 
once DAPT or TT was discontinued was inadequately described in all studies; therefore, 




The existing literature comparing DAPT to TT for this patient group was poor in quality, 
consisting predominantly of retrospective studies with mixed ACS and PCI patients. 
There was a lack of detail on treatment allocation, and important differences in the 
clinical characteristics of DAPT and TT treatment arms were often not accounted for. 
There was not consistent evidence of reduced stroke or composite ischaemic endpoints 
associated with TT, however the largest study indicated that TT offered significant 
reductions in mortality and stroke. Where adjusted results were presented, TT was 
consistently associated with an increase in bleeding risk. Due to the heterogeneity of 
bleeding endpoints utilised we remain uncertain as to the characteristics of the 
increased bleeding seen with TT. It also remains unclear how the increases in bleeding 
associated with TT are offset by reductions in thromboembolic events or mortality for 
ACS patients with AF. Therefore, we believe a decision analysis model may provide 
guidance regarding the thresholds at which TT results in benefit from stroke prevention 




5  Decision analysis model:  
balancing bleeding risk with stroke 




Chapter 4 demonstrated that the evidence base that informs clinicians when managing 
ACS patients with AF is poor. To date only 10 studies have compared DAPT and TT in 
pure AF with ACS/PCI populations, and these were mostly retrospective in design. 
However despite the small number of studies examined in the previous chapter we 
consistently observed that use of TT in this patient group was associated with increased 
rates of bleeding 240, and this has previously been identified as an independent driver of 
mortality after an ACS event 235,241. With regard to stroke prevention with TT, the largest 
study saw a significant reduction in stroke endpoints on the basis of adjusted results. 
This was also supported by 6 smaller studies that presented lower stroke rates with TT, 
however, these were not all statistically significant 240. To further describe this trade-off 
between increased bleeding risk and decreased stroke risk with TT, additional 
investigation is required.     
On the basis of clinical guidelines for the management of ACS patients with AF, patients 
at high risk of stroke are suggested to receive TT; in this context TT is likely to offer 
protection against stroke that exceeds the increased harm from bleeding, and is 
therefore beneficial. Conversely, patients at high risk of bleeding are suggested to 
receive DAPT over TT; in this instance TT would likely result in harm from bleeding that 
exceeds benefit from stroke prevention, and is therefore harmful.  Accurately defining 
the thresholds to indicate TT use is challenging, and currently there is not consensus 
across guideline publications regarding the definitions of high risk of stroke and high risk 
of bleeding as outlined in Chapter 1 of this thesis. 
In the absence of RCTs, a decision analysis model may be a useful tool as it provides a 
theoretical, systematic and transparent approach to clinical decision making. In brief, a 
decision analysis model utilises quantitative inputs from published literature to 
construct a decision tree, taking into account the associated probabilities and utilities of 
possible health outcomes, and in doing so provides a logical framework to compare 
treatment strategies 242. Similar challenges have arisen in AF alone populations where 
the administration of OAC is required for thromboprophylaxis, but also results in excess 
bleeding that could cause harm. Decision models have been used previously to 
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determine circumstances that favour OAC therapy for AF patients requiring protection 
from stroke who are at risk of intracranial haemorrhage 243, upper gastrointestinal 
bleeding 244 or those at risk of bleeding from falls 245. Decision models have also been 
used to determine the tipping point between different antithrombotic therapies for AF 
patients by taking into account both risk of stroke and risk of bleeding 246,247.  
Using a similar approach to that seen in AF cohorts we set out to construct a decision 
analysis model to examine the use of TT and DAPT in ACS patients with AF. Our model 
was constructed to identify the theoretical tipping points at which TT would result in 
benefit from stroke protection that outweighed the harm from excess bleeding. Health 
outcomes were evaluated with regard to quality-adjusted life years (QALY) and risk of 
mortality.  
Therefore, the aims of this study were: 
 To construct a decision analysis model to evaluate bleeding and stroke risk in ACS 
patients with AF 
 To determine likely thresholds of stroke risk at which the benefits of TT may 




The utilisation of a decision analysis model is a theoretical approach to evaluating the 
potential outcomes of clinical decisions and therefore must be custom built. We 
constructed this decision analysis model utilising LabVIEW 8.5 software (National 
Instruments, Austin, Texas). The decision analysis model was used to determine the 
tipping point, the stroke risk threshold at which the benefit of TT exceeds harm from 
bleeding, for ACS patients with AF in the 12 months post ACS event. We explored these 
tipping points at varying levels of stroke and haemorrhagic risk. A schematic of the 
decision analysis model can be seen in Figure 5-1. The decision model was run in the 
first instance to represent a base case scenario. Following this the model was run an 
additional two times, once for worst case stroke distribution and once for worst case 
stroke utilities, as found in published literature respectively.
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Figure 5-1 Schematic of the decision analysis model 
Flow diagram of the components of the decision model. Bleeding events categorised as fatal, non-fatal intracranial, major and minor. Stroke events 
categorised as fatal, major disability, moderate disability and minor disability. Model outputs were evaluated with regard to total quality adjusted life years 
(QALYs) and total mortality for both stroke and bleeding events.  
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5.2.1 Baseline conditions 
Baseline conditions for the model were a patient’s one-year risk of bleeding and one-
year risk of stroke. For both conditions level of risk was determined from published 
literature with respect to DAPT.  Defining bleeding rates in ACS populations is difficult, 
largely due to the heterogeneity of bleeding definitions available and the challenges of 
accurately recording low acuity bleeding events 227,248. Therefore literature that reports 
any bleeding rates in ACS cohorts are likely to offer greater accuracy (see the CURE and 
APPRAISE-2 trials in Table 5-1). On the basis of this we entered one-year risk of bleeding 
(on DAPT) into the model at 7.5%.   In addition, we modelled bleeding rates both lower 
and higher than this, at 5% and 10%, to cover a range of probable circumstances (Table 
5-1).  
 
Table 5-1 Bleeding rates of patients from contemporary ACS trials 
ACS Trial Bleeding definition Total rate 
CURE 83 Any bleeding 6.8% 
PCI-CURE 84 Study criteria: 
Major bleeding (incl. blood 
transfusion)  
Minor bleeding  
7.4%ᵻ 
TRITON TIMI-38 237 TIMI major and minor bleeding 4% ᵻ 
PLATO 238 TIMI major or minor bleeding 10.1% ᵻ 
ATLAS ACS 2-TIMI 51ǂ 
179 
TIMI major or minor bleeding  6.3% ᵻ 
APPRAISE -2ǂ 178 Any bleeding 8.4% 
ǂ Indicates bleeding rates from DAPT arm only. ᵻ Bleeding rates do not include lower acuity events (e.g. TIMI minimal or similar) as 
indicated by bleeding definitions presented. 
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One-year risk of stroke (on DAPT) was entered into the model at 2.2%, 3.2%, 4.0%, 6.7% 
and 9.8% and these values equate to the annual risk of stroke for CHA2DS2VASc scores 2 
through to 6 209. The CHA2DS2VASc risk stratification tool was originally derived from 
non-anticoagulated AF patients, and therefore the risk percentages are not strictly 
transferrable to annual stroke risk on DAPT, given antiplatelet medication will provide a 
level of protection against stroke. The consequence of using CHA2DS2VASc rates as a 
surrogate for risk of stroke on DAPT, is that the model will overestimate the risk of stroke 
for any given CHA2DS2VASc score in this study. As benefit from TT is driven by stroke risk 
this was a deliberate step to ensure TT was not at a disadvantage in the model. For ease 
of interpretation, when the condition one-year risk of stroke is mentioned hereafter it is 
most commonly referred to by its corresponding CHA2DS2VASc score.  
 
5.2.2 Adjustment to baseline conditions by therapy 
Baseline conditions were adjusted on the basis of treatment strategy. One-year risk of 
bleeding was unadjusted in the DAPT arm of the model, but increased in the TT arm.  
When bleeding rates for TT and DAPT are compared, most studies reports significant 
increases in bleeding on TT; the strongest evidence of this has emerged from RCTs of 
ACS patients (Table 5-2). Taking this in account, bleeding on TT was entered into the 
model at two values, relative risks of 2 and 2.5 fold that of DAPT.  
Similarly, one-year risk of stroke was unadjusted in the DAPT arm of the model, but 
decreased in the TT arm, representing increased stroke protection from TT. Estimating 
the benefit TT offers over DAPT with regard to stroke protection was more challenging 
as overall there is less literature available to quantify this. The APPRAISE-2 and ATLAS 
ACS 2-TIMI 51 RCTs did not demonstrate significant reductions in ischaemic stroke with 
TT, however these were cohorts of ACS patients, and not ACS patients with AF who by 
comparison have increased stroke risk. The observational study of 12,165 AF patients 
with MI/PCI, conducted by Lamberts et al, found TT significantly reduced ischaemic 
stroke when compared to DAPT, reporting an odds ratio of 0.67 (0.46-0.98) (Table 5-2); 
to date this is the best evidence available for stroke prevention in AF patient with ACS. 
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Overall there is less certainty as to the level of protection TT offers over DAPT with 
regard to protection from ischemic stroke. Therefore we modelled varying degrees of 
protection with TT in the form of odds ratios (0.65, 0.7, 0.75, and 0.8). An odds ratio of 
0.65 represented TT at its most protective, and an odds ratio of 0.8 represented TT at 
its least protective. 
 
Table 5-2 Summary of TT versus DAPT studies examining stroke and 
bleeding endpoints 
Study Description RR of bleeding 
with TT  
OR of ischaemic 
stroke with TT 
APPRAISE -2 178 Randomised control trial: 
ACS cohort 
2.59 (1.5-4.46)* 0.68 (0.4-1.15) 
ATLAS ACS 2-
TIMI 51 179 














Information obtained from these studies pertains to DAPT in the form of aspirin and clopidogrel, and TT in the form of aspirin, 
clopidogrel and OAC (VKA or NOAC). * indicates statistical significance, p<0.05. MI= myocardial infarction; OR = odds ratio; PCI = 
percutaneous coronary intervention; RR = relative risk. 
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5.2.3 Distribution of events by severity 
With the rates of stroke and bleeding established for each treatment arm, the 
distribution of events by severity were calculated. Bleeding events were defined using 
the TIMI criteria as fatal bleeding, non-fatal intracranial bleeding, major bleeding and 
minor bleeding, and all were non-CABG related 227. Bleeding event distribution for the 
base case was taken from a cost-effectiveness analysis of randomised trials pertaining 
to ACS patients on DAPT 249 (Table 5-3). 
Stroke events were defined using the modified Rankin score (mR) and stratified as fatal 
(mR 6), major disability (mR 5), moderate disability (mR 3-4) and minor disability (mR 0-
2) 250. For the base case, the distribution of stroke events was taken from a cost-
effectiveness analysis 251 of randomised trial data regarding thromboprophylaxis in over 
23,000 AF patients (ARISTOTLE and AVERRORES [Apixaban Versus Acetylsalicylic Acid to 
Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for 
Vitamin K Antagonist Treatment] cohorts) 165,252 (Table 5-3).  
 
5.2.4 QALY weighting (utility) by severity 
Each event was then allocated a corresponding QALY weighting, also known as a utility 
measure. A utility of zero equates to death, and a utility of 1 equates to perfect health. 
The utility measures for bleeding events were taken from the same cost-effectiveness 
analysis that bleeding distribution was sourced from; these utilities in turn were sourced 
from multiple previous ACS decision models 249. For the base case, stroke utilities were 
taken from the same cost-effectiveness analysis that stroke distribution was taken 
from251; these utilities originated from the EQ-5D health assessment tool which is a 
standardised measure of quality of life 253 (Table 5-3).  
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Table 5-3 Model parameters 
Parameter Distribution     QALY weight (utility) 
Stroke Base case Worse case Base case Worse case 
 Fatal stroke 0.11 0.232 - - 
 Major disability 0.15 0.219 0.5141 0.11 
 Moderate disability  0.38 0.21 0.5646 0.39 
 Minor disability  0.36 0.339 0.6151 0.6151 
 Reference 251 254 251 251,255 
Bleeding     
 Fatal bleeding 0.03  -  
 Non-fatal intracranial bleeding 0.03  0.61  
 Major bleeding 0.5  0.96  
 Reference 249  249  
Annual risk of stroke according to  CHA2DS2VASc score 209 
 1:  1.3% 4: 4.0% 7:  9.6%  
 2:  2.2% 5: 6.7% 8: 6.7% 
 3:  3.2% 6: 9.8% 9: 15.2% 
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5.2.5 Model outputs 
The final step in the decision model was to generate model outputs on the basis of the 
above-mentioned stroke and bleeding event rates, distributions and utilities.  For each 
set of input parameters the model was iterated 1000 times to generate the model 
outputs in the form of total QALY or total mortality measures. 
Total QALY outputs were calculated for each treatment arm and took into account all 
stroke events (fatal, major, moderate and minor) and all bleeding events (fatal, intra-
cranial and major). We explored this for the range of baseline bleeding and stroke risks, 
across all adjustment by therapy parameters, to determine the tipping points. Under 
each combination of variables the therapy, DAPT or TT, which maximised QALY was 
determined as the treatment of choice.  
Mortality outputs were fatal bleeding risk and fatal stroke risk. All models for mortality 
were generated using a 7.5% one-year rate of bleeding, and base case distributions and 
utilities. The therapy with the lowest mortality risk was selected as treatment of choice. 
Benefit was calculated as the absolute difference when compared to the higher risk 
therapy. In addition to this, pooled mortality risk was calculated by combining fatal 
bleeding risk and fatal stroke risk for each treatment arm.  
 
5.2.6 Modifications to stroke distribution and utility 
After the base case scenario the decision analysis model was run an additional two 
times, to test TT under a set of parameters where it had potential to be most useful. The 
second run of the model substituted in worst case stroke distribution as found in 
published literature, and this was  identified in a cost-effectiveness analysis of DAPT for 
stroke prevention in AF patients254, and was based on the ACTIVE-A (Atrial Fibrillation 
Clopidogrel Trial with Irbesartan for Prevention of Vascular Events–A) trial 256. Compared 
to the base case this change in parameters saw an increase in strokes that were fatal or 
resulted in major disability (Table 5-1). The third run of the model returned stroke event 
distribution back to base case settings, but substituted in worst case stroke utilities, 
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which were found in a utility elicitation study where AF patients were interviewed about 
their quality of life 255. This change to parameters saw the utility of major and moderate 
disability strokes decrease, however the utility of stroke with minor disability remained 
the same, as per the base case (Table 5-3).     
 
5.2.7 Model assumptions 
Firstly, DAPT either alone or as part of TT, is the recommended preventative measure 
for secondary cardiovascular ischaemic events (e.g. MI, stent thrombosis) 88-91. On 
consideration of TT versus DAPT literature, the model assumes that the addition of OAC 
to DAPT to form TT is dependent on stroke/bleeding consequences, but independent of 
secondary cardiovascular ischaemic events; predominantly there are no differences in 
secondary cardiovascular ischaemic events when TT and DAPT are compared 
178,179,199,217,222,223 and therefore these events were not included in the model.  
Secondly, patient age was not entered into the model. As the clinical dilemma in 
question pertains to the first 12 months post ACS event, the consequence of the model 
does not extend beyond this time frame; the assumption being both arms are equal 
after 12 months and return to routine therapy.  
Thirdly, for simplicity the model assumed that all stroke and bleeding events occurred 
at the same time, essentially on day one post index event. This is because the inputs for 
risk of stroke and risk of bleeding were not modified to account for changes in risk over 
the 12 month period. For similar reasons the model also assumed no transition between 
health states; in reality a patient is likely to have medication changes should they 
experience either a stroke or bleeding complication within the 12 months post ACS and 
it is unlikely that these circumstances could be replicated in a model with certainty.  
Lastly, a utility for minor bleeding was not entered into the model as the consequences 




5.3.1 Total QALY – base case 
The results from the base case model can be seen in Table 5-4 and this iteration takes 
into account all events (stroke: fatal, major, moderate and minor; bleeding: fatal, 
intracranial and major). The treatment which maximise QALY for each set of conditions 
is displayed. Under all conditions for patients with a CHA2DS2VASc score of 2 or less, 
treatment with DAPT is preferred over TT. The implication at this level is that TT results 
in bleeding harm that exceeds benefit from stroke protection. On the other hand, when 
stroke risk increases to a CHA2DS2VASc score of 6, under all conditions treatment with 
TT is preferred. In this instance TT results in benefit from stroke protection that exceeds 
harm from bleeding. The tipping point at which benefit from TT outweighs the 
associated harm lies between the CHA2DS2VASc scores of 2 and 6, and depends upon 
the risk parameters applied.   
When we consider the 7.5% one-year risk of bleeding we observe that all patients with 
a CHA2DS2VASc score of 3 have QALY maximised with DAPT. For these patients the 
tipping point in favour of TT occurs at a CHA2DS2VASc score of 4 at a minimum, if not a 
CHA2DS2VASc score of 5 and less often 6. However if one-year bleeding risk is lower at 
5% the tipping point in favour of TT also lowers and occurs most commonly at 
CHA2DS2VASc scores 3-4. Where one-year bleeding risk is higher at 10%, we see a clear 
indication that for all conditions, patients with CHA2DS2VASc scores of 4 have QALY 
maximised with DAPT. The increased annual risk of bleeding seen here has resulted in 
bleeding harm from TT that exceeds stroke protection until at least CHA2DS2VASc 5 and 
sometimes 6.  
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Table 5-4 Base case total QALY outputs 
   TT bleeding relative risk = 2  TT bleeding relative risk = 2.5 
  TT Stroke 
OR 
0.65 0.7 0.75 0.8  0.65 0.7 0.75 0.8 
  CHA2DS2VASc 




















1 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
2 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
3 TT TT TT DAPT  DAPT DAPT DAPT DAPT 
4 TT TT TT DAPT  TT TT DAPT DAPT 
5 TT TT TT TT  TT TT TT TT 
 6 TT TT TT TT  TT TT TT TT 





1 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
2 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
3 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
4 TT TT DAPT DAPT  DAPT DAPT DAPT DAPT 
5 TT TT TT TT  TT TT DAPT DAPT 
 6 TT TT TT TT  TT TT TT TT 





1 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
2 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
3 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
4 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
5 TT TT TT DAPT  DAPT DAPT DAPT DAPT 
  6 TT TT TT TT  TT TT TT TT 
DAPT = dual antiplatelet therapy; OR = odds ratio; TT = triple therapy.  
124 
5.3.2 Total QALY – worst case stroke distribution 
The decision analysis model was run a second time according to worst case stroke 
distributions as found in published literature. The proportion of fatal and major strokes 
were increased to 23.2% and 21.9% respectively, while moderate and minor stroke 
proportions decreased to 21.0% and 33.9% respectively.  The outcomes from this model 
can be seen in Table 5-5. Despite large changes in the rate of fatal and major strokes 
there was little change in treatment recommendations when compared to the base case 
scenario. All changes (white boxes) were in favour of TT where DAPT had been 
previously.  
In only one circumstance did a CHA2DS2VASc score of 2 result in benefit from TT that 
exceeded harm, and that was when all variables assumed TT to be at its most favourable, 
with a one-year bleeding risk of 5%, the lowest relative risk of bleeding lowest (relative 
risk 2) and the greatest stroke protection (odds ratio 0.65). For all other conditions a 
CHA2DS2VASc score of 2 resulted in DAPT as the preferred therapy. Consistent with the 
base case, under every set of conditions a CHA2DS2VASc score of 6 resulted in benefit 
from TT. Although the distribution of stroke is at its worse in this model, we have once 
again observed that for TT, the tipping point to indicate stroke prevention benefit that 
exceeds harm from excess bleeding, occurs around a CHA2DS2VASc score of 3-5.  
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Table 5-5 Total QALY model outputs - worst case stroke distribution 
   TT bleeding relative risk = 2  TT bleeding relative risk = 2.5 
  TT Stroke 
OR 
0.65 0.7 0.75 0.8  0.65 0.7 0.75 0.8 
  
CHA2DS2VASc 



















1 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
2 TT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
3 TT TT TT DAPT  TT DAPT DAPT DAPT 
4 TT TT TT TT  TT TT DAPT DAPT 
5 TT TT TT TT  TT TT TT TT 
 6 TT TT TT TT  TT TT TT TT 





1 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
2 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
3 TT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
4 TT TT DAPT DAPT  DAPT DAPT DAPT DAPT 
5 TT TT TT TT  TT TT TT DAPT 
 6 TT TT TT TT  TT TT TT TT 





1 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
2 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
3 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
4 TT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
5 TT TT TT DAPT  TT DAPT DAPT DAPT 
  6 TT TT TT TT  TT TT TT TT 
DAPT = dual antiplatelet therapy; OR = odds ratio; TT = triple therapy. White boxes indicate a change from the base case as seen in 
Table 5-4.  
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5.3.3 Total QALY – worst case stroke utilities 
The third iteration of the model was run using worse case stroke utilities.  This saw a 
large reduction in major stroke utility (from 0.51 to 0.11) and moderate stroke utility 
(from 0.56 to 0.39), while minor stroke utility remained constant (0.62).  The results 
from this can be seen in Table 5-6.  With the post-stroke quality of life utilities greatly 
reduced there were moderate changes in therapeutic recommendations (white boxes), 
all in favour of TT over DAPT when compared to the base case.  
On the basis of 7.5% one-year bleeding risk, the tipping points to indicate TT occurred 
most commonly at scores of CHA2DS2VASc 3-5, where in the base case the tipping points 
were most commonly higher at CHA2DS2VASc 4-6.  However, consistent with the base 
case, a CHA2DS2VASc of 2 or less results in DAPT still being preferable. If one-year 
bleeding risk increased to 10% the tipping points alter moderately, with a CHA2DS2VASc 
score of 5 for the most part necessary to favour TT, and in one circumstance a 
CHA2DS2VASc of 4 resulted in TT (when TT offered greatest stroke protection with an 
odds ratio of 0.65). When we consider the lowest one-year risk of bleeding, 5%, we see 
that treatment with TT is recommended more so. For all CHA2DS2VASc scores of 1, DAPT 
is the preferred therapy however, benefit from TT exceeds harm for a range of 
circumstances at CHA2DS2VASc 2, 3 and most of CHA2DS2VASc 4.   
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Table 5-6 Total QALY model outputs - worst case stroke utilities 
   TT bleeding relative risk = 2  TT bleeding relative risk = 2.5 
  TT Stroke 
OR 
0.65 0.7 0.75 0.8  0.65 0.7 0.75 0.8 
  
CHA2DS2VASc 



















1 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
2 TT TT DAPT DAPT  DAPT DAPT DAPT DAPT 
3 TT TT TT TT  TT TT DAPT DAPT 
4 TT TT TT TT  TT TT TT DAPT 
5 TT TT TT TT  TT TT TT TT 
 6 TT TT TT TT  TT TT TT TT 





1 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
2 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
3 TT TT DAPT DAPT  DAPT DAPT DAPT DAPT 
4 TT TT TT DAPT  DAPT DAPT DAPT DAPT 
5 TT TT TT TT  TT TT TT DAPT 
 6 TT TT TT TT  TT TT TT TT 





1 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
2 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
3 DAPT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
4 TT DAPT DAPT DAPT  DAPT DAPT DAPT DAPT 
5 TT TT TT TT  TT TT DAPT DAPT 
  6 TT TT TT TT  TT TT TT TT 
DAPT = dual antiplatelet therapy; OR = odds ratio; TT = triple therapy. White boxes indicate a change from the base case as seen in 
Table 5-4.  
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5.3.4 Mortality 
Probabilities of stroke mortality and bleeding mortality were generated from the 
decision model using base case parameters and a 7.5% rate of one-year bleeding. Table 
5-7 displays probabilities of fatal stroke and fatal bleeding.  When mortality from stroke 
alone is considered, we observe that with increasing CHA2DS2VASc scores, the 
associated stroke mortality increases also. Across the range of risk reductions associated 
with TT (odds ratios 0.65- 0.8) there is a proportional decrease in stroke mortality 
compared to DAPT, but the absolute reduction in stroke mortality from TT was greatest 
at CHA2DS2VASc 6 (Table 5-7). In this model, bleeding risk was held constant and the 
relative risk of bleeding associated with TT was modelled; we see this reflected in 
mortality outputs where fatal bleeding remains constant on DAPT, and is 2 or 2.5 times 
higher in the respective TT arms (Table 5-7).  
Figure 5-2 displays preferential therapy with respect to fatal bleeding risk, fatal stroke 
risk and combined mortality risk for each CHA2DS2VASc score. These outputs were 
generated under base case conditions, and with TT offering greatest protection from 
stroke (odds ratio 0.65) and lowest relative risk of bleeding lowest (relative risk 2). When 
absolute differences were considered, bleeding mortality risk favours treatment with 
DAPT for each CHA2DS2VASc score. Stroke mortality risk favours TT for every 
CHA2DS2VASc score and absolute differences increases as stroke risk increases; at 
CHA2DS2VASc 2 the absolute difference favours TT by 0.065% and increases to 0.302% 
at CHA2DS2VASc 6. With respect to combined mortality, DAPT is the preferred treatment 
from CHA2DS2VASc 2 to 5, and at CHA2DS2VASc 6 combined mortality tips to favour TT.  
Numerically, at CHA2DS2VASc 2 combined mortality risk favours DAPT by 0.16% and this 






Table 5-7 Mortality outputs 
   Stroke Mortality (%) Bleeding Mortality (%)  Stroke Mortality (%) Bleeding Mortality (%) 
CHA2DS2
VASc 







































0.194 0.129 0.225 0.562 
0.7 0.194 0.136 0.225 0.45 0.194 0.136 0.225 0.562 
0.75 0.194 0.145 0.225 0.45 0.194 0.145 0.225 0.562 
0.8 0.194 0.155 0.225 0.45 0.194 0.155 0.225 0.562 
 
3 
0.65 0.282 0.183 0.225 0.45 0.282 0.183 0.225 0.562 
0.75 0.282 0.197 0.225 0.45 0.282 0.197 0.225 0.562 
0.75 0.282 0.211 0.225 0.45 0.282 0.211 0.225 0.562 
0.8 0.282 0.225 0.225 0.45 0.282 0.225 0.225 0.562 
 
4 
0.65 0.352 0.228 0.225 0.45 0.352 0.228 0.225 0.562 
0.7 0.352 0.246 0.225 0.45 0.352 0.246 0.225 0.562 
0.75 0.352 0.264 0.225 0.45 0.352 0.264 0.225 0.562 
0.8 0.352 0.282 0.225 0.45 0.352 0.282 0.225 0.562 
 
5 
0.65 0.589 0.383 0.225 0.45 0.589 0.383 0.225 0.562 
0.7 0.589 0.412 0.225 0.45 0.589 0.412 0.225 0.562 
0.75 0.589 0.442 0.225 0.45 0.589 0.442 0.225 0.562 
0.8 0.589 0.472 0.225 0.45 0.589 0.472 0.225 0.562 
 
6 
0.65 0.862 0.560 0.225 0.45 0.862 0.560 0.225 0.562 
0.7 0.862 0.603 0.225 0.45 0.862 0.603 0.225 0.562 
0.75 0.862 0.648 0.225 0.45 0.862 0.648 0.225 0.562 
0.8 0.862 0.689 0.225 0.45 0.862 0.689 0.225 0.562 
DAPT = dual antiplatelet therapy; OR = odds ratio; TT =triple therapy.
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Figure 5-2 Mortality risk 
Chance of mortality is presented as the absolute difference in mortality risk (%) when 
compared to the higher risk therapy. The light blue bars represent the therapy that is 
preferred when risk of fatal bleeding and risk of fatal stroke are considered separately. The 
dark blue bars represents the therapy that is favoured when risk of fatal bleeding and risk of 
fatal stroke are considered together. As stroke risk (CHA2DS2VASc) increases overall favour 






When the risk of mortality from bleeding or stroke was pooled we found that DAPT 
generated less mortality risk than TT for CHA2DS2VASc scores 2 to 5 (Figure 5-3). At 
CHA2DS2VASc 2, 3 and 4 there is a clear delineation between DAPT and TT with respect 
to pooled mortality risk (0.41% vs. 0.59%, 0.5% vs. 0.65% and 0.58% vs. 0.71%, 
respectively). At CHA2DS2VASc 5 pooled mortality risk begins to converge with DAPT 
still carrying less pooled mortality risk (0.81% vs. 0.88%). At CHA2DS2VASc 6, pooled 
mortality risk was comparable between the two treatments however, at this level TT 
generated slightly less risk (1.075% vs. 1.08%) and was therefore the tipping point 





Figure 5-3 Pooled fatal bleeding and fatal stroke mortality risk 
Plots represent the pooled risk of death from bleeding or stroke at each CHA2DS2VASc score. DAPT carries a lower pooled annual mortality risk for 
CHA2DS2VASc scores 2 through 5, and at CHA2DS2VASc 6 favour tips to TT. 
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5.4 Discussion 
This study was designed to determine the likely tipping points at which treatment with 
TT resulted in benefit from stroke protection that outweighed harm from bleeding. 
When total QALY was considered we found the tipping point to be higher than a 
CHA2DS2VASc score of 2, and lower than a CHA2DS2VASc score of 6, and was dependent 
upon the risk parameters applied.  When the model was repeated with worst case stroke 
parameters the results only moderately changed. When we assumed lower one-year 
bleeding risk and worst case stroke parameters, on occasion a CHA2DS2VASc score 2 was 
the tipping point to indicate TT.   However under most conditions excess bleeding with 
TT will cause more harm than benefit until stroke risk is higher; somewhere in the 
vicinity of CHA2DS2VASc score 3, 4 and 5.  
The quality of model inputs sourced from available literature directly impacts the quality 
of model outputs. The distribution and utility of bleeding events were derived from a 
cost-effectiveness analysis of patients on DAPT, which was centred on the all-important 
ACS trials, CURE 83, TRITON-TIMI 38 237, and PLATO 238; we consider these ACS trials to 
be high-quality, large-scale and contemporary and therefore a reliable source of 
information for bleeding in our model.  For the base case bleeding on DAPT was 
estimated at 7.5% per annum and this equated to a fatal bleeding rate of 0.225% per 
annum and an intracranial bleeding rate of 0.225%. When compared to the above 
mentioned DAPT trials we see that our distribution of fatal bleeding and intracranial 
haemorrhage (ICH) is not dissimilar (CURE: fatal bleeding 0.2%, ICH 0.1%; TRITON-TIMI 
38: fatal bleeding 0.1-0.4%, ICH 0.3%; PLATO: fatal bleeding 0.3%, ICH 0.2-0.3%). The 
7.5% annual bleeding rate also generated a non-CABG TIMI major bleeding event rate 
of 3.75% in our model and although there was slightly less consistency between this and 
DAPT trials, rates were not largely different (CURE: 2.7-3.7%; TRITON-TIMI 38: 1.8-2.4%; 
PLATO: 2.2-2.8%). Overall, we consider the 7.5% annual bleeding rate entered into the 
model to be a reasonable proxy, and with the addition of the low bleeding risk (5%) and 
higher bleeding risk (10%) iterations, an accurate estimate of real-world conditions is 
likely represented within our model.  
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The increased risk of bleeding on TT compared to DAPT is large and consistently 
recorded throughout published literature. The APPRAISE-2 178 and ATLAS ACS 2-TIMI 51 
179 trials mentioned above resulted in significantly more TIMI major bleeding with TT 
(hazard ratios 2.59 [1.5-4.46] and 3.96 [2.46-6.38] respectively). In addition, multiple 
observational studies of AF patients with ACS/PCI demonstrate increases in bleeding 
with TT over DAPT with statistically significant odds ratios ranging from 1.79-2.97 
199,214,223. We entered the relative risk of bleeding with TT to be 2-2.5 fold that of DAPT 
and it is possible that this may be a conservative estimate, and by extending this RR this 
would have disadvantage TT more so.  
In estimating stroke parameters, the distribution and utilities were based on 
predominant randomised control trials of therapy for AF, namely ARISTOTLE 165, 
AVERROES 252 and ACTIVE-A 256. Research of this calibre does not yet exist for ACS 
patients with AF, but the use of this quality AF data as a surrogate does provide 
satisfactory confidence in the stroke inputs we utilised.  
Estimating the degree of stroke protection from TT compared to DAPT was more 
challenging. The RCTs APPRAISE-2 178 and ATLAS ACS 2-TIMI 51 179 added NOAC therapy 
to standard ACS management (80% DAPT and 93% DAPT, respectively) and neither study 
found TT to significantly reduce ischaemic stroke (APPRAISE-2: odds ratio 0.68, [0.40-
1.15]; ATLAS ACS 2-TIMI 51: odds ratio 0.97, [0.64-1.14]). However, it is important to 
note that these studies were of ACS patients that did not necessarily have significant risk 
factors for stroke. Beyond this we considered lesser-quality observational studies of AF 
patients with PCI and/or ACS. The largest was a study of over 12,000 AF patients with 
ACS/PCI which reported TT significantly increased stroke protection over DAPT (odds 
ratio 0.67, [0.46-0.98]) 199. Another two studies showed benefit from TT with odds ratios 
of 0.71 and 0.76 and however these were unadjusted and neither reached statistically 
significance 217,220.  On the basis of the ACTIVE-W trial (Atrial Fibrillation Clopidogrel Trial 
With Irbesartan for Prevention of Vascular Events) we also know that warfarin alone is 
superior to DAPT for protection against ischaemic stroke in AF patients (without ACS) 
(odds ratio 0.46, [0.32-0.66]) 198, and this may provide a signal towards the TT-DAPT 
dynamic for stroke protection.  
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As we were less certain about the stroke protection received with TT we ran the model 
with varying degrees of protection when compared to DAPT, with odds ratios ranging 
from 0.65-0.8; how accurate this is remains unknown due to the quality of the source 
literature. This variable has impacted largely on the outputs of the model, and 
contributes greatly to the lack precision with regard to tipping points. Had we more 
confidence in the degree of stroke prevention with TT, our model outputs may have 
been more exact in defining thresholds where benefit from TT exceeds harm.  However 
despite these challenges it remains evident that stroke protection from TT is relatively 
small compared to the increased risk of bleeding that accompanies this therapy, and 
hence the tipping points for the most part exceed a CHA2DS2VASc score of 2.  
This model was designed to examine the benefit-harm ratio for 12 months after ACS 
however long term implications also warrant discussion. We may have inadvertently 
introduced a bias into our model on the basis that the long term effects of bleeding 
events are in general terms less permanent than those of stroke events. With this in 
mind it is important to consider the mortality outputs, as by definition fatal endpoints 
have zero utility and therefore no ongoing consequence. Under base case parameters 
we observed that TT consistently resulted in more harm from fatal bleeding, than 
benefit from fatal stroke prevention, for all CHA2DS2VASc scores 2 to 5. Only at a 
CHA2DS2VASc score of 6 did DAPT result in greater harm from mortality, and therefore 
this was the tipping point to indicate treatment with TT. Therefore, irrespective of any 
potential long term bias the message is consistent; TT results in excess harm from 
bleeding that is greater than the benefit of reduced stroke until higher CHA2DS2VASc 
scores.  
On the basis of our results the model indicates that as CHA2DS2VASc scores increase, TT 
is likely to become a better treatment option for ACS patients with AF. However, neither 
the single-centre study (Chapter 2) nor the ANZACS-QI study (Chapter 3) demonstrated 
that elevated CHA2DS2VASc scores were strongly influencing clinician use of TT.  Across 
both the single-centre and ANZACS-QI studies TT use was low, not only for patients with 
lower CHA2DS2VASc scores where the model indicates this is appropriate, but for all 
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CHA2DS2VASc scores, including those at very high risk of stroke who would benefit from 
TT.     
The results of this model, taken together with the TT prescription rates outlined above, 
highlight the need for further prospective work examining the use of TT in ACS patients 
with AF. As we have covered in previous chapters there is inconsistency across clinical 
guidelines as to the definition of high risk of stroke, and therefore inconsistency as to 
when TT is indicated. The New Zealand and American guidelines do not define a 
threshold however the ESC suggest CHA2DS2VASc score of 1, the Australian guidelines 
suggest a CHA2DS2VASc ≥2, and Canadian Cardiac Society uses a threshold akin to 
CHA2DS2VASc 2 (CHADS2 ≥ 1 or age over 65). On the basis of our decision model it is 
evident that despite the discrepancies between guidelines, in all instances the TT 
threshold is likely too low. Whilst this model lacks precision in being able to define an 
exact threshold to indicate benefit from TT, it does provide valuable hypothesis 
generating information, and indicates that future RCTs would be well place to test a TT 
threshold around CHA2DS2VASc scores 3 -5.  
 
5.4.1 Model assumptions 
In the construction of this model we implemented deliberate assumptions to ensure TT 
was not disadvantaged when compared to DAPT. Firstly, we used absolute CHA2DS2VASc 
stroke rates as a surrogate for annual stroke risk on DAPT. In doing so, this did not take 
into account any thromboprophylaxis as a result from DAPT, thereby enhancing the 
relative stroke protection from TT.  Secondly, we may have been conservative with our 
estimate of the relative risk of bleeding on TT. Lastly, we ran the model additional times 
to implement the worst case stroke rate distribution and worst case stroke utilities, in 
effect to examine scenarios where TT would be most beneficial.  Whilst doing this made 
some adjustments to the model outputs, the overall message remained constant- that 
the tipping point between DAPT and TT did not occur until higher CHA2DS2VASc scores. 
We did not perform worst case bleeding rates and utilities for bleeding as this would 
have only favoured DAPT more so.  
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Another major assumption within the model is that DAPT and TT treatment strategies 
are neutral with regard to recurrent ischaemic events in the 12 months post ACS event.  
This assumption was driven largely by the fact that both arms receive DAPT, the 
standard of care for secondary prevention, however, it could be argued that TT may 
provide a greater level of protection due to the thromboprophylaxis attributed to oral 
anticoagulation. With regard to disease pathophysiology it is important to note that 
thrombi formed in the arterial system, like those in ACS are predominantly platelet rich, 
in contrast to thrombi formed in low pressure systems (e.g. atria) which are fibrin rich 
27. Therefore any efficacy in recurrent ischaemic events attributed to OAC is likely to be 
inconsistent and variable.  
 
5.4.2 Limitations 
Firstly, the construction of this decision model was based largely on inputs from 
observational studies that were not the quality we would have ideally wanted. Ideally 
all utilities and probabilities used in this model would have been derived from detail-
rich, randomised trials of pure AF with ACS populations however currently no such 
information is available. Therefore probabilities and utilities were derived from best 
quality cost-effectiveness analyses and/or utility elicitation studies in either AF 
populations (for stroke information) or ACS populations (for haemorrhagic information). 
Whilst we are confident that the inputs utilised were the best available from published 
literature, the quality of the source studies adds limitations to the interpretation of our 
results as discussed above. Fundamentally we imposed a level of confidence on every 
parameter entered into the model of which we cannot be certain of accuracy.  
Secondly, our utilisation of CHA2DS2VASc for annual stroke risk, whilst practical from a 
clinical perspective does add limitations to the interpretation of results. Not all 
components of the CHA2DS2VASc risk stratification tool carry equal weight, therefore 
equal CHA2DS2VASc scores may indeed carry variable stroke risks depending on the 
factors that compose the score 257.  What’s more, other patient characteristics that are 
linked with stroke risk such as atrial fibrosis and left atrial appendage morphology are 
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not included in the CHA2DS2VASc score and would impact a patient’s actual stroke risk 
258,259.   
Lastly, we did not enter a variable for age into our decision model and therefore outputs 
do not account for consequences extending beyond 12 months. The construction of this 
model was complex as it was made up of multiple variables and resulted in hundreds of 
model outputs; as discussed previously this was largely driven by the need to model 
multiple scenarios. The addition of another variable, age, which is subject to utility 
changes over time, would have added further complexity to the model with unknown 
benefit. The clinical dilemma in question pertains to a 12 month period hence this was 
the duration modelled. As a consequence we cannot extrapolate our total QALY outputs 
to represent time-frames beyond this.   
 
5.5 Conclusion 
Our theoretical decision model has demonstrated that bleeding from TT impacts greatly 
on the overall risk-benefit balance for ACS patients with AF. For the most part bleeding 
from TT will do more harm than good unless stroke risk is sufficiently high, around 
CHA2DS2VASc scores 3 to 5. The consequences of bleeding with TT seen in this model 
highlight the need for clinicians to accurately predict patients at risk of experiencing a 
haemorrhagic event, as this is a fundamental consideration of prescribing TT.  Whether 
contemporary bleeding risk tools accurately predict post ACS bleeding events is 




6 Evaluating the ability of ACS bleeding 




In the previous chapter we established that TT results in bleeding harm which impacts 
largely on the overall risk-benefit ratio after an ACS event. Under many circumstances 
the administration of TT results in bleeding risk that exceeds any benefit gained from 
stroke prevention. As such, careful assessment of bleeding risk is a strategy that may be 
effective at identifying patients with an increased bleeding risk profile, and in turn may 
help to mitigate the risks associated with antithrombotic therapy. Consistent with this, 
most guidelines favour DAPT over TT in patients with high bleeding risk. However, 
assessment of bleeding risk will only be an effective strategy if the assessment tools are 
accurate.  
Among ACS bleeding risk stratification tools available, the CRUSADE 187 and ACTION 
(Acute Coronary Treatment and Intervention Outcomes Network registry) 260 bleeding 
scores are commonly used, and were developed and validated in large-scale cohorts. 
However, these scores were designed to be predictive of in-hospital bleeding events, 
yet previous studies have shown that the majority of bleeding events occur following 
discharge from hospital after an ACS 261. Therefore, accurate prediction of bleeding 
events for the out-of-hospital phase is also important, particularly when we consider 
that patients may be on multiple antithrombotic agents for up to one-year following an 
ACS event. 
In addition to bleeding risk scores, there is emerging evidence that identification of low 
platelet reactivity (LPR) by platelet function testing may be predictive of bleeding events 
both in-hospital and at one-year. However, most observational studies have been in 
patients undergoing PCI and findings have been variable 262. It is also unknown whether 
platelet function testing provides additive prognostic information to existing bleeding 
scores. 
To optimise outcomes for patients after an ACS accurate assessment of bleeding risk is 
essential. It may also help to mitigate bleeding harm in patients eligible for therapies 
with increased bleeding risk, such as TT. In this chapter we set out to characterise 
bleeding events in-hospital and up to one-year, in a real-world MI cohort.  We then 
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investigated the performance of the CRUSADE and ACTION risk scores to predict in-
hospital bleeding and one-year major bleeding events in patients with MI undergoing an 
invasive approach. In addition, we assessed the predictive value of platelet function 
testing to establish whether this added value to existing risk scores. 
Therefore, the aims of this study were: 
 To characterise in-hospital and one-year bleeding events in a real world MI 
cohort 
 To evaluate the ability of CRUSADE and ACTION bleeding risk scores to predict 
in-hospital and one-year bleeding events 





6.2.1 Study design and population 
In this prospective, single-centre, cohort study we in enrolled 1000 patients between 
January 2012 and May 2015. Patients with acute MI undergoing invasive management, 
who were adequately pre-treated with DAPT, were eligible for enrolment. Patients were 
excluded if they had a platelet count <100 x 109/L, a known platelet function disorder, 
administration of a fibrinolytic agent within 24 hours prior to enrolment or a 
glycoprotein IIb/IIIa antagonist within 1 week prior to enrolment. Patient management 
was at the discretion of the attending physician. This study was approved by the Lower 
Regional South Ethics Committee (LRS/11/09/035/AM01). Written informed consent 
was obtained from all subjects. 
 
6.2.2 Data Collection 
Patient demographics, clinical characteristics, clinical management, procedural 
variables and in-hospital outcomes were collected prospectively from review of medical 
records and the cardiac catheterisation database. Follow up data was collected from the 
National Admissions Database and telephone calls at 30 days and one-year. Where 
necessary, a review of case notes was performed and the appropriate general 
practitioner contacted to further classify clinical outcomes. 
 
6.2.3 Definitions 
Acute MI was defined according to the third universal definition of myocardial infarction 
263. Adequate pre-treatment on DAPT was defined as administration of aspirin (chronic 
therapy with ≥75mg/day or a loading dose with ≥300mg) with either clopidogrel (chronic 
therapy ≥75mg/day or ≥300mg loading dose) or ticagrelor (chronic therapy 90mg/bd or 
180mg loading dose). Bleeding was defined using the TIMI major and minor criteria 
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(Table 6-1) 264. The primary endpoint of this study was the combination of non-CABG 
related TIMI major and minor bleeding at one-year. 
Clinical risk factors and characteristics were defined according to the American College 
of Cardiology key data elements and definitions for measuring the clinical management 
and outcomes of patients with acute coronary syndromes 265. Anaemia was defined as 
haemoglobin <12g/dL for women, and <13g/dL for men 266. When the CRUSADE 
bleeding risk score 187 was applied patients were categorised as very low risk (score ≤20), 
low risk (score 21-30), moderate risk (score 31-40) or combined high/very high risk 
(score 41-100) (see chapter 2, Table 2-2). Likewise when the ACTION bleeding risk score 
260 was applied patients were categorised as very low risk (score ≤20), low risk (score 21-
30), moderate risk (score 31-40) or combined high/very high risk (score 41-100) (Table 
6-2). Within the ACTION risk score 2 points are attributed to patients with home warfarin 




Table 6-1 TIMI bleeding criteria 
Non-CABG TIMI bleeding  Definition 
TIMI Major Any intracranial bleeding (excluding micro-haemorrhages 
<10 mm evident only on gradient-echo MRI). 
Clinically overt signs of haemorrhage associated with a 
drop in haemoglobin of ≥5 g/dL. 
Fatal bleeding (bleeding that directly results in death 
within 7 days). 
TIMI Minor  Clinically overt (including imaging), resulting in 
haemoglobin drop of 3 to <5 g/dL. 
No observed blood loss: ≥4 g/dL decrease in haemoglobin. 
Any overt sign of haemorrhage that meets one of the 
following criteria and does not meet criteria for a major 
or minor bleeding event, as defined above: 
  Requiring intervention (medical practitioner-guided 
medical or surgical treatment to stop or treat 
bleeding, including temporarily or permanently 
discontinuing or changing the dose of a medication 
or study drug); 
Leading to or prolonging hospitalisation; 
Prompting evaluation (leading to an unscheduled 
visit to a healthcare professional and diagnostic 
testing, either laboratory or imaging). 
TIMI Minimal Any overt bleeding event that does not meet the criteria 
above. 
MRI = magnetic resonance imaging 
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Table 6-2 ACTION bleeding score 
Age (years) Systolic Blood Pressure Heart rate on admission Heart Failure ± Shock on Admission 
≤40 0 ≤90 4 ≤40 0 None 0 
41-50 1 91-100 3 41-60 2 Heart failure only 3 
51-60 2 101-120 2 61-70 3 Heart failure with shock 15 
61-70 3 121-140 1 71-80 5 ECG changes 
71-80 4 141-170 0 81-100 6 No ST-segment changes 0 
81-90 5 171-200 1 101-110 8 ST-segment changes 3 
≥91 6 ≥201 2 111-120 9 ST-segment elevation 7 
Baseline Serum Creatinine (mg/dl) Baseline haemoglobin (g/dl) 121-130 11 Peripheral artery disease 
<0.8 0 <5 17 131-150 12 No 0 
0.8-1.59 1 5-7.9 15 ≥151 14 Yes 3 
1.6-1.99 2 8-9.9 13 Weight (kg) Gender 
2.0-2.99 4 10-10.9 12 ≤50 5 Female 4 
3.0-3.99 6 11-13.9 9 51-70 4 Male 0 
4.0-4.99 8 14-15.9 6 71-100 3 Diabetes mellitus 
5.0-5.99 10 ≥16 2 101-120 2 No 0 
≥6 11 Home warfarin use 121-140 1 Yes 3 
On dialysis 11 No 0 ≥140 0   
  Yes 2     
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6.2.4 Platelet function testing 
On-treatment platelet reactivity to ADP was quantified using the Multiplate analyser 
(Roche Diagnostics, Rotkreuz, Switzerland), a multiple electrode impedance 
aggregometer that assesses platelet function in whole blood as previously described 267. 
Briefly, whole blood was added to the test cuvettes, diluted (1:2 with 0.9% NaCl 
solution), stirred and warmed to 37 °C. ADP was added to a final concentration of 6.4 
mM and aggregation was then continuously recorded for 6 min. Aggregation values are 
quantified as area under the aggregation curve expressed as aggregation units × minutes 
(AU). All material used for platelet function testing was obtained from the manufacturer 
(Roche Diagnostics, Rotkreuz, Switzerland).  Thresholds for LPR were defined as <19 AU 
268. 
 
6.2.5 Statistical analysis 
Continuous variables are presented as mean ± standard deviation, and comparisons 
between groups were performed using independent sample t-tests. Categorical 
variables are presented as frequency (percentage) and chi-square analyses were used 
to compare groups. In univariate analysis (those with non-CABG bleeding compared to 
those without) variables with p-values <0.05 were included in the multinomial model. 
All p-values were 2-sided and a value <0.05 was considered statistically significant. 
Receiver operator characteristic (ROC) curve analysis was used to examine the 
relationship between risk scores and the primary endpoint and reported as area under 
the curve measures (AUC). All statistical tests were performed using SPSS version 22 




The demographics and clinical characteristics of the 1000 acute MI patients enrolled in 
this study were typical of an ACS population and can be seen in Table 6-3. This group 
had an average age of 63 ± 11 years, 27.7% were female and 19.4% had diabetes. 
NSTEMI was the presentation in 80.6% of patients and STEMI in 19.4%. Clinical 
management was PCI in 60.5%, CABG surgery in 14.3% and medical management in 
25.2%. All patients were on DAPT at the time of enrolment with 84.1% being discharged 
on DAPT. DAPT at discharge was aspirin and clopidogrel in 628 patients (74.6%), and 
aspirin and ticagrelor in 213 patients (25.4%). 
The primary endpoint of non-CABG TIMI major and minor bleeding at one-year occurred 
in 133 (13.3%) of subjects (Table 6-3). Of the 133 bleeding events, 46 (34.5%) occurred 
in-hospital and 87 (65.4%) occurred between discharge and one-year. Seven of the 
bleeding events (5.3%) were TIMI major bleeds, and this consisted of 1 intracranial 
haemorrhage occurring in-hospital, and 6 clinically overt bleeds with a haemoglobin 
drop of >5g/dL, all occurring out-of-hospital. No fatal bleeding events occurred. The 
remaining 126 bleeding events (94.7%) were categorised as TIMI minor. Thirteen of 
these were clinically overt with a haemoglobin drop 3-5g/dL (5 occurred in-hospital and 
8 out-of-hospital), and 113 required medical attention (40 in-hospital events vs. 73 out-
of-hospital events) (Table 6-4). 
A total of 143 (14.3%) patients in the study were managed with CABG surgery, and in 
this group 14 patients experienced TIMI major CABG related bleeding. There were 4 
cases where reoperation to control bleeding was required, and 10 cases where the 
patient received 5 units of blood products. In this group there were 4 perioperative 
deaths, but none of these was due to bleeding. There were no cases of intracranial 
bleeding associated with CABG (Table 6-4).
BMI = body mass index; eGFR = estimated glomerular filtration rate; PI = Pacific Islander.  148 
Table 6-3 Demographics and clinical characteristics 







Age (years) 63 ± 11 65 ± 10 63 ± 11 0.03 
Female gender 277 (27.7) 48 (36.1) 229 (26.4) 0.02 
Weight 86 ±18 85 ± 17 86 ± 18 0.81 
BMI <20/underweight 24 (2.4) 3 (2.3) 21 (2.4) 0.907 
Ethnicity 
European 


















Risk Factors     
Hypertension 611 (61.1) 92 (69.2) 519 (59.9) 0.04 
Dyslipidaemia 692 (69.2) 90 (67.7) 602 (69.4) 0.68 
Diabetes 194 (19.4) 28 (21.1) 166 (19.1) 0.61 
Current Smoker 227 (22.7) 27 (20.3) 200 (23.0) 0.175 
Previous MI 238 (23.8) 35 (26.3) 203 (23.4) 0.46 
Previous stroke 68 (6.8) 11 (8.3) 57 (6.6) 0.47 

























Anaemia 122 (12.2) 21 (15.8) 101 (11.6) 0.17 
Low platelet reactivity 174 (17) 20 (15) 154 (17.8) 0.431 
Clinical presentation     
STEMI 194 (19.4) 23 (17.3) 171 (19.7)  
0.51 
NSTEMI 806 (80.6) 110 (82.7) 696 (80.3) 
CRUSADE score 22 ± 10 23 ± 10 22 ± 10 0.20 
ACTION score 23 ± 6.6 24 ± 6.7 23 ± 6.5 0.44 
GRACE score 124 ± 31 125 ± 32 124 ± 31 0.72 
















Discharged on DAPT 841 (84.1) 123 (92.5) 718 (82.8) 0.005 
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Table 6-4 Bleeding events by TIMI criteria 
 In-hospital Out-of-hospital Total 
Primary endpoint: Non-
CABG TIMI Major & Minor 
 
46 (34.5 %) 
 
87 (65.4 %) 
 
133 (100%) 
TIMI Major 1 6 7 
Intracranial bleeding 1 - 1 
Clinically overt ǂ - 6 6 
Fatal bleeding - - 0 
TIMI Minor 45 81 126 
Clinically overt ᵻ 5 8 13 
Requiring medical attention 40 73 113 
TIMI CABG Bleeding 14 (100%)  14 (100%) 
Fatal Bleeding - - 0 
Perioperative intracranial 
bleeding 
-  - 0 
Reoperation to control 
bleeding 
4 - 4 
Transfusion of  5 units 
blood 
10 - 10 
Chest tube output >2L 
within 24 hours 
- - 0 




6.3.1 Predictors of Non-CABG bleeding 
The demographics and clinical characteristic of those with non-CABG bleeding compared 
to those without are shown in Table 6-3. In univariate analyses a number of factors were 
associated with an increased risk of non-CABG related TIMI major or minor bleeding at 
one-year. These were increasing age (per 10-year increments) (odds ratio 1.21, [1.02-
1.43]), female gender (odds ratio 1.57, [1.07-2.31]), history of hypertension (odds ratio 
1.51, [1.02-2.23]), history of renal dysfunction (odds ratio 1.95, [1.00-3.80]), PCI (odds 
ratio 2.2, [1.43-3.3]) and DAPT at discharge (odds ratio 2.55, [1.31-4.98]); all were 
significant to a level p<0.05. In multinomial analysis both female gender (odds ratio 1.5, 
[1.01-2.2], p=0.044) and clinical management with PCI (odds ratio 1.96, [1.2-3.1], 
p=0.005) remained as independent predictors of bleeding. 
 
6.3.2 CRUSADE bleeding score 
Using the CRUSADE scoring criteria to assess for bleeding risk, most patients were 
categorised as very low risk (46.8%), followed by low risk (33.2%), moderate risk (16%) 
and high/very high risk (4%). Within each of these risk categories bleeding rates were 
13%, 12%, 15.6% and 17.5% respectively (Table 6-5).  At one-year most non-CABG 
related bleeding events occurred in those at very low risk of bleeding (n=61) and low 
risk (n=40) and this is likely reflective of the large number of patients in these groups.    
When looking at the ability to predict the primary endpoint of non-CABG related TIMI 
major or minor bleeding, our analysis found no difference in mean CRUSADE scores for 
patients who had a bleeding event compared with  those who did not (23 ± 10 vs. 22 ± 
10, p=0.20). ROC curve analysis to assess the relationship between CRUSADE scores and 
non-CABG related TIMI major or minor bleeding was performed and with an AUC of 
0.533 (p=0.226) and was therefore not predictive of bleeding in our cohort (Figure 6-1). 
Analysis of in-hospital bleeding events only, showed CRUSADE to have modest 
predictive ability with an AUC of 0.610 (p=0.012). This was also evident as patients who 
had an in-hospital bleed had significantly higher mean CRUSADE scores compared to 
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those who did not (26.0 ± 10.4 vs. 22.1 ± 10.0, p=0.01). With regard to out-of-hospital 
bleeding, once again CRUSADE was not predictive of bleeding events using both ROC 
curve analysis (AUC=0.487, p=0.679) and mean CRUSADE scores (out-of-hospital 
bleeding event vs. no bleeding event, 21.9 ± 9.9 vs. 22.4 ± 10.0 respectively, p=0.71).  
 
Table 6-5 Bleeding events by risk stratification 











Very low (n=468) 3 (0.6) 58 (12.4) 61 (13) 
Low (n=332) 1 (0.3) 39 (11.7) 40 (12) 
Moderate (n=160) 3 (1.9) 22 (13.8) 25 (15.6) 










Very low (n=366) 1 (0.3) 48 (13.1) 49 (13.4) 
Low (n=489) 3 (0.6) 55 (11.2) 58 (11.9) 
Moderate (n=136) 3 (2.2) 23 (16.9) 26 (19.1) 
High/very high (n=9) - - - 
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A) One-year bleeding  B) In-hospital bleeding  C) Out-of-hospital bleeding 
   
Figure 6-1 ROC curves showing predictive ability of CRUSADE bleeding risk score 
The ROC curves are graphs of sensitivity (y-axes) versus 1-specificity (x-axes). CRUSADE was not predictive of one-year bleeding events (A) or out-of-hospital 
bleeding events (C). CRUSADE was modestly predictive of in-hospital bleeding (B). 
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6.3.3 ACTION bleeding score 
When the action bleeding score was applied the distribution of patients into risk 
categories was different to that of CRUSADE. Nearly half the patients were categorised 
as being at low risk of bleeding (48.9%), followed by very low risk (36.6%), moderate risk 
(13.6%) and high/very high risk (0.9%).  There was some variability in bleeding event 
rates between the risk categories. The moderate risk group had the highest bleeding 
event rate (19.1%), followed by the very low risk group (13.4%) and low risk group 
(11.9%). No bleeding events occurred in the high/very high risk patients. At one-year 
most non-CABG related bleeding events occurred in the low risk (n=58) and very low risk 
(n=49) groups, and once again this is probably reflective of the large patient numbers in 
these groups (Table 6-5).  
The predictive ability of the ACTION risk score was also assessed (Figure 6-2). The mean 
ACTION score for patients who experienced a non-CABG TIMI major or minor bleed was 
not different to the non-bleeders (24 ± 6.7 vs. 23 ± 6.5, 0.44). ROC curve analysis also 
showed that the ACTION risk score was not predictive of these bleeding events 
(AUC=0.522, p=0.414). ACTION had very modest predictive power with regard to in-
hospital bleeding events with an AUC value of 0.583 (p=0.056), however the mean 
ACTION scores for these patients did not reach statistical significance (in-hospital 
bleeding event vs. no bleeding event, 25 ± 6.6 vs. 23 ± 6.5, p=0.075). ACTION did not 
exhibit any ability to predict out-of-hospital non-CABG TIMI major or minor bleeding 
events, with equal mean ACTION scores in both the out-of-hospital bleeding and no 
bleeding groups (23 ± 6.6 vs. 23 ± 6.5, p=0.688), and a AUC value of 0.486 (p=0.662). 
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A) One-year bleeding  B) In-hospital bleeding  C) Out-of-hospital bleeding 
   
Figure 6-2 ROC curves showing predictive ability of ACTION bleeding risk score 
The ROC curves are graphs of sensitivity (y-axes) versus 1-specificity (x-axes). ACTION was not predictive of one-year bleeding events (A) or out-of-hospital 
bleeding events (C). ACTION was only modestly predictive of in-hospital bleeding (B).  
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6.3.4 Low on-treatment platelet reactivity 
When examining the relationship between LPR and non-CABG related TIMI major and 
minor bleeding there was no statistically significant difference in the frequency of LPR 
in those who had a bleeding event compared to those who did not, either in-hospital 
(8.7% vs. 17.9%, p=0.11), out-of-hospital (18.4% vs. 17.4%, p=0.81) or overall at one-
year (15% vs. 17.8%, p=0.43) (Table 6-6). The ability of residual platelet reactivity to 
predict bleeding events for patients was also examined using ROC curve analysis. We 
found that platelet reactivity was not predictive of non-CABG related TIMI major and 
minor bleeding events either in-hospital (AUC=0.5, p=0.991), out-of-hospital bleeding 
(AUC=0.506, p=0.858) or overall at one-year (AUC=0.504, p=0.876) (Figure 6-3).   
 
Table 6-6 Low platelet reactivity by bleeding event 
 Low platelet reactivity 
n (%) 
p-value 
In-hospital bleeding (n=46) 4 (8.7)  
0.11 
No in-hospital bleeding (n=954) 170 (17.9) 
Out-of-hospital bleeding (n=87) 16 (18.4)  
0.81 
No out-of-hospital bleeding (n=913) 158 (17.4) 
One-year bleeding (n=133) 20 (15)  
0.43 




   
A) One-year bleeding  B) In-hospital bleeding  C) Out-of-hospital bleeding 
   
Figure 6-3 ROC curves showing predictive ability of platelet reactivity 
The ROC curves are graphs of sensitivity (y-axes) versus 1-specificity (x-axes). Platelet reactivity was not predictive of one-year bleeding (A), in-hospital 
bleeding (B) or out-of-hospital bleeding (C).  
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6.3.5 PCI subgroup analysis 
A total of 605 patients (60.5%) were managed with PCI and non-CABG related TIMI major 
or minor bleeding occurred in 100 of these patients (16.5%).  Of these, in-hospital 
bleeding events occurred in 35 patients and out-of-hospital bleeding events in 65 
patients.  Five of these bleeding events were defined as TIMI major (1 in-hospital and 4 
out-of-hospital), and 95 as TIMI minor (34 in-hospital and 61 out-of-hospital).  
Those managed with PCI in the in-hospital bleeding group had a significantly higher 
mean CRUSADE score compared to those without bleeding (24.8 ± 10.0 vs. 21.2 ± 9.6, 
p=0.033).  ROC curve analysis showed the CRUSADE risk score had a modest ability to 
predict in-hospital bleeding events for those managed by PCI (AUC=0.608, p= 0.032). 
With regard to out-of-hospital bleeding events CRUSADE was not predictive 
(AUC=0.503, p=0.928), nor were mean CRUSADE scores statistically different in those 
with bleeding compared to those without bleeding (21.5 ± 9.8 vs. 21.4 ± 9.7, p = 0.917). 
For overall non-CABG related TIMI major and minor bleeding at one-year again the 
CRUSADE score  was not predictive of events (AUC=0.545, p=0.155), and mean CRUSADE 
scores in those with bleeding compared to those without bleeding were very similar 
(22.7 ± 9.9 vs. 21.2 ± 9.6, p=0.155) (Figure 6-4). 
The predictability of the ACTION risk score for patients managed with PCI was also 
examined. We found that ACTION was not predictive of bleeding events for in-hospital 
bleeding (AUC=0.572, p=0.152), out-of-hospital bleeding (AUC=0.509, p=0.830) or 
overall non-CABG bleeding events at one-year (AUC=0.534, p=0.280). Likewise no 
statistical difference was found between mean ACTION scores comparing those with 
bleeding to those without for in-hospital bleeding (24.4 ± 6.8 vs. 22.9 ± 6.5, p=0.171), 
out-of-hospital bleeding (23.1 ± 6.5 vs. 23.0 ± 6.5, p= 0.855) and all non-CABG related 
TIMI major and minor bleeding (23.6 ± 6.6 vs. 22.8 ± 6.5, p=0.312) (Figure 6-5).  
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A) One-year bleeding  B) In-hospital bleeding  C) Out-of-hospital bleeding 
   
Figure 6-4 PCI subset - predictive ability of CRUSADE bleeding risk score 
The ROC curves are graphs of sensitivity (y-axes) versus 1-specificity (x-axes). In the PCI subset (n=605) CRUSADE was not predictive of one-year bleeding 
events (A) or out-of-hospital bleeding events (C). CRUSADE was modestly predictive of in-hospital bleeding in those managed with PCI (B).   
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A) One-year bleeding  B) In-hospital bleeding  C) Out-of-hospital bleeding 
   
Figure 6-5 PCI subset - predictive ability of ACTION bleeding risk score 
The ROC curves are graphs of sensitivity (y-axes) versus 1-specificity (x-axes). In the PCI subset (n=605) ACTION was not predictive of one-year bleeding (A), 
in-hospital bleeding (B) or out-of-hospital bleeding (C). 
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In addition, for those managed with PCI there was no statistical difference in the 
frequency  with which people were classified as having LPR in those with bleeding 
compared to those without bleeding either in-hospital (8.6% vs. 17.5%, p=0.17), out-of-
hospital (20% vs. 16.7%, p=0.5) or overall at one-year (17% vs. 17%, p=0.76). The 
predictability of residual platelet reactivity for patients managed with PCI was also 
examined using ROC curve analysis. We found that platelet reactivity was not predictive 
of non-CABG related TIMI major and minor bleeding events either in-hospital (AUC = 
0.483, p=0.746), out-of-hospital bleeding (AUC = 0.517, p=0.647) or overall at one-year 
(AUC= 0.506, p=0.858) (Figure 6-6).   
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A) One-year bleeding  B) In-hospital bleeding  C) Out-of-hospital bleeding 
   
Figure 6-6 PCI subset – predictive ability of platelet reactivity 
The ROC curves are graphs of sensitivity (y-axes) versus 1-specificity (x-axes). In the PCI subset (n=605) platelet reactivity was not predictive of one-year 
bleeding (A), in-hospital bleeding (B) or out-of-hospital bleeding (C). 
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6.4 Discussion 
In this prospective real-world cohort we found a 13.3% rate of non-CABG TIMI major or 
minor bleeding within one-year following MI, with the majority of these events 
occurring following discharge from hospital. The CRUSADE score but not the ACTION 
score or LPR was predictive of in-hospital bleeding. However, neither bleeding score nor 
LPR was predictive of out-of-hospital bleeding or overall bleeding at one-year. The 
predictive ability of CRUSADE in-hospital was modest with the majority of bleeding 
events occurring in patients classified as low risk. 
The incidence of bleeding after ACS varies depending on the population studied, the 
time frames examined and the definitions used. The more recent utilisation of intensive 
antithrombotic drugs also lend themselves to increased bleeding rates 237,238.  Keeping 
in mind the variability in these parameters the rate of major bleeding in the wider 
literature is reported anywhere between 2-12% 237,241,269-273. The overall one-year rate 
of TIMI major or minor non-CABG related bleeding in this cohort was 13.3% and was 
comparable with other ACS cohorts utilising the same TIMI bleeding definitions. The 
PLATO trial reported TIMI major or minor bleeding rates of 11.4% and 10.9% in the 
ticagrelor and clopidogrel arms respectively238. The slightly higher rate seen in our study 
may reflect the broader patient population enrolled in this registry when compared to 
a clinical trial.  
Whatever the definitions employed it is clear that bleeding after an ACS event has a 
negative impact on prognosis 235,274-277. We also know that bleeding events (fatal, 
intracranial or major) impact heavily on the overall risk-benefit balance for ACS patients 
with AF, as demonstrated in the previous chapter. It is therefore sensible that NSTEACS 
and STEMI specific guidelines suggest altering treatment on the basis of bleeding risk 88-
91. However, to achieve this clinicians require accurate tools to assess bleeding risk. Two 
bleeding scores that are used commonly are the CRUSADE and ACTION bleeding scores.  
These have been shown to perform better when compared to other bleeding risk scores 
273,278,279. The CRUSADE and ACTION scores were both developed and validated in very 
large cohorts of NSTEMI patients to quantify the risk of in-hospital major bleeding events 
and were found to be reasonably predictive (AUC 0.72 and 0.73 respectively). Whilst 
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CRUSADE and ACTION were developed to predict in-hospital events, patients discharged 
on antithrombotic regimens are still at risk from bleeding long after their hospital 
admission 261. 
In our study CRUSADE and ACTION were only very modestly predictive of in-hospital 
non-CABG related bleeding events. This may be because we enrolled a mixed 
population. However, when we looked at a PCI population alone the predictive ability 
did not increase significantly. An alternative explanation may be that clinical practice has 
changed significantly from the time when these scores were derived. In particular there 
is less use of glycoprotein IIb/IIIa inhibitors and greater use of radial access. These 
factors may impact on the predictive value of these scores. Neither the CRUSADE nor 
the ACTION scores were predictive of bleeding post discharge or overall at one-year. 
This may be because the drivers for bleeding may differ pre- and post-discharge.  
Despite enrolling a broad range of patients into the study relatively few patients were 
classified as being at high risk of bleeding by the CRUSADE and ACTION scores. As a result 
most bleeding occurred in those classified as being at low to moderate bleeding risk.  
The implications being that we need better risk stratification tools to target bleeding 
avoidance strategies, or alternatively we must use bleeding avoidance strategies that 
can be applied to the whole ACS population. What’s more, in the context of patients at 
increased risk of bleeding, such as ACS patients with AF prescribed TT, CRUSADE and 
ACTION are likely ineffective assessment tools, and therefore will not help to mitigate 
harm from bleeding through accurate prediction of bleeding events.  
As mentioned, guidelines frequently advocate that we should consider both bleeding 
risk and ischaemic risk when deciding on therapeutic strategies. Whilst this is sound in 
theory, the practicalities of achieving this are challenging.  An additional factor that 
makes this challenging in clinical practice is the fact that bleeding and ischaemic risk are 
linked with many of the independent risk factors for bleeding also being independent 
risk factors for recurrent ischaemic events. The GRACE score (Global Registry of Acute 
Coronary Events) is a predominant risk profile tool designed to predict 6 month 
readmission and mortality for patients admitted with an ACS, and consists of 8 
predictors280. Four of the predictors from GRACE are also present in CRUSADE (heart 
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rate, systolic blood pressure, renal function [creatinine/creatinine clearance] and heart 
failure at admission), while 6 predictors are also present in ACTION (age, heart rate, 
systolic blood pressure, creatinine, ST-segment deviation and heart failure at 
admission). Indeed this overlap is emphasized in a recent study of 1,587 ACS patients 
comparing GRACE and CRUSADE, and their ability to predict major bleeding events. 
When CRUSADE bleeding definitions were applied both scoring systems performed 
equally well (AUC = 0.79 vs 0.79, p=0.921), but when BARC major bleeding definitions 
were used227 the GRACE score outperformed CRUSADE (AUC = 0.80 vs. 0.73 respectively, 
p=0.028)281. This finding in addition to our current results, highlight the fact that 
bleeding risk scores derived in large-scale studies may not be applicable to daily routines 
that are currently guiding therapeutic decision making.  
As major bleeding events have proven difficult to predict accurately even using a 
combination of traditional bleeding risk factors, alternative approaches are required. 
Platelet function testing may represent an alternative approach to help stratify bleeding 
risk and ischaemic risk 262,282. However, the value and accuracy of LPR to predict bleeding 
events in patients exposed to P2Y12 inhibitors is not as clearly established as for HPR and 
stent thrombosis, with both positive 283-288 and negative studies published so far 289 
290,291. A meta-analysis of seventeen studies including 20 839 patients found that those 
with LPR had a significant, 1.7-fold higher risk of major bleeding in comparison to those 
with platelet reactivity in the optimal range (relative risk 1.74, [1.47–2.06], p < 0.00001) 
292. In the current study we did not find a statistically significant difference in the 
frequency of LPR in those who had a bleeding event compared to those who did not, 
either in-hospital, out-of-hospital, or overall at one-year. There are a number of 
important differences in our study when compared to those included in the meta-
analysis. All studies included in the meta-analysis were performed on patients 
undergoing PCI with only a minority of patients presenting with ACS. The meta-analysis 
included studies using a variety of bleeding definitions, a variety of platelet function 
tests and follow-up durations between 1 and 17 months which may have also influenced 
findings 292. 
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Recently, a novel risk score, the PRECISE-DAPT score (age, creatinine clearance, 
haemoglobin, white blood cell count and previous bleeding) 293, was developed for the 
prediction of out-of-hospital bleeding during treatment with DAPT. This retrospective 
study included patients with both stable CAD (44%) and ACS (56%) who were treated 
with PCI, largely from previously performed clinical trials. The score was reasonably 
predictive with an AUC for out-of-hospital TIMI major or minor bleeding of 0.73 (95% CI 
0.61–0.85). Whether the score predicted in-hospital bleeding was not examined. This 
score is a relatively simple five-item risk score, which can be calculated on-line. One of 
the components included in this risk score is “a history of spontaneous bleeding” and in 
fact is by far the most predictive element. As we did not collect information on whether 
or not patients had a history of spontaneous bleeding we could not examine this score 
in our cohort. 
 
6.4.1 Limitations 
Our study has inherent limitations associated with being an observational study; as such 
it may be susceptible to bias or confounding influences we could not control for. Our 
results rely heavily on the data collection of patient details and bleeding events, of which 
we cannot be certain of accuracy.  
Weak relationships between bleeding scores were challenging to identify and may have 
been more evident in a larger cohort, however this was beyond the constraints of this 
thesis. However, given we found TIMI major or minor bleeding occurred in 13% of 
patients, a rate higher than some larger ACS cohorts, it is also possible that a larger 
cohort would not have helped to identify relationships if they are truly negligible. 
Furthermore, the usefulness of weak relationships is questionable and will likely offer 
little value in the setting of clinical assessment. It is also possible that our study was 
underpowered to detect small associations between LPR and bleeding events, however 
our cohort of 1000 MI patients was larger than many previous studies to examine this 
relationship 286,287,294-301. 
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As we discussed earlier there is vast heterogeneity across bleeding definitions in wider 
literature; both CRUSADE and ACTION used study derived bleeding criteria. We designed 
this study to examine bleeding using the TIMI bleeding criteria as it frequently used in 
published literature, especially in predominant ACS trials, and we considered it to be a 
reasonable common endpoint for both scoring systems and platelet reactivity. 
Utilisation of CRUSADE’s and ACTION’s respective bleeding criteria may have resulted in 
findings that demonstrated predictability, however, we would have not been able to 
compare the performance of scores. What’s more, this study was designed to evaluate 
the accuracy of bleeding scores used in clinical settings, and the usefulness of CRUSADE 
and ACTION to predict their own study criteria would have not been of value.  
In the time since we completed this study the PRECISE-DAPT bleeding score has been 
developed as previously discussed. This scoring system demonstrated ability to predict 
TIMI major or minor bleeding and it is possible that this may be of value moving forward. 
Like CRUSADE and ACTION, PRECISE-DAPT was derived from a large cohort (14,963 
patients) and we do not know its predictive ability in smaller real-world cohorts like ours. 
We were unable to calculate PRECISE-DAPT as “a history of spontaneous bleeding”, a 
component of the score, was not collected in our study database. 
 
6.5 Conclusion 
In our real world cohort we found a 13.3% rate of clinically significant bleeding within 
one-year of MI. Two common ACS bleeding risk scores, CRUSADE and ACTION, were 
analysed and despite being predictive in large populations, performed poorly in our 
patient cohort. CRUSADE demonstrated a very modest ability to predict in-hospital 
bleeding events, but neither score was predictive of out-of-hospital events up to one-
year. Platelet reactivity has been suggested as an alternative risk stratification tool 
however it did not demonstrate predictive ability in our cohort. An accurate risk 
assessment tool that predicts bleeding events for the duration of antithrombotic 





7  Summary and future directions 
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7.1 Summary 
In this thesis, the aim of the first study was to describe the discharge prescription of 
antiplatelet and anticoagulant therapy in ACS patients with AF. We found DAPT to be 
the preferred discharge regimen, and OAC use was very low despite most patients being 
at high risk of stroke. Discharge OAC use was not associated with stroke risk as assessed 
by CHA2DS2VASc score, bleeding risk as assessed by CRUSADE score, nor any other 
clinical characteristic. The only predictor of OAC use at discharge was prehospital use of 
OAC. We also identified a large group of patients characterised by high stoke risk and 
low bleeding risk whom may have been suitable candidates for OAC therapy 302.  
The aims of the second study were to describe national prescription patterns of 
antiplatelet and anticoagulant therapies in ACS patients with AF, and to examine 
whether therapies were associated with one-year outcomes.  Despite expanding our 
patient cohort to include those treated nationwide, we found no clear treatment 
strategy for the 12 months post ACS event. Consistent with study one we found DAPT 
to be the most common regimen prescribed. TT was the second most prescribed therapy 
at discharge, and the use of DAPT compared with TT was not driven by stroke risk.  Event 
rates were unexpectedly low and therefore we could not detect differences in outcomes 
between therapies due to a lack of statistical power. Overtime, treatment with DAPT 
and TT decreased and therapy with a single antiplatelet agent or no therapy increased, 
resulting in many patients being undertreated when compared to well-established ACS 
guidelines. Patients with higher CHA2DS2VASc scores were more likely to receive OAC 
therapy, however overall OAC use was low.  
On the basis of the first and second study no clear treatment strategy for ACS patients 
with AF was evident. Therefore in the third study we aimed to systematically review 
published literature in an attempt to determine whether DAPT or TT was optimal 
therapy for ACS patients with AF. Studies of pure AF patients with ACS or coronary artery 
disease undergoing intervention, which compared DAPT and TT, and published 
ischaemic and/or bleeding endpoints were included in the review.  We found that 
overall the quality of literature was poor with most studies being retrospective analyses 
on smaller single-centre cohorts.  We concluded that TT was consistently associated 
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with increases in bleeding risk. There was not consistent evidence of reduced stroke or 
composite ischaemic endpoints associated with TT, however the largest study indicated 
that TT offered significant reductions in mortality and stroke 240. We therefore remained 
uncertain as to whether the increase in bleeding seen with TT was associated with a 
decrease in stroke endpoints.   
The aims of the fourth study were to construct a decision analysis model to evaluate 
bleeding and stroke risk in ACS patients with AF, and, to determine likely thresholds of 
stroke risk at which the benefits of TT may exceed harm from bleeding. We found that 
risk of bleeding with TT impacted heavily on the overall benefit-risk balance. As a result 
the trade-off between increased stroke protection and excess bleeding events only 
favoured TT when stroke risk was high, in most instances at a CHA2DS2VASc score of 3-
5, dependant on the risk parameters applied. This theoretical approach generated the 
hypothesis that current thresholds to indicate TT (CHA2DS2VASc ≥1 [ESC], CHA2DS2VASc 
≥ 2 [Australian] and CHADS2 ≥ 1 or age over 65 [Canadian], are all likely too low. 
With the systematic literature review and the decision model both highlighting the 
significant impact of bleeding events with TT we set out to explore whether we could 
accurately predict bleeding events in those presenting with ACS. Therefore, the aims of 
our final study were to: characterise in-hospital and one-year bleeding events in a real 
world MI cohort; evaluate the ability of CRUSADE and ACTION bleeding risk scores to 
predict in-hospital and one-year bleeding events; and, examine whether LPR is 
predictive of in-hospital and one-year bleeding events. We found the one-year bleeding 
rate of non-CABG related TIMI major or minor bleeding to be 13%, and identified female 
gender and management with PCI as independent predictors of bleeding. The CRUSADE 
bleeding score showed modest ability to predict in-hospital events but ACTION and LPR 
did not. Neither bleeding score nor LPR was predictive of out-of-hospital bleeding or 
overall bleeding at one-year. The majority of bleeding events occurred in patients 
classified as low risk. We concluded that at the individual patient level, contemporary 
ACS bleeding scores and LPR were not effective at predicting one-year bleeding events. 
Taken together these studies reflect a large amount of clinical uncertainty for the 
treatment of ACS patients with concurrent AF. Both in single-centre and nationwide 
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settings no clear treatment strategy was evident and did not appear to be based on 
assessments of risk. It is likely that the poor quality of literature identified in the 
systematic literature review has contributed to this confusion; that is, the absence of 
high-quality prospective trials has resulted in prescribing patterns that are not guided 
by a scientifically rigorous evidence base.  During the course of this thesis we have also 
identified that bleeding risk with TT impacts largely on the overall stroke prevention-
bleeding risk balance. Accurate prediction of bleeding events would be useful to help 
mitigate haemorrhagic consequences for ACS patients with AF, particularly those eligible 
for TT. However, better tools are required as the contemporary ACS bleeding risk scores, 
CRUSADE and ACTION, as well as platelet reactivity, lack predictive accuracy in a real-
world setting.   
 
7.2 Limitations  
Throughout this thesis there have been certain limitations that may have influenced our 
findings and these have been acknowledged within respective chapters. However, there 
are also overarching limitations that must be acknowledged.  
Where drug therapies have been investigated we have primarily examined a DAPT or TT 
paradigm as these are the current guideline recommendations.  However it is entirely 
possible that other drug combinations have value in this setting, for example OAC + 
single antiplatelet therapy. There has been a small amount of research conducted on 
OAC + single antiplatelet regimens which are worth mentioning. The WOEST (What is 
Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and 
coronary STenting) trial compared OAC + single antiplatelet (clopidogrel) versus TT, but 
in a slightly different population (69% AF and only 25-30% ACS) and found favour with 
the former (less bleeding complications with no difference in thrombotic events) 303.  
The PIONEER-AF PCI study was an open-label, randomized, controlled, multi-centre 
study exploring assessing the risk of bleeding complications in AF patients undergoing 
PCI (50% ACS) with three different treatment regimens: rivaroxaban 15 mg once daily 
plus clopidogrel 75 mg daily for 12 months (a WOEST trial–like strategy), or rivaroxaban 
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2.5 mg twice daily (with DAPT for 1 to 12 months, an ATLAS trial–like strategy), or dose-
adjusted VKA once daily (with DAPT for 1 to12 months, traditional triple therapy) ).  This 
study demonstrated that treatment with either low-dose rivaroxaban plus a P2Y12 
inhibitor for 12 months or very-low-dose rivaroxaban plus DAPT for 1 to 12 months was 
associated with a lower rate of clinically significant bleeding when compared to therapy 
with a vitamin K antagonist plus DAPT. The rates of death from cardiovascular causes, 
MI or stroke were similar in the three groups but the study was not powered for this 
endpoint 304,305.  
Most recently, the RE-DUAL PCI trial (Randomized Evaluation of Dual Antithrombotic 
Therapy with Dabigatran versus Triple Therapy with Warfarin in Patients with 
Nonvalvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention) 
compared OAC + single antiplatelet therapy (dabigatran with P2Y12 inhibitor) to TT (with 
warfarin, P2Y12 inhibitor and aspirin) in patients with AF undergoing PCI (approximately 
60% ACS). An OAC + antiplatelet resulted in significantly less bleeding and was non-
inferior to TT with respect to thrombotic events 306. It is evident that these trials indicate 
potential value in a NOAC + P2Y12 inhibitor combination. However these studies were 
not conducted exclusively in our interest group of ACS patients with AF and did not 
perform comparisons with DAPT. Therefore, while an OAC + single antiplatelet regimen 
looks promising, as yet superiority over DAPT has not been demonstrated.   
It is also difficult to know what drugs optimally make up OAC + single antiplatelet. There 
are a myriad of possible drug combinations that could constitute this regimen (Figure 7-
1), particularly when the combinations of dosing (e.g. high dose vs. low dose), patient 
characteristics (e.g. variations in kidney function) and patient risk (e.g. stroke and 
bleeding risk) are considered. In actuality, even less research has been conducted on 
these alternative drug regimens when compared to DAPT and TT, and this likely explains 
their omission from guidelines and consensus documents at the commencement of this 
thesis. On balance, while we cannot rule out OAC + single antiplatelet as a valid 
treatment strategy for ACS patients with AF, we also cannot be certain of its efficacy-
safety profile in this patient group as yet. 
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 Aspirin Clopidogrel Prasugrel Ticagrelor  
Select 1 
antiplatelet: 
Low dose High dose Low dose High dose Low dose High dose Low dose High dose  
          
 Warfarin Dabigatran Apixaban Rivaroxaban  
Select 1 
OAC: 
Low dose High dose Low dose High dose Low dose High dose Low dose High dose  
          
Figure 7-1 Possible combinations of OAC + single antiplatelet regimens 
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Another major limitation that may have affected our findings is the quality of data used 
from the observational registries. We have used both a single-centre study (Wellington) 
and a nationwide (ANZACS-QI) ACS registry to detail the treatment of ACS patients with 
AF, however neither registry was designed to study this patient group specifically. With 
regard to the ANZACS-QI registry we cannot be certain as to the degree of accuracy that 
AF data has been recorded, and it is clear that improvements are greatly needed to 
better capture AF status. Moving forward, improvements to ACS registries would ensure 
greater confidence in AF-related research, and this is integral if we look to these 
registries in the absence of RCTs. The limitations of the ANZACS-QI registry design with 
regard to AF status have been a catalyst for change; as a direct result of the research 
conducted within this thesis, modifications to the ANZACS-QI database are occurring 
presently, with data fields specifically pertaining to AF being added. This has the 
potential to provide an accurate nationwide cohort of ACS patient with AF that will 
overcome the limitations we have experienced with capturing AF status. Further, it will 
provide a reliable data source as we look to determine better bleeding and stroke risk 
models which are desperately needed.  
Lastly, we were not able to further define AF into the categories of paroxysmal, 
persistent and permanent. The current consensus is that stroke risk in AF patients is 
independent of AF classification 106,113,188,189 and this is based largely on findings that AF 
patterns do not correspond well to AF burden 113. What’s more, no stroke risk 
stratification tool, including the widely used CHA2DS2VASc score, includes AF pattern in 
its assessment of patients 154-156. This has resulted in clinical guideline recommendations 
that selection of antithrombotic therapy should be based on risk of stroke irrespective 
of whether the AF pattern in paroxysmal, persistent or permanent.  In contrast to this 
there have been some findings suggesting that AF pattern may influence stroke risk 307-
309 however this evidence is generally weak and guidelines suggest that this should not 
be a major factor in deciding the usefulness of an intervention 113. Furthermore, a 2016 
meta-analysis found that when compared to paroxysmal AF, non-paroxysmal AF is 
associated with a highly significant increase in thromboembolism (adjusted HR 1.4, [1.2-
1.6] p<0.001), with no detectable difference in bleeding 158. On the basis of the above, 
grouping all AF categories together as we have done may not be problematic in the 
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current AF setting; but we cannot exclude the possibility that stroke risk is indeed 
different across the different AF categories and had we been able to separate out our 
AF cohorts our findings may have been different.   
     
7.3 Future directions 
The findings of this thesis demonstrate that optimal therapy for ACS patients with AF 
remains unresolved. This has led to a large amount of clinical uncertainty that must be 
addressed given the number of ACS patients with concurrent AF is substantial and is 
expected to rise further over time.  On the basis of our findings two avenues for future 
research are apparent.  
Firstly, further prospective testing of DAPT and TT treatment regimens would be 
advantageous. The foundations for this have been established within this thesis, with 
the following points identified:  
 There is no clear treatment strategy for ACS patients with AF  
 TT is associated with excess bleeding risk compared to DAPT 
 Stroke protection achieved from TT will be outweighed by excess haemorrhagic 
risk unless stroke risk is high, around a CHA2DS2VASc score of 3-5.  
The design of prospective studies would be complex and it is likely that significant 
preliminary work would be needed to establish what OAC and P2Y12 inhibitor would 
accompany aspirin in the TT arm.  The range of possible combinations is vast when the 
options for OAC (warfarin, dabigatran, rivaroxaban or apixaban) and P2Y12 inhibitor 
(clopidogrel, prasugrel or ticagrelor) and various doses are considered.  It is sensible to 
suggest that the DAPT arm would consist of an aspirin-ticagrelor combination due its 
demonstrated superiority over an aspirin-clopidogrel combination in the PLATO trial, 
and its wide availability through New Zealand government funding (unlike prasugrel)238. 
Whatever the components, the proposed TT and DAPT regimens would also need to 
receive widespread acceptance from practicing clinicians which in itself brings about a 
set of challenges.  
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We believe there is genuine equipoise regarding optimal therapy for patients with a 
CHA2DS2VASc score of 3-5 and therefore a trial to address this would have merit.  A 
simplified schematic of a prospective trial to assess DAPT versus TT can be seen in Figure 
7-2. It would be advantageous to conduct this across multiple centres, not necessarily 
limited to New Zealand centres, as large patient numbers would be needed in each 
treatment arm.  A suitable primary efficacy end point would be combined cardiovascular 
death, stroke and MI at one-year and a suitable primary safety endpoint would be TIMI 
major bleeding at one-year.  It is also possible for net clinical benefit calculations to be 
performed for the treatment arms at CHA2DS2VASc 3, 4 and 5, to establish the tipping 
point that would overall favour TT.  
With regard to patient population we suggest pure ACS patients with a medical history 
of AF, not the mixed stable and acute coronary populations seen in trials such as WOEST, 
PIONEER-AF PCI and RE-DUAL PCI. This is because patients with stable coronary disease 
have different risk features than those presenting with an acute coronary event. We also 
propose restricting patients to those managed with PCI to ensure a uniform ACS patient 
group with obstructive disease.  Whilst optimal therapy for all ACS patients’ needs to be 
defined, select issues associated with CABG surgery and those medically managed would 
likely introduce complexities that may be difficult to control for. In brief, patients 
managed with CABG require interruption of antithrombotic therapy prior to surgery and 
are subject to periprocedural complications including new-onset AF, thrombosis and 
bleeding. Patients who are medically managed do not always have obstructive disease 
(rather mild or extensive diffuse disease), and may have frailty issues that alter their 
thrombotic and bleeding risk, and consequently deter management with PCI. Restricting 
the study cohort to PCI patients attempts to make the patient group as homogenous as 
possible and would be favourable given treatment effect is easier to identify when other 
variability has been reduced. Subsequent investigation into ACS patients managed 
medically or with CABG surgery would be well placed to occur after the proposed study, 
where findings regarding a PCI cohort can be taken into account during the study design 
phase.  
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Patients with active bleeding, recent spontaneous bleeding, previous intracranial 
bleeding, platelet function disorders, coagulopathies, alcohol dependence, mechanical 
valves and mitral stenosis would be excluded due to obvious safety concerns. However, 
we propose that a high bleeding risk exclusion criteria may not be reasonable given the 
lack of validated scores in this patient group, and the inaccuracy of pre-existing scores. 
The inference is that patients incorrectly deemed to be at high risk of bleeding maybe 
excluded from the trial, and patients incorrectly deemed to be at low risk of bleeding 
likely included. Should bleeding risk be erroneously assessed this may confound results 
to an unknown degree and undermine study findings. Further work would need to be 
done to develop or refute this idea.    
Subgroup analysis would also provide valuable information moving forward. Within the 
CHA2DS2VASc 3, 4 and 5 treatment arms we may be able to evaluate the treatment 
effects for a specific endpoint (efficacy or safety), in subgroups of patients defined by a 
common baseline characteristic.  That is, the tipping point for TT may vary across 
different patient groups. This may be of particular value when identifying subgroups of 
patients who experience excess harm from bleeding. On completion of a trial such as 
this, subsequent comparisons can be made with other treatment regimens (e.g. OAC + 




Figure 7-2 Simplified scheme of future prospective work examining DAPT and TT 
Diagram displays a basic schematic of a prospective study designed to assess CHA2DS2VASc 3, 4 and 5 as thresholds between DAPT and TT.   
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The second avenue for future research centres on the development of bleeding risk 
models for ACS patients with AF. Accurate prediction of bleeding risk in this patient 
group is desperately needed. Both the systematic review (Chapter 4) and the decision 
model (Chapter 5) highlighted the impact of bleeding risk, when the stroke 
protection/bleeding risk balance was evaluated. Chapter 6 also established that the 
contemporary ACS scores of CRUSADE and ACTION were not predictive of bleeding 
events. Clinicians are therefore trying to manage a group of patients at risk of bleeding, 
without accurate tools to predict bleeding events. The utilisation of AF based bleeding 
scores does not seem a feasible solution to model risk in ACS patients with AF. No AF 
bleeding score accounts for changes in risk profile when a patient presents acutely 
unwell, as in the case in ACS, nor have these scores been validated in an ACS setting. 
This is also supported by a 2014 study that examined the predictive ability of the AF 
bleeding scores HAS-BLED, ATRIA and mOBRI (modified Outpatient Bleeding Risk Index), 
as well as REACH (Reduction of Atherothrombosis for Continued Health), in a cohort of 
AF patients undergoing PCI (57% for ACS), with the authors concluding “the performance 
of ATRIA, HAS-BLED, mOBRI, and REACH scores in predicting bleeding complications in 
this high-risk patient subset was useless” (pg. 1) 310.  
However, mitigation of bleeding risk for ACS patients with AF is crucial. We must 
therefore look to the development of newer risk models. The above-mentioned 
prospective trial would provide an ideal setting to develop bleeding risk stratification 
models. However should a trial such as this not occur or be substantially delayed, the 
use of pre-existing registry data may be a suitable second-tier option. As mentioned 
previously, forthcoming improvements to the pre-existing ANZACS-QI registry make this 
a feasible alternative. In Chapter 3 we outlined that over a 3-year period a total of 3,730 
patients were identified as having ACS and AF from the ANZACS-QI registry (see Chapter 
3, Figure 3-1) (as we chose to examine the PCI subgroup only, and all the one-year follow 
up data was not available this was reduced to a final cohort of 610). With the addition 
of an AF data field to the ANZACS-QI registry it is anticipated that the prospective data 
collection for ACS patients with AF will be more accurate and reliable. With 3,730 
patients over 3-years as a proxy expectation, within a matter of years we may be well-
placed to derive novel bleeding risk stratification models from a New Zealand cohort of 
179 
ACS patients with AF. By comparison, CHADS2 was derived in 1,733 patients 156, 
CHA2DS2VASc in 1,084 patients 155 and HAS-BLED in 3,978 patients 200. Should it be 
decided that the development of a bleeding risk model should be restricted to those 
managed with PCI only, data collection would naturally take longer.   
Patients with ACS and AF are common and absolute numbers are expected to rise 
overtime. These patients are high risk and as such careful management is required. 
Despite this there is an absence of quality prospective data on therapy in this patient 
group, and this has led to a lack of clarity in clinical guidelines and clinical practice.  
Ensuring adequate stroke protection without excess bleeding harm is multifaceted and 
complex. As such, high quality prospective trials are desperately needed to define 
optimal care for ACS patients with AF.  
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